Publicaciones Google Scholar de
1980 a
2024
| Título |
Fuente |
Fecha |
| Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma |
Advances in therapy 41 (4), 1576-1593 , 2024 |
2024 |
| Abstract P22: PVR (CD155) epigenetic status mediates adoptive cell therapy and anti-TIGIT response in Multiple Myeloma |
Blood Cancer Discovery 5 (2_Supplement), P22-P22 , 2024 |
2024 |
| P-018 Updated Comparative Effectiveness of Talquetamab vs Real-World Physician's Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed … |
Clinical Lymphoma Myeloma and Leukemia 24, S50-S51 , 2024 |
2024 |
| OA-29 Mezigdomide (MEZI), Tazemetostat (TAZ), and Dexamethasone (DEX) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results From the CA057-003 … |
Clinical Lymphoma Myeloma and Leukemia 24, S19 , 2024 |
2024 |
| Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. |
Journal of Clinical Oncology 42 (16_suppl), 7540-7540 , 2024 |
2024 |
| MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk |
Clinical Lymphoma Myeloma and Leukemia 24, S572-S573 , 2024 |
2024 |
| Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized … |
Haematologica 109 (7), 2219 , 2024 |
2024 |
| O4-3. MagnetisMM-3 trial: updated long-term efficacy and safety of elranatamab in relapsed or refractory multiple myeloma |
International Journal of Myeloma 14 (3), 98-98 , 2024 |
2024 |
| P-364 A Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years |
Clinical Lymphoma Myeloma and Leukemia 24, S243-S244 , 2024 |
2024 |
| Communications orales 19 Myélome (2) |
Hématologie 30 (2), 330 , 2024 |
2024 |
| 480P Clinical utility of ctDNA detection by NGS for diagnosis of CNS lymphoma |
Annals of Oncology 35, S420 , 2024 |
2024 |
| Long-term follow-up of ARI0002h (cesnicabtagene autoleucel), an academic point-of-care B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell strategy … |
Journal of Clinical Oncology 42 (16_suppl), 7544-7544 , 2024 |
2024 |
| Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases |
Microscopy and Microanalysis 30 (1), 151-159 , 2024 |
2024 |
| Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study |
Clinical Lymphoma Myeloma and Leukemia 24 (3), 194-202 , 2024 |
2024 |
| P-050 Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 … |
Clinical Lymphoma Myeloma and Leukemia 24, S69-S70 , 2024 |
2024 |
| Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma |
Journal of Clinical Oncology, JCO. 24.01008 , 2024 |
2024 |
| Pulmonary thrombosis associated with COVID‐19 pneumonia: Beyond classical pulmonary thromboembolism |
European journal of clinical investigation, e14176 , 2024 |
2024 |
| IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up |
Clinical Lymphoma Myeloma and Leukemia 24, S495-S496 , 2024 |
2024 |
| Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study |
Annals of Hematology, 1-11 , 2024 |
2024 |
| Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma |
Leukemia & Lymphoma 65 (3), 323-332 , 2024 |
2024 |
| P-090 Infections and Immune Reconstitution in the Phase 3 CARTITUDE-4 Trial of Ciltacabtagene Autoleucel vs Standard Care in Patients with Lenalidomide-Refractory Multiple … |
Clinical Lymphoma Myeloma and Leukemia 24, S94 , 2024 |
2024 |
| 30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis |
HemaSphere 8 (11), e70041 , 2024 |
2024 |
| Rearrangements involving 11q23.3/ KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study |
Leukemia 38 (9), 1929-1937 , 2024 |
2024 |
| Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma |
Blood 143 (7), 597-603 , 2024 |
2024 |
| Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance |
Journal of Clinical Oncology 42 (27), 3247-3256 , 2024 |
2024 |
| The mechanoreceptor PIEZO1 is a novel oncogene in glioma by promoting astrocyte reactivity |
bioRxiv, 2024.04. 30.591858 , 2024 |
2024 |
| Author Correction: Detection of kinase domain mutations in BCR:: ABL1 leukemia by ultra-deep sequencing of genomic DNA |
Scientific Reports 14 (1), 7400 , 2024 |
2024 |
| Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial |
Leukemia 38 (8), 1722-1730 , 2024 |
2024 |
| MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) |
Clinical Lymphoma Myeloma and Leukemia 24, S548 , 2024 |
2024 |
| OA-05 Assessing the Effect of Previous Antibiotic Usage on Bispecific Monoclonal Antibody Therapy in Multiple Myeloma Patients |
Clinical Lymphoma Myeloma and Leukemia 24, S3-S4 , 2024 |
2024 |
| Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk |
Hematology, Transfusion and Cell Therapy 46, S533-S534 , 2024 |
2024 |
| Cardiopulmonary Complications after Pulmonary Embolism in COVID-19 |
International Journal of Molecular Sciences 25 (13), 7270 , 2024 |
2024 |
| Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience |
Cancers 16 (18), 3149 , 2024 |
2024 |
| Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up |
Transplantation and Cellular Therapy, Official Publication of the American … , 2024 |
2024 |
| MM-549 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis |
Clinical Lymphoma Myeloma and Leukemia 24, S569-S570 , 2024 |
2024 |
| Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma |
Advances in therapy 41 (2), 696-715 , 2024 |
2024 |
| P-165 Advanced circulating tumor DNA (ctDNA) Profiling: Enhancing Non-Invasive Detection and Characterization of Measurable Residual Disease (MRD) in Multiple Myeloma (MM) |
Clinical Lymphoma Myeloma and Leukemia 24, S134 , 2024 |
2024 |
| Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma |
HemaSphere 8 (7), e110 , 2024 |
2024 |
| Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease … |
Haematologica 109 (6), 1909 , 2024 |
2024 |
| OA-02 Multiplex CRISPR/Cas9 Genome Editing of Cord Blood-derived CAR NK Cells to Improve Their Persistence and Antitumoral Potential Against Multiple Myeloma |
Clinical Lymphoma Myeloma and Leukemia 24, S1-S2 , 2024 |
2024 |
| Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges |
Frontiers in Immunology 15, 1252258 , 2024 |
2024 |
| Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma |
Journal of Clinical Oncology, JCO. 24.00635 , 2024 |
2024 |
| Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM … |
Ferrata Storti Foundation , 2024 |
2024 |
| Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. |
Journal of Clinical Oncology 42 (16_suppl), 7504-7504 , 2024 |
2024 |
| P-199 Artificial Intelligence System To Predict t (11, 14) Status in Multiple Myeloma Patients by Leveraging the Correlation of Plasma Cell Morphology and Genetics |
Clinical Lymphoma Myeloma and Leukemia 24, S152-S153 , 2024 |
2024 |
| P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma |
Clinical Lymphoma Myeloma and Leukemia 24, S80 , 2024 |
2024 |
| P-084 Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1 |
Clinical lymphoma, myeloma and leukemia 24, S90-S91 , 2024 |
2024 |
| LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES |
Hematology, Transfusion and Cell Therapy 46, S515 , 2024 |
2024 |
| P-082 Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functionally High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis |
Clinical Lymphoma Myeloma and Leukemia 24, S89 , 2024 |
2024 |
| Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia |
Blood Neoplasia 1 (3), 100027 , 2024 |
2024 |
| Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease |
Annals of Hematology, 1-11 , 2024 |
2024 |
| Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or … |
Cancer research (Chicago, Ill.) 84 (7_Supplement), CT001-CT001 , 2024 |
2024 |
| Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma |
New England Journal of Medicine 390 (4), 301-313 , 2024 |
2024 |
| COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant |
Cancers 16 (2), 379 , 2024 |
2024 |
| European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission |
Journal of Clinical Oncology 42 (16), 1875-1880 , 2024 |
2024 |
| Use of CT for Diagnosis and Characterization of Subchondral Bone Lesions of the Metacarpo/Metatarsophalangeal Joints in Horses: 65 Cases (2021–2023) |
Veterinary and Comparative Orthopaedics and Traumatology 37 (05), A005 , 2024 |
2024 |
| Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry |
Haematologica 109 (8), 2682 , 2024 |
2024 |
| Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update |
Blood 143 (17), 1713-1725 , 2024 |
2024 |
| PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma |
Leukemia, 1-5 , 2024 |
2024 |
| Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real‐world setting |
HemaSphere 8 (7), e81 , 2024 |
2024 |
| Use of Computed Tomography for Diagnosis and Management of Lumbar Spine Stress Fractures in Two Quarter Horse Racehorses |
Veterinary and Comparative Orthopaedics and Traumatology 37 (05), A023 , 2024 |
2024 |
| Detection of kinase domain mutations in BCR:: ABL1 leukemia by ultra-deep sequencing of genomic DNA (vol 12, 13057, 2022) |
SCIENTIFIC REPORTS 14 (1) , 2024 |
2024 |
| Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) |
Clinical Lymphoma, Myeloma and Leukemia 24, S235 , 2024 |
2024 |
| ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior … |
Clinical Lymphoma Myeloma and Leukemia 24, S473 , 2024 |
2024 |
| Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up |
Clinical Lymphoma Myeloma and Leukemia 24, S222 , 2024 |
2024 |
| The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression |
Blood cancer journal 14 (1), 74 , 2024 |
2024 |
| Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma |
Clinical Cancer Research 30 (10), 2085-2096 , 2024 |
2024 |
| Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory … |
The Lancet Oncology , 2024 |
2024 |
| OA-64 Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label … |
Clinical Lymphoma Myeloma and Leukemia 24, S289-S290 , 2024 |
2024 |
| Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma |
Clinical Cancer Research 30 (4), 904-917 , 2024 |
2024 |
| P-427 Real-world Prevalence and Multi-omic Analysis of t (11; 14)-Positive Multiple Myeloma: Final Analysis from the MEDICI Study |
Clinical Lymphoma Myeloma and Leukemia 24, S291-S292 , 2024 |
2024 |
| Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM). |
Journal of Clinical Oncology 42 (16_suppl), 7539-7539 , 2024 |
2024 |
| Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence |
Blood Cancer Journal 14 (1), 131 , 2024 |
2024 |
| P-034 Real world Experience of Talquetamab in Relapsed Refractory Myeloma, First Report From the IMWG Consortium |
Clinical Lymphoma Myeloma and Leukemia 24, S60-S61 , 2024 |
2024 |
| 825P Ultra-sensitive cfDNA analysis for minimally invasive measurable residual disease detection and profiling in multiple myeloma |
Annals of Oncology 35, S606 , 2024 |
2024 |
| Cancer-Stem-Cell Phenotype-Guided Discovery of a Microbiota-Inspired Synthetic Compound Targeting NPM1 for Leukemia |
JACS Au , 2024 |
2024 |
| Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results |
HemaSphere 8 (4) , 2024 |
2024 |
| Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study |
HemaSphere 8 (7) , 2024 |
2024 |
| Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for … |
Leukemia 38 (9), 1985-1991 , 2024 |
2024 |
| A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis |
Cancers 16 (9), 1689 , 2024 |
2024 |
| 1176P Potential utility of ctDNA to detect false positive PET/CT in the evaluation of lymphoma response |
Annals of Oncology 35, S763 , 2024 |
2024 |
| Correction to: Detection of kinase domain mutations in BCR:: ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports,(2022), 12, 1,(13057), 10.1038/s41598-022 … |
Scientific reports 14 (1), 7400 , 2024 |
2024 |
| Osmotic Stress Influences Microtubule Drug Response Via WNK1 Kinase Signaling |
bioRxiv, 2024.07. 08.602030 , 2024 |
2024 |
| Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses |
Haematologica 109 (1), 272 , 2024 |
2024 |
| Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo |
Science translational medicine 16 (734), eadg7962 , 2024 |
2024 |
| Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma |
Blood Journal, blood. 2024024995 , 2024 |
2024 |
| Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple … |
American Journal Of Hematology 98, S25-S26 , 2023 |
2023 |
| Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease |
US Patent 11,781,189 , 2023 |
2023 |
| Hnrnpk Overexpression Drives Nucleolar Aberrancies Causing Ribosomopathies |
Blood 142, 5659 , 2023 |
2023 |
| Glofitamab monotherapy in relapsed or refractory large B-Cell lymphoma: extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric … |
Blood 142, 433 , 2023 |
2023 |
| POSTER: CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R … |
Clinical Lymphoma Myeloma and Leukemia 23, S233 , 2023 |
2023 |
| Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE |
Frontiers in Pharmacology 14, 1206893 , 2023 |
2023 |
| A machine learning tool for the diagnosis of SARS‐CoV‐2 infection from hemogram parameters |
Journal of Cellular and Molecular Medicine 27 (22), 3423-3430 , 2023 |
2023 |
| Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach |
Diagnostics 13 (6), 1071 , 2023 |
2023 |
| Laboratories can reliably detect clinically relevant variants in the TP53 gene below 10% allelic frequency: a multicenter study of ERIC, the European Research Initiative on CLL |
Blood 142 (Supplement 1), 200-200 , 2023 |
2023 |
| Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial |
Blood 142, 1795 , 2023 |
2023 |
| Impact of IPSS-M implementation in real-life clinical practice |
Frontiers in Oncology 13, 1199023 , 2023 |
2023 |
| S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY … |
HemaSphere 7, e1309654 , 2023 |
2023 |
| Mm-372 a Phase Iii, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (Mezivd) Versus Pomalidomide, Bortezomib, and Dexamethasone (Pvd) in Relapsed … |
Clinical Lymphoma Myeloma and Leukemia 23, S495-S496 , 2023 |
2023 |
| Polymorphisms within autophagy-related genes as susceptibility biomarkers for multiple myeloma: a meta-analysis of three large cohorts and functional characterization |
International journal of molecular sciences 24 (10), 8500 , 2023 |
2023 |
| Molecular landscape and validation of new genomic classification in 2668 adult AML patients: real life data from the PETHEMA registry |
Cancers 15 (2), 438 , 2023 |
2023 |
| Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease |
Cancers 15 (16), 4022 , 2023 |
2023 |
| Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant |
Blood 142, 6781 , 2023 |
2023 |
| Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and … |
Blood 142, 4 , 2023 |
2023 |
| Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study … |
Blood 142, 2854 , 2023 |
2023 |
| Pulmonary Thrombosis in Patients With COVID-19 Pneumonia. Is It Really a True Pulmonary Thromboembolism? |
|
2023 |
| Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring. |
Journal of Clinical Oncology 41 (16_suppl), 8028-8028 , 2023 |
2023 |
| GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and … |
Blood 142, 209 , 2023 |
2023 |
| Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma |
Blood 142 (18), 1518-1528 , 2023 |
2023 |
| A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema … |
Blood 142, 2960 , 2023 |
2023 |
| Phase 1b study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients. |
Wolters Kluwer Health , 2023 |
2023 |
| P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) |
HemaSphere 7 (S3), e62475d0 , 2023 |
2023 |
| Biological and clinical significance of undetectable circulating tumor cells (CTCs) in patients (pts) with multiple myeloma (MM) |
Blood 142, 646 , 2023 |
2023 |
| S132: UPDATED RESULTS OF VEN‐A‐QUI STUDY: A PHASE 1‐2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW‐DOSE … |
HemaSphere 7, e8385270 , 2023 |
2023 |
| Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma |
Journal of Thrombosis and Thrombolysis 55 (3), 464-473 , 2023 |
2023 |
| Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma |
Communications Biology 6 (1), 1299 , 2023 |
2023 |
| MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial |
Clinical Lymphoma Myeloma and Leukemia 23, S492-S493 , 2023 |
2023 |
| Large-scale real-life analysis of survival and usage of therapies in multiple myeloma |
Journal of hematology & oncology 16 (1), 76 , 2023 |
2023 |
| Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates |
Clinical and Translational Medicine 13 (9), e1329 , 2023 |
2023 |
| Long-term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) With Relapsed/Refractory (r/r) Follicular Lymphoma (FL) Treated With Tisagenlecleucel in the … |
ONCOLOGY RESEARCH AND TREATMENT 46, 306-308 , 2023 |
2023 |
| NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells |
Frontiers in immunology 14, 1187665 , 2023 |
2023 |
| Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated … |
Blood 142, 645 , 2023 |
2023 |
| AL amyloidosis and multiple myeloma: A complex scenario in which cardiac involvement remains the key prognostic factor |
Life 13 (7), 1518 , 2023 |
2023 |
| P-463 Patient characteristics and burden in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey |
Clinical Lymphoma Myeloma and Leukemia 23, S294-S295 , 2023 |
2023 |
| Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia |
British Journal of Haematology 201 (6), 1239-1244 , 2023 |
2023 |
| P913: LOW-DOSE BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH NIROGACESTAT VS BELAMAF MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1/2 … |
HemaSphere 7 (S3), e9722122 , 2023 |
2023 |
| A contact line force model for the simulation of drop impacts on solid surfaces using volume of fluid methods |
Computers & Fluids 263, 105946 , 2023 |
2023 |
| P840: ASSESSMENT OF CONVENTIONAL TRANSLOCATIONS AND IG REARRANGEMENTS IN THE DIAGNOSIS OF MULTIPLE MYELOMA PATIENTS USING A TARGETED CAPTURE-HYBRIDIZATION RNA SEQUENCING PANEL. |
HemaSphere 7 (S3), e20966e6 , 2023 |
2023 |
| Long-term efficacy and safety of elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM) |
Blood 142, 3385 , 2023 |
2023 |
| Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML) |
Blood 142, 1571 , 2023 |
2023 |
| Assessment of Artificial Intelligence Language Models and Information Retrieval Strategies for QA in Hematology |
Blood 142, 7175 , 2023 |
2023 |
| Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15 |
Blood Advances 7 (1), 9-19 , 2023 |
2023 |
| 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13-17 June, 2023 |
Hematological oncology 41, 449-451 , 2023 |
2023 |
| Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF IPSS-M IMPLEMENTATION IN REAL-LIFE CLINICAL PRACTICE |
Leukemia Research 128, 107235 , 2023 |
2023 |
| The nucleolar aberrancies that drive ribosome impairment induced by RNA binding proteins are hallmarks of aging |
bioRxiv, 2023.03. 07.531270 , 2023 |
2023 |
| MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) |
Clinical Lymphoma Myeloma and Leukemia 23, S506-S507 , 2023 |
2023 |
| THE ROLE OF CHEST RADIOGRAPHY IN THE EVALUATION OF FIRST FEBRILE NEUTROPENIA IN PATIENTS UNDERGOING HSCT |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 438-438 , 2023 |
2023 |
| P-062 Real-world evidence of bisphosphonates and denosumab for multiple myeloma |
Clinical Lymphoma Myeloma and Leukemia 23, S69 , 2023 |
2023 |
| Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia |
Leukemia 37 (8), 1649-1659 , 2023 |
2023 |
| # 2634 ROLE OF LIGHT CHAIN CLEARANCE IN THE RECOVERY OF RENAL FUNCTION IN MULTIPLE MYELOMA: ANOTHER POINT OF VIEW |
Nephrology Dialysis Transplantation 38 (Supplement_1), gfad063c_2634 , 2023 |
2023 |
| P-033 Real world evaluation of teclistamab in patients with RRMM: results from the IMF immunotherapy database project |
Clinical Lymphoma Myeloma and Leukemia 23, S52 , 2023 |
2023 |
| POSTER: MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in … |
Clinical Lymphoma Myeloma and Leukemia 23, S228 , 2023 |
2023 |
| COVID-19 severity and survival over time in patients with hematologic malignancies: a population-based registry study |
Cancers 15 (5), 1497 , 2023 |
2023 |
| P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM … |
HemaSphere 7 (S3), e7140563 , 2023 |
2023 |
| MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly … |
Clinical Lymphoma Myeloma and Leukemia 23, S493-S494 , 2023 |
2023 |
| Phase 1b study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients |
HemaSphere 7 (2), e829 , 2023 |
2023 |
| POSTER: MM-527 Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) |
Clinical Lymphoma Myeloma and Leukemia 23, S222 , 2023 |
2023 |
| PB0990 Changes in Thrombin Generation Parameters in Newly Diagnosed Multiple Myeloma Patients in Response to Anti-Myeloma Therapy |
Research and Practice in Thrombosis and Haemostasis 7 , 2023 |
2023 |
| Longitudinal Screening of Mutant Hematopoietic Progenitor Cells (HPC) in Multiple Myeloma (MM) and Its Association with Secondary Primary Malignancies (SPM) |
Blood 142, 533 , 2023 |
2023 |
| P-211 Antiviral treatment improves outcome for individuals with multiple myeloma and other monoclonal gammopathies associated with Hepatitis B or C viruses |
Clinical Lymphoma Myeloma and Leukemia 23, S151-S152 , 2023 |
2023 |
| MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA)× CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) |
Clinical Lymphoma Myeloma and Leukemia 23, S477-S478 , 2023 |
2023 |
| A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk |
International journal of cancer 152 (2), 239-248 , 2023 |
2023 |
| INCIDENCE OF GRAFT FAILURE AND DELAYED ENGRAFTMENT AFTER ASCT IN SPANISH HOSPITAL: SUCCESSFUL OUTCOME WITH THE USE OF CYCLOSPORINE |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 529-529 , 2023 |
2023 |
| Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/Refractory Multiple Myeloma |
Blood 142 (Supplement 1), 3323-3323 , 2023 |
2023 |
| Global real-life analysis of survival and usage of therapies in multiple myeloma |
|
2023 |
| PET interim results could promptly select Follicular Lymphoma patients in need of maintenance therapy. Potential additional value of ctDNA. |
Hematological Oncology 41 , 2023 |
2023 |
| Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for … |
Blood 142, 3130 , 2023 |
2023 |
| Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper |
Revista Española de Quimioterapia 36 (1), 1 , 2023 |
2023 |
| Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t‐cell therapy in non‐Hodgkin B cell lymphoma. |
Hematological Oncology 41 , 2023 |
2023 |
| TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES |
Hematology, Transfusion and Cell Therapy 45, S397-S398 , 2023 |
2023 |
| Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients-Results from the Harmony Platform |
Blood 142, 62 , 2023 |
2023 |
| Identification of Immunoglobulin Gene Rearrangement Biomarkers in Multiple Myeloma through cfDNA-Based Liquid Biopsy Using tchDNA-Seq |
Cancers 15 (11), 2911 , 2023 |
2023 |
| Personalized Monitoring of Circulating Tumor DNA By a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor t-Cell Therapy in Non-Hodgkin B Cell Lymphoma |
Blood 142, 6087 , 2023 |
2023 |
| POSTER: AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML) |
Clinical Lymphoma Myeloma and Leukemia 23, S163 , 2023 |
2023 |
| P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL … |
HemaSphere 7 (S3), e2371389 , 2023 |
2023 |
| Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT |
Leukemia 37 (3), 659-669 , 2023 |
2023 |
| Patterns of response to 200 mg linvoseltamab in patients with relapsed/refractory multiple myeloma: longer follow-up of the linker-MM1 study |
Blood 142, 4746 , 2023 |
2023 |
| Outcome of second primary malignancies developing in multiple myeloma patients |
Cancers 15 (17), 4359 , 2023 |
2023 |
| P1129: Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study |
HemaSphere 7 (S3), e458981a , 2023 |
2023 |
| Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure |
Life 13 (9), 1841 , 2023 |
2023 |
| Prognostic factors for cellular therapies‐CART and allogeneic SCT‐in relapsed/refractory large B cell lymphoma (LBCL). |
Hematological Oncology 41 , 2023 |
2023 |
| Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT |
Bone Marrow Transplantation 58 (4), 424-429 , 2023 |
2023 |
| POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple … |
Clinical Lymphoma Myeloma and Leukemia 23, S224 , 2023 |
2023 |
| Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance |
Nature communications 14 (1), 5825 , 2023 |
2023 |
| POLYMORPHISMS WITHIN AUTOPHAGY-RELATED GENES AS SUSCEPTIBILITY BIOMARKERS FOR MULTIPLE MYELOMA: A META-ANALYSIS OF THREE LARGE COHORTS |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 480-481 , 2023 |
2023 |
| P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES |
HemaSphere 7 (S3), e404615e , 2023 |
2023 |
| S179: HNRNPK OVEREXPRESSION DRIVES NUCLEOLAR ABERRANCIES CAUSING RIBOSOMPATHIES |
HemaSphere 7, e8819188 , 2023 |
2023 |
| POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and … |
Clinical lymphoma, myeloma and leukemia 23 (Suppl. 1), S225-S225 , 2023 |
2023 |
| Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group |
Blood Cancer Journal 13 (1), 77 , 2023 |
2023 |
| GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY. |
Hematological Oncology 41 , 2023 |
2023 |
| Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular … |
Corrigendum: Personalized monitoring of circulating tumor DNA with a … , 2023 |
2023 |
| Regulation of miRNA expression by α4β1 integrin‐dependent multiple myeloma cell adhesion |
EJHaem 4 (3), 631-638 , 2023 |
2023 |
| P-247 Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study |
Clinical Lymphoma Myeloma and Leukemia 23, S172 , 2023 |
2023 |
| P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA |
HemaSphere 7 (S3), e77404fb , 2023 |
2023 |
| POSTER: MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial |
Clinical Lymphoma Myeloma and Leukemia 23, S226 , 2023 |
2023 |
| CT-564 ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) |
Clinical Lymphoma Myeloma and Leukemia 23, S534-S535 , 2023 |
2023 |
| 30-Minute Infusion of Isatuximab in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Results of a Phase 1b Study |
Blood 142, 6717 , 2023 |
2023 |
| PB1779: FLT3-ITD MUTATION CHARACTERIZATION WITH CLASSICAL PCR METHODOLOGY VERSUS CAPTURE-AND AMPLICON-BASED NGS PLATFORMS: A PETHEMA NGS-AML PROJECT |
HemaSphere 7 (S3), e93539a0 , 2023 |
2023 |
| PB2681: GAPS IN THE ASSESSMENT AND MONITORING OF CARDIOVASCULAR RISK AND PSYCHOLOGICAL BURDEN IN POLYCYTHEMIA VERA: LANDMARK 2.0: A WORLDWIDE HEALTH SURVEY |
HemaSphere 7 (S3), e1488093 , 2023 |
2023 |
| PB1781: THE APPLICATION OF CF-DNA FOR NGS MRD STUDIES IN PATIENTS WITH LMA IMPROVES THE SENSITIVITY OF THE METHOD WITH RESPECT TO CTC. |
HemaSphere 7 (S3), e64045e0 , 2023 |
2023 |
| Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling |
Haematologica 109 (3), 877 , 2023 |
2023 |
| ARI0002h (Cesnicabtagene Autoleucel), an Academic Point-of-Care B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Strategy: Activity and Safety … |
Blood 142, 1026 , 2023 |
2023 |
| Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia |
Blood 142, 3163 , 2023 |
2023 |
| Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients |
Blood 142, 4405 , 2023 |
2023 |
| VARIATION IN EASIX SCORE AS A PREDICTOR OF SINUSOIDAL OBSTRUCTION SYNDROME AND OVERALL SURVIVAL |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 518-518 , 2023 |
2023 |
| OA-20 Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial |
Clinical Lymphoma Myeloma and Leukemia 23, S12-S13 , 2023 |
2023 |
| Cilta-cel or standard care in lenalidomide-refractory multiple myeloma |
New England Journal of Medicine 389 (4), 335-347 , 2023 |
2023 |
| P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA. |
HemaSphere 7 (S3), e8080195 , 2023 |
2023 |
| Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard … |
Journal of Clinical Oncology 41 (16_suppl), 7526-7526 , 2023 |
2023 |
| A comparative study of two open-source state-of-the-art geometric VOF methods |
Computers & Fluids 250, 105725 , 2023 |
2023 |
| Identification of novel genetic loci for risk of multiple myeloma by functional annotation |
Leukemia 37 (11), 2326-2329 , 2023 |
2023 |
| TRANSFERRING AUTOLOGOUS STEM CELL TRANSPLANTATION PATIENTS ON DAY AFTER INFUSION: A FEASIBLE PROCEDURE AND A RELIEF FOR TRANSPLANTATION CENTERS |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 690-691 , 2023 |
2023 |
| P-473 Real-world evidence of statins and oral antidiabetics for multiple myeloma |
Clinical Lymphoma Myeloma and Leukemia 23, S300 , 2023 |
2023 |
| AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML) |
Clinical Lymphoma Myeloma and Leukemia 23, S301 , 2023 |
2023 |
| Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study |
EJHaem 4 (2), 401-409 , 2023 |
2023 |
| S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL TO ASSESS THE SAFETY AND EFFICACY OF TRIPLETS FOR NEWLY DIAGNOSED UNFIT AML PATIENTS: AZACITIDINE OR LOW-DOSE … |
HemaSphere 7 (S3), e8385270 , 2023 |
2023 |
| OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1–3 prior lines of therapy |
Clinical Lymphoma Myeloma and Leukemia 23, S29-S30 , 2023 |
2023 |
| Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM) |
Blood 142, 339 , 2023 |
2023 |
| DataSheet_1_NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells. pdf [Dataset] |
Frontiers Media , 2023 |
2023 |
| Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular … |
Frontiers in immunology 14, 1243241 , 2023 |
2023 |
| OA-12 Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients |
Clinical Lymphoma Myeloma and Leukemia 23, S7-S8 , 2023 |
2023 |
| Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 |
Haematologica 108 (1), 34 , 2023 |
2023 |
| OA-02 α-NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells |
Clinical Lymphoma Myeloma and Leukemia 23, S1-S2 , 2023 |
2023 |
| Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study |
HemaSphere 7 (9), e942 , 2023 |
2023 |
| Differential CD38 Expression on Daratumumab-Naïve Vs. Resistant Multiple Myeloma-a Direct Stochastic Optical Reconstruction Microscopy (dSTORM) Analysis in 53 Patients |
Blood 142 (Supplement 1), 1992-1992 , 2023 |
2023 |
| Mechanosensitive ion channels: their physiological importance and potential key role in cancer |
International Journal of Molecular Sciences 24 (18), 13710 , 2023 |
2023 |
| OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial |
Clinical lymphoma, myeloma and leukemia 23 (Suppl. 2), S28 , 2023 |
2023 |
| Preliminary results from phase 2 of CC-92480-MM-001: Mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) |
BRITISH JOURNAL OF HAEMATOLOGY 201, 66-67 , 2023 |
2023 |
| Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital |
Blood 142, 4490 , 2023 |
2023 |
| Radiomics analysis of bone marrow biopsy locations in [ 18 F]FDG PET/CT images for measurable residual disease assessment in multiple myeloma |
Physical and Engineering Sciences in Medicine 46 (2), 903-913 , 2023 |
2023 |
| EARLY MEMORY-ENRICHED ALLOGENEIC CAR-T CELLS TARGETING NKG2D LIGANDS: A FURTHER STEP TOWARDS UNIVERSAL CANCER IMMUNOTHERAPY |
HUMAN GENE THERAPY 34 (21-22), A29-A29 , 2023 |
2023 |
| P878: SELINEXOR IN COMBINATION WITH DARATUMUMAB-BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF RELAPSE OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF THE PHASE 2 … |
HemaSphere 7 (S3), e954902c , 2023 |
2023 |
| Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view |
Clinical Kidney Journal 16 (6), 1014-1021 , 2023 |
2023 |
| CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies |
Blood 142, 6567 , 2023 |
2023 |
| Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma |
Cancers 15 (2), 532 , 2023 |
2023 |
| LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING MONITORING IMPROVES EARLY RELAPSE DETECTION AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN FOLLICULAR LYMPHOMA PATIENTS |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 447-447 , 2023 |
2023 |
| Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe |
Future Oncology 19 (31), 2103-2121 , 2023 |
2023 |
| Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study. |
Journal of Clinical Oncology 41 (16_suppl), 7550-7550 , 2023 |
2023 |
| Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly … |
Journal of Clinical Oncology 41 (16_suppl), 8039-8039 , 2023 |
2023 |
| S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY |
HemaSphere 7 (S3), e16745e9 , 2023 |
2023 |
| Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma |
New England Journal of Medicine 389 (11), 1009-1022 , 2023 |
2023 |
| Definition and clinical significance of the monoclonal gammopathy of undetermined significance–like phenotype in patients with monoclonal gammopathies |
Journal of Clinical Oncology 41 (16), 3019-3031 , 2023 |
2023 |
| Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma: cohort a of magnetisMM-3 |
|
2023 |
| COMPREHENSIVE MANAGEMENT SYSTEM FOR THE IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) IN THE CLINICAL PRACTICE IN MADRID AND ITS RESULTS |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 681-682 , 2023 |
2023 |
| P832: PROSPECTIVE REAL-WORLD EVALUATION OF THE PREVALENCE OF T (11; 14) IN MULTIPLE MYELOMA: THIRD INTERIM ANALYSIS FROM THE MEDICI STUDY |
HemaSphere 7 (S3), e9381810 , 2023 |
2023 |
| Glofitamab (Glofit) plus R-CHOP has a favorable safety profile and induces high response rates in patients with previously untreated (1L) large B-cell lymphoma (LBCL) defined … |
Blood 142, 858 , 2023 |
2023 |
| Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM) |
Blood 142, 871 , 2023 |
2023 |
| Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY |
Leukemia 37 (2), 339-347 , 2023 |
2023 |
| P-293 Real-world treatment patterns and outcomes in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey |
Clinical Lymphoma Myeloma and Leukemia 23, S198-S199 , 2023 |
2023 |
| P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA |
HemaSphere 7 (S3), e473480a , 2023 |
2023 |
| S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY |
HemaSphere 7, e0972454 , 2023 |
2023 |
| S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL |
HemaSphere 7, e230884b , 2023 |
2023 |
| P846: GENERATION OF A FIRST-IN-CLASS INHIBITOR FOR THE MASTER ONCOREGULATOR HNRNP K IN HAEMATOLOGICAL MALIGNANCIES |
HemaSphere 7 (S3), e16620e5 , 2023 |
2023 |
| Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia |
Blood Advances 7 (1), 167-173 , 2023 |
2023 |
| P1100: PET INTERIM RESULTS COULD PROMPTLY SELECT FOLLICULAR LYMPHOMA PATIENTS IN NEED OF MAINTENANCE THERAPY. POTENTIAL ADDITIONAL VALUE OF CFDNA. |
HemaSphere 7 (S3), e8923396 , 2023 |
2023 |
| Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients |
Frontiers in Immunology 14, 1188818 , 2023 |
2023 |
| P850: THE EFFECT OF UROLITHIN PRODUCTION BY GUT MICROBIOTA IN MULTIPLE MYELOMA |
HemaSphere 7 (S3), e8650867 , 2023 |
2023 |
| P6-3. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Cohort A of MagnetisMM-3 (Encore) |
International Journal of Myeloma 13 (3), 164-164 , 2023 |
2023 |
| HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY |
HemaSphere 7 (S3) , 2023 |
2023 |
| Clinical significance of measurable residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients (Pts) treated with chimeric antigen receptor (CAR) T cells … |
Blood 142, 94 , 2023 |
2023 |
| ACUTE MYELOID LEUKEMIA AND ALLOGENEIC TRANSPLANTATION: SINGLE-CENTER EXPERIENCE |
BONE MARROW TRANSPLANTATION 58 (SUPP 1), 175-175 , 2023 |
2023 |
| Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). |
Journal of Clinical Oncology 41 (16_suppl), 8011-8011 , 2023 |
2023 |
| Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia |
JCI insight 8 (2) , 2023 |
2023 |
| Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for … |
Leukemia 37 (7), 1521-1529 , 2023 |
2023 |
| Single-nucleotide variants and epimutations induce proteasome inhibitor resistance in multiple myeloma |
Clinical Cancer Research 29 (1), 279-288 , 2023 |
2023 |
| MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1 … |
Clinical Lymphoma Myeloma and Leukemia 23, S507-S508 , 2023 |
2023 |
| CNL and aCML should be considered as a single entity based on molecular profiles and outcomes |
Blood Advances 7 (9), 1672-1681 , 2023 |
2023 |
| Real-world outcomes of belantamab mafodotin for relapsed/refractory multiple myeloma (RRMM): preliminary results of a Spanish expanded access program (EAP) |
Oncology and Therapy 11 (1), 83-96 , 2023 |
2023 |
| P-212 The effect of urolithin production by gut microbiota in multiple myeloma |
Clinical Lymphoma Myeloma and Leukemia 23, S152 , 2023 |
2023 |
| Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim … |
Blood 142, 3359 , 2023 |
2023 |
| Clinical outcomes of patients with relapsed/refractory follicular lymphoma treated with tisagenlecleucel: phase 2 Elara 3-year follow-up |
Blood 142, 601 , 2023 |
2023 |
| Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study |
|
2023 |
| Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis |
American Journal of Hematology 98 (1), E15 , 2023 |
2023 |
| Modeling subduction on the kitchen table |
Journal of Structural Geology 166, 104772 , 2023 |
2023 |
| P-367 High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience |
Clinical Lymphoma Myeloma and Leukemia 23, S241-S242 , 2023 |
2023 |
| P-356 Effect of amplification or gain of 1Q21 in patients with multiple myeloma treated with daratumumab |
Clinical Lymphoma Myeloma and Leukemia 23, S235-S236 , 2023 |
2023 |
| Analysis of Peripheral Blood and Bone Marrow Residual Disease Dynamics during Intensive Treatment and Maintenance in Patients with Multiple Myeloma Included in the GEM12MENOS65 … |
Blood 142, 3324 , 2023 |
2023 |
| POSTER: MM-533 Low-Dose Belantamab Mafodotin (Belamaf) in Combination With Nirogacestat Versus Belamaf Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM … |
Clinical Lymphoma Myeloma and Leukemia 23, S224 , 2023 |
2023 |
| Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR:: ABL1-like Acute Lymphoblastic Leukemia |
Blood 142, 1461 , 2023 |
2023 |
| Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease |
Blood 142, 1958 , 2023 |
2023 |
| Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM) |
Blood 142, 3347 , 2023 |
2023 |
| P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED … |
HemaSphere 7 (S3), e5183528 , 2023 |
2023 |
| Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients |
Haematologica 108 (10), 2753 , 2023 |
2023 |
| Intracytoplasmatic BCMA Point Mutation and Teclistamab Resistance: Genomic Assessment of a Multidrug-Resistant Multiple Myeloma Patient |
Blood 142, 1925 , 2023 |
2023 |
| Large Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older Than 65 Years |
Blood 142, 7064 , 2023 |
2023 |
| Method of treatment of disease and method for quantifying the level of minimal residual disease in a subject |
US Patent 11,702,692 , 2023 |
2023 |
| Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results |
Nature medicine 29 (9), 2259-2267 , 2023 |
2023 |
| 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13-17 June, 2023 |
Hematological oncology 41, 322-323 , 2023 |
2023 |
| ANTI-TUMOR POTENTIAL OF NKG2D CAR T CELLS AGAINST PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS |
HUMAN GENE THERAPY 34 (21-22), A10-A10 , 2023 |
2023 |
| Lisocabtagene maraleucel (liso-cel) versus standard of care (SoC) as second-line therapy in large B-cell lymphoma (TRANSFORM study): subgroup analyses by prior therapy response |
Wiley Periodicals, Inc. , 2023 |
2023 |
| Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS |
Blood cancer journal 13 (1), 33 , 2023 |
2023 |
| Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community |
Blood 142, 7248 , 2023 |
2023 |
| Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study |
BMJ open 13 (7), e071371 , 2023 |
2023 |
| Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma |
Future Oncology 19 (12), 811-818 , 2023 |
2023 |
| NOVEL CRISPR/CAS9-BASED ALLOGENEIC CAR-T CELLS TARGETING NKG2D LIGANDS: A POTENTIAL UNIVERSAL CELL THERAPY AGAINST CANCER |
HUMAN GENE THERAPY 33 (7-8), A28-A28 , 2022 |
2022 |
| Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma |
Clinical Cancer Research 28 (21), 4771-4781 , 2022 |
2022 |
| Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow |
Blood 140 (Supplement 1), 2095-2097 , 2022 |
2022 |
| Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the … |
Blood 140 (Supplement 1), 3438-3440 , 2022 |
2022 |
| P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM … |
HemaSphere 6, 811-812 , 2022 |
2022 |
| Infusion of haploidentical NKG2D-CAR-T CD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no … |
Leukemia & Lymphoma 63 (8), 1970-1974 , 2022 |
2022 |
| A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma |
Blood cancer journal 12 (4), 68 , 2022 |
2022 |
| P869: PRODUCTION BY GUT MICROBIOTA AS PROGNOSTIC BIOMARKER IN MM |
HemaSphere 6, 762-763 , 2022 |
2022 |
| Comparative Efficacy and Safety of Tisagenlecleucel (tisa-cel) and Axicabtagene Ciloleucel (axi-cel) in Relapsed/Refractory Follicular Lymphoma (r/r FL) |
2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT … , 2022 |
2022 |
| S130: NPM1 mutated AML: impact of co-mutational patterns-results of the European Harmony Alliance |
HemaSphere 6, 31-32 , 2022 |
2022 |
| P1284: LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS |
HemaSphere 6, 1169-1170 , 2022 |
2022 |
| Cell therapy based on nkg2d-car transduced cytotoxic cells against acute myeloid leukemia |
BONE MARROW TRANSPLANTATION 57 (SUPPL 1), 148-149 , 2022 |
2022 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma |
New England Journal of Medicine 386 (7), 629-639 , 2022 |
2022 |
| Microscopy vs. molecular biology in the diagnosis of intestinal protozoal infections, is it time for a change? |
Revista Espanola de Quimioterapia: Publicacion Oficial de la Sociedad … , 2022 |
2022 |
| P1425: ACTIVATED AND EXPANDED NATURAL KILLER CELLS TRANSDUCED WITH AN NKG2D CHIMERIC ANTIGEN RECEPTOR AGAINST ACUTE MYELOID LEUKEMIA |
HemaSphere 6, 1308-1309 , 2022 |
2022 |
| The minimal residual disease using liquid biopsies in hematological malignancies |
Cancers 14 (5), 1310 , 2022 |
2022 |
| [PRE-RECORD] Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase 2 Elara Study |
2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT … , 2022 |
2022 |
| P863: GENERATION OF A FIRST-IN-CLASS INHIBITOR FOR THE MASTER ONCOREGULATOR HNRNP K IN MULTIPLE MYELOMA |
HemaSphere 6, 756-757 , 2022 |
2022 |
| A Systems Biology-and Machine Learning-Based Study to Unravel Potential Therapeutic Mechanisms of Midostaurin as a Multitarget Therapy on FLT3-Mutated AML |
BioMedInformatics 2 (3), 375-397 , 2022 |
2022 |
| Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network |
Blood Cancer Journal 12 (6), 94 , 2022 |
2022 |
| Factors associated with use of HIV prevention and health care among transgender women—Seven Urban Areas, 2019–2020 |
MMWR. Morbidity and Mortality Weekly Report 71 , 2022 |
2022 |
| Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia |
Blood advances 6 (18), 5395-5402 , 2022 |
2022 |
| P1328: SUCCESFUL TREATMENT OF GRAFT FAILURE IN AUTOLOGOUS STEM CELL TRANSPLANTATION WITH CYCLOSPORINE |
HemaSphere 6, 1213-1214 , 2022 |
2022 |
| FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology |
Blood Advances 6 (2), 690-703 , 2022 |
2022 |
| Digital system augmented by artificial intelligence to interpret bone marrow samples for hematological disease diagnosis |
MedRxiv, 2022.08. 30.22279373 , 2022 |
2022 |
| Usability evaluation of a noninvasive neutropenia screening device (pointcheck) for patients undergoing cancer chemotherapy: mixed methods observational study |
Journal of Medical Internet Research 24 (8), e37368 , 2022 |
2022 |
| Does a multiple myeloma polygenic risk score predict overall survival of myeloma patients? |
Cancer epidemiology, biomarkers & prevention: a publication of the American … , 2022 |
2022 |
| Mezigdomide (CC-92480), a potent, novel cereblon E3 ligase modulator (CELMoD), combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma … |
Blood 140 (Supplement 1), 1366-1368 , 2022 |
2022 |
| Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group |
Blood cancer journal 12 (4), 76 , 2022 |
2022 |
| P1639: UTILITY OF NEXT GENERATION SEQUENCING TECHNIQUES TO EVALUATE POSSIBLE CAUSES OF REFRACTORINESS TO TREATMENT WITH ELTROMBOPAG IN ADULT PATIENTS WITH PRIMARY IMMUNE … |
HemaSphere 6, 1520-1521 , 2022 |
2022 |
| Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: updated safety run-in results from the randomized phase 3 … |
Blood 140 (Supplement 1), 7317-7319 , 2022 |
2022 |
| The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients |
Frontiers in Oncology 12, 1054458 , 2022 |
2022 |
| Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML) |
Blood 140 (Supplement 1), 2270-2272 , 2022 |
2022 |
| Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific … |
Journal of Clinical Oncology 40 (16_suppl), 8033-8033 , 2022 |
2022 |
| A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper |
Clinical and Translational Oncology 24 (6), 968-980 , 2022 |
2022 |
| P-113: infectious toxicities in patients treated with bispecific antibodies in multiple myeloma |
Clinical Lymphoma Myeloma and Leukemia 22, S97-S98 , 2022 |
2022 |
| P845: IDENTIFICATION OF MULTIPLE MYELOMA BIOMARKERS VIA LIQUID BIOPSY BASED ON CELL-FREE DNA USING A CAPTURE-HYBRIDIZATION PANEL |
HemaSphere 6, 739-740 , 2022 |
2022 |
| Updated results from the phase 1/2 MajesTEC-1 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma |
BRITISH JOURNAL OF HAEMATOLOGY 197, 35-36 , 2022 |
2022 |
| Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia |
Medicine International 2 (2), 7 , 2022 |
2022 |
| P-015: Comprehensive comparison of allogenic CAR NK cells for MM treatment |
Clinical Lymphoma Myeloma and Leukemia 22, S44 , 2022 |
2022 |
| Hip Replacement Surgery and Anticoagulation; A Mortality, Transfusion Need and Venous Thromboembolism Rate Analysis with Trinetx |
Blood 140 (Supplement 1), 8540-8541 , 2022 |
2022 |
| Clinical impact of next generation flow in bone marrow vs Qip-Mass Spectrometry in peripheral blood to assess minimal residual disease in newly diagnosed multiple myeloma … |
Blood 140 (Supplement 1), 2098-2100 , 2022 |
2022 |
| Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial |
Nature medicine 28 (2), 325-332 , 2022 |
2022 |
| OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone … |
Clinical Lymphoma Myeloma and Leukemia 22, S24-S25 , 2022 |
2022 |
| Volume-conservative modeling of structures manufactured by molten drop-on-drop deposition |
Materials & Design 221, 110970 , 2022 |
2022 |
| BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final … |
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 22, S24-S25 , 2022 |
2022 |
| OAB-046: Depth of response of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: IKEMA updated analysis |
Clinical Lymphoma Myeloma and Leukemia 22, S28-S29 , 2022 |
2022 |
| P1732: EVALUATION OF A DIGITAL SYSTEM LEVERAGING MOBILE TECHNOLOGY AND ARTIFICIAL INTELLIGENCE FOR DIGITALIZATION, REMOTE ANALYSIS AND SUPPORTED DIFFERENTIAL CELL COUNT OF BONE … |
HemaSphere 6, 1613-1614 , 2022 |
2022 |
| Cryopreservation of Natural Killer cells in droplets |
MicroTAS 2022-26th International Conference on Miniaturized Systems for … , 2022 |
2022 |
| Poster: MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis |
Clinical Lymphoma, Myeloma and Leukemia 22, S178 , 2022 |
2022 |
| Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry |
Leukemia Research 115, 106821 , 2022 |
2022 |
| Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of … |
Blood 140 (Supplement 1), 2101-2103 , 2022 |
2022 |
| Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results … |
Journal of Clinical Oncology 40 (16_suppl), 8007-8007 , 2022 |
2022 |
| P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
HemaSphere 6, 812-813 , 2022 |
2022 |
| P716: outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network |
HemaSphere 6, 611-612 , 2022 |
2022 |
| IMMUNE EFFECTOR CELLS TRANSDUCED WITH AN NKG2D CHIMERIC ANTIGEN RECEPTOR TO TREAT ACUTE MYELOID LEUKEMIA |
HUMAN GENE THERAPY 33 (7-8), A13-A13 , 2022 |
2022 |
| Overcoming tumor resistance mechanisms in CAR-NK cell therapy |
Frontiers in Immunology 13, 953849 , 2022 |
2022 |
| S104: RBPs dysregulation cause hyper-nucleoli and ribosome gain-of-function driving bone marrow failure |
HemaSphere 6, 5-6 , 2022 |
2022 |
| P1430: GUT MICROBIOTA DIVERSITY AND BUTYRATE PRODUCERS IMPACTS ON NON-HODGKIN LYMPHOMA PATIENTS RESPONSE TO CD19 CAR-T THERAPY |
HemaSphere 6, 1313-1314 , 2022 |
2022 |
| Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy |
Blood 140 (Supplement 1), 3514-3515 , 2022 |
2022 |
| gVOF: An open-source package for unsplit geometric volume of fluid methods on arbitrary grids |
Computer Physics Communications 277, 108400 , 2022 |
2022 |
| VOF tests |
VOF tests , 2022 |
2022 |
| DNA Epimutationen als neuer Resistenzmechanismus fur Proteasom Inhibitoren im Multiplen Myelom |
ONCOLOGY RESEARCH AND TREATMENT 45 (SUPPL 2), 306-306 , 2022 |
2022 |
| NGS-based molecular karyotyping of multiple myeloma: results from the GEM12 clinical trial |
Cancers 14 (20), 5169 , 2022 |
2022 |
| Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM) |
Blood 140 (Supplement 1), 246-248 , 2022 |
2022 |
| Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal. Cancers 2022, 14, 5247 |
s Note: MDPI stays neutral with regard to jurisdictional claims in published … , 2022 |
2022 |
| The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates |
Blood 140 (Supplement 1), 10736-10737 , 2022 |
2022 |
| Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration |
Blood 140 (Supplement 1), 6053-6055 , 2022 |
2022 |
| Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications-Results of the Harmony Alliance AML Database |
Blood 140 (Supplement 1), 551-554 , 2022 |
2022 |
| P426: A SINGLE-CENTER RETROSPECTIVE ANALYISIS OF THE MUTATIONAL PROFILE IN ACUTE MYELOID LEUKEMIA PATIENTS |
HemaSphere 6, 326-327 , 2022 |
2022 |
| Belantamab mafodotin in combination with Vrd for the treatment of newly diagnosed transplant eligible multiple myeloma patients: Results from the Phase II, open label … |
Blood 140 (Supplement 1), 7286-7288 , 2022 |
2022 |
| Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma |
Journal of Clinical Oncology 40 (27), 3151-3161 , 2022 |
2022 |
| Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021 |
Blood 140 (Supplement 1), 10965-10966 , 2022 |
2022 |
| COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies |
Blood 140 (Supplement 1), 7924-7925 , 2022 |
2022 |
| Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal … |
Blood 140 (Supplement 1), 2344-2346 , 2022 |
2022 |
| Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3 -ITD Mutation-Positive Acute Myeloid Leukemia |
Cancers 14 (11), 2817 , 2022 |
2022 |
| Bone marrow segmentation and radiomics analysis of [18F] FDG PET/CT images for measurable residual disease assessment in multiple myeloma |
Computer Methods and Programs in Biomedicine 225, 107083 , 2022 |
2022 |
| Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications |
Blood 140 (Supplement 1), 3422-3424 , 2022 |
2022 |
| No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients … |
Disease markers 2022 (1), 3132941 , 2022 |
2022 |
| Does a multiple myeloma polygenic risk score predict overall survival of patients with myeloma? |
Cancer Epidemiology, Biomarkers & Prevention 31 (9), 1863-1866 , 2022 |
2022 |
| Depth of Response of Isatuximab (Isa) plus Carfilzomib (K) and Dexamethasone (d) in Relapsed Multiple Myeloma: IKEMA Updated Analysis |
AMERICAN JOURNAL OF HEMATOLOGY 97, S12-S12 , 2022 |
2022 |
| NKG2D-CAR TCD45RA-CELLS BYPASS THE CANONIC TUMOR IMMUNOESCAPE MECHANISMS |
HUMAN GENE THERAPY 33 (7-8), A14-A14 , 2022 |
2022 |
| P1111: comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel in relapsed/refractory follicular lymphoma |
Hemasphere 6, 1001-1002 , 2022 |
2022 |
| Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study |
The Lancet Haematology 9 (2), e98-e110 , 2022 |
2022 |
| Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort a of … |
Blood 140 (Supplement 1), 391-393 , 2022 |
2022 |
| P1132: PET INTERIM RESULTS PREDICT PROGRESSION-FREE-SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS WITH ADVANCED STAGE |
HemaSphere 6, 1022-1023 , 2022 |
2022 |
| High-throughput CRISPR screening in hematological neoplasms |
Cancers 14 (15), 3612 , 2022 |
2022 |
| P383: USING CF-DNA AS STARTING MATERIAL FOR MRD STUDIES BY NGS IMPROVES THE SENSITIVITY OF THE METHOD AGAINST CTCS. |
HemaSphere 6, 283-284 , 2022 |
2022 |
| Machine learning allows the identification of new Co-mutational patterns with prognostic implications in NPM1 mutated AML-results of the European harmony alliance |
Blood 140 (Supplement 1), 739-742 , 2022 |
2022 |
| Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study |
Multidisciplinary Digital Publishing Institute , 2022 |
2022 |
| P512: Preliminary results of ven-a-qui study: A phase 1-2 trial to assess the safety and efficacy of the combination of azacitidine or low-dose cytarabine with venetoclax and … |
HemaSphere 6, 411-412 , 2022 |
2022 |
| Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19 |
International Journal of Infectious Diseases 117, 56-64 , 2022 |
2022 |
| PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA |
HemaSphere 6, 1962-1963 , 2022 |
2022 |
| Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma |
Blood advances 6 (22), 5835-5843 , 2022 |
2022 |
| MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis |
Clinical Lymphoma Myeloma and Leukemia 22, S411-S412 , 2022 |
2022 |
| A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma |
Clinical Cancer Research 28 (12), 2598-2609 , 2022 |
2022 |
| OAB-050: Randomized phase 2 study of weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple (MM) patients (GEMKyCyDex) |
Clinical Lymphoma Myeloma and Leukemia 22, S30-S31 , 2022 |
2022 |
| Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM |
Blood 140 (Supplement 1), 4226-4227 , 2022 |
2022 |
| Detection of kinase domain mutations in BCR:: ABL1 leukemia by ultra-deep sequencing of genomic DNA |
Scientific reports 12 (1), 13057 , 2022 |
2022 |
| Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML-Results of the European Harmony Alliance |
Blood 140, 739-742 , 2022 |
2022 |
| P928: REAL-LIFE ANALYSIS OF THE MULTIPLE MYELOMA PATIENT’S SURVIVAL IN A LARGE COHORT OF PATIENTS |
HemaSphere 6, 818-819 , 2022 |
2022 |
| Expression of p53 protein isoforms predicts survival in patients with multiple myeloma |
American Journal of Hematology 97 (6), 700-710 , 2022 |
2022 |
| Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey |
Blood 140 (Supplement 1), 12162-12164 , 2022 |
2022 |
| Teclistamab in relapsed or refractory multiple myeloma |
New England Journal of Medicine 387 (6), 495-505 , 2022 |
2022 |
| Efficacy of antiviral treatment in hepatitis C virus (HCV)-driven monoclonal gammopathies including myeloma |
Frontiers in Immunology 12, 797209 , 2022 |
2022 |
| P474: PIEZO1 AND THE THERAPEUTIC POTENTIAL OF MECHANORECEPTORS IN ACUTE MYELOID LEUKAEMIA |
HemaSphere 6, 373-374 , 2022 |
2022 |
| P06: updated results from the phase 1/2 MAJESTEC-1 study of teclistamab, a B-cell maturation antigen X CD3 bispecific antibody, in patients with relapsed/refractory multiple … |
HemaSphere 6, 14 , 2022 |
2022 |
| Liver Toxicity As Dose Limiting Toxicity of Bosutinib in Combination with Atezolizumab in Chronic Myeloid Leukemia. Results from the Phase Ib/II Zerolmc Trial |
Blood 140 (Supplement 1), 12206-12207 , 2022 |
2022 |
| Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study |
Cancers 14 (23), 5799 , 2022 |
2022 |
| Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma |
Blood advances 6 (11), 3234-3239 , 2022 |
2022 |
| Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study) |
Blood 140 (Supplement 1), 9100-9102 , 2022 |
2022 |
| Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase 2 Elara Study |
Transplantation and Cellular Therapy 28 (3), S63-S64 , 2022 |
2022 |
| Long-term clinical outcomes and correlative efficacy analyses in patients (Pts) with Relapsed/Refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the elara … |
Blood 140 (Supplement 1), 1459-1463 , 2022 |
2022 |
| Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients |
Blood 140 (Supplement 1), 4230-4231 , 2022 |
2022 |
| Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP … |
Blood 140 (Supplement 1), 4318-4319 , 2022 |
2022 |
| Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): post-hoc analysis of sustained undetectable measurable residual disease (MRD) |
Blood 140 (Supplement 1), 292-294 , 2022 |
2022 |
| CART Therapy or Allogeneic Stem Cell Transplantation in≥ Third Line Treatment of Large B Cell Lymphoma (LBCL) |
Blood 140 (Supplement 1), 7509-7511 , 2022 |
2022 |
| Monoclonal gammopathies of clinical significance: a critical appraisal |
Cancers 14 (21), 5247 , 2022 |
2022 |
| OAB-035: Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study |
Clinical Lymphoma Myeloma and Leukemia 21, S22-S23 , 2021 |
2021 |
| Impact of Gender on Molecular AML Subclasses-a Harmony Alliance Study |
Blood 138, 3438 , 2021 |
2021 |
| Efficacy of tisagenlecleucel in adult patients (Pts) with high-risk relapsed/refractory follicular lymphoma (r/r FL): subgroup analysis of the phase II Elara study |
Blood 138, 131 , 2021 |
2021 |
| NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma |
Blood Cancer Journal 11 (8), 146 , 2021 |
2021 |
| Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML) |
Blood 138, 520 , 2021 |
2021 |
| A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia |
Cancer 127 (12), 2003-2014 , 2021 |
2021 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial |
The Lancet 397 (10292), 2361-2371 , 2021 |
2021 |
| Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study |
Blood 138, LBA-6 , 2021 |
2021 |
| Harmony alliance provides a machine learning researching tool to predict the risk of relapse after first remission in AML patients treated without allogeneic haematopoietic … |
Blood 138, 4041 , 2021 |
2021 |
| Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma |
Cancers 13 (19), 4924 , 2021 |
2021 |
| Long-Term Human Hematopoietic Stem Cell Culture in Microdroplets. Micromachines 2021, 12, 90 |
s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in … , 2021 |
2021 |
| Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group |
Blood 138, 1302 , 2021 |
2021 |
| A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients |
Annals of Hematology 100 (6), 1497-1508 , 2021 |
2021 |
| ALL-154: t (1; 19)(q23; p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented … |
Clinical Lymphoma Myeloma and Leukemia 21, S270-S271 , 2021 |
2021 |
| IS DARATUMUMAB ELIMINATED IN THE URINE OF PATIENTS WITH AL AMYLOIDOSIS? |
HAEMATOLOGICA 106 (10), 150-150 , 2021 |
2021 |
| Different prognostic impact of recurrent gene mutations in IGHV-mutated and IGHV-unmutated chronic lymphocytic leukemia: a retrospective, multi-center cohort study by Eric, the … |
Blood 138 (Supplement 1), 2617-2617 , 2021 |
2021 |
| Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia |
Leukemia 35 (8), 2358-2370 , 2021 |
2021 |
| Pathogenetic and prognostic implications of increased mitochondrial content in multiple myeloma |
Cancers 13 (13), 3189 , 2021 |
2021 |
| The Spliceosome As a New Therapeutic Target in Cytarabine-Resistant Acute Myeloid Leukemia |
Blood 138, 3334 , 2021 |
2021 |
| Updated results from MajesTEC-1: phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma |
Blood 138, 896 , 2021 |
2021 |
| Potential utility of circulating tumor DNA monitoring in primary mediastinal B-cell lymphoma treated with R-DA-EPOCH |
Blood 138, 4491 , 2021 |
2021 |
| Reversal of vitamin K antagonists with prothrombin complex in patients undergoing liver transplantation: a single-centre experience |
TRANSPLANTATION 105 (8), 13-13 , 2021 |
2021 |
| The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial |
Cancers 13 (10), 2458 , 2021 |
2021 |
| Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survival |
International Journal of Cancer 148 (8), 1887-1894 , 2021 |
2021 |
| Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase … |
British Journal of Haematology 192 (3), 522-530 , 2021 |
2021 |
| Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: Are these times of change |
Blood 138 (19), 1901-1905 , 2021 |
2021 |
| ANALYSIS OF RESIDUAL DISEASE IN PERIPHERAL BLOOD BY MEANS OF MASS SPECTROMETRY IN PATIENTS WITH MULTIPLE MYELOMA OF THE GEM 2012 MINUS65. COMPARISON WITH THE IMWG STANDARD … |
HAEMATOLOGICA 106 (10), 72-73 , 2021 |
2021 |
| Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow … |
Leukemia 35 (12), 3585-3588 , 2021 |
2021 |
| Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world study |
Cancer Medicine 10 (21), 7629-7640 , 2021 |
2021 |
| HEMOLYTIC DISEASE OF THE NEWBORN IN PREGNANT WOMEN WITH COLD ANTIBODIES |
HAEMATOLOGICA 106 (10), 162-162 , 2021 |
2021 |
| The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: an evidence-based approach |
Diagnostics 11 (11), 2020 , 2021 |
2021 |
| Selinexor in combination with daratumumab-bortezomib and dexamethasone for the treatment of relapse or refractory multiple myeloma: Initial results of the phase 2, open-label … |
Blood 138, 1677 , 2021 |
2021 |
| Efficacy And Safety Of Tisagenlecleucel (Tisa‐Cel) In Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (R/R Fl): Primary Analysis Of The Phase 2 Elara Trial |
Wiley Periodicals, Inc. , 2021 |
2021 |
| Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma |
Blood 138, 1631 , 2021 |
2021 |
| FINAL analysis of a PAN European STOP tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study |
Blood 138, 633 , 2021 |
2021 |
| Toward Sézary Syndrome immunotherapy |
The Journal of Immunology 206 (1_Supplement), 67.20-67.20 , 2021 |
2021 |
| A Phase 1 study Of CC-92480, a novel CELMoD agent, in patients with relapsed/refractory multiple myeloma: pharmacodynamic effects of dose and schedule |
BRITISH JOURNAL OF HAEMATOLOGY 193, 152-153 , 2021 |
2021 |
| PREGNANT WOMEN SENSITIZED WITH ANTIBODIES TO NON-RHESUS ANTIGENS D. VALUE OF THE SUM OF ANTI-ERYTHROCYTE ANTIBODIES |
HAEMATOLOGICA 106 (10), 162-162 , 2021 |
2021 |
| Ponatinib and chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of PONALFIL clinical trial |
Blood 138, 1230 , 2021 |
2021 |
| Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): mechanism of egression, clinical significance and therapeutic endpoints |
Blood 138, 76 , 2021 |
2021 |
| Usability and Performance Testing of Pointcheck™: A Noninvasive Neutropenia Screening Device for Chemotherapy Outpatients |
Blood 138, 4924 , 2021 |
2021 |
| P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy |
Clinical Lymphoma Myeloma and Leukemia 21, S42-S43 , 2021 |
2021 |
| Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse |
Haematologica 106 (9), 2325 , 2021 |
2021 |
| Natural killer cells efficiently target multiple myeloma clonogenic tumor cells |
Cancer Immunology, Immunotherapy, 1-14 , 2021 |
2021 |
| INCIDENCE AND SURVIVAL OF MULTIPLE MYELOMA. ANALYSIS OF A 5-YEAR PERIOD OF THE REGISTRY OF TUMORS OF THE COMMUNITY OF MADRID (RTMAD) |
HAEMATOLOGICA 106 (10), 139-139 , 2021 |
2021 |
| OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible … |
Clinical Lymphoma Myeloma and Leukemia 21, S3-S4 , 2021 |
2021 |
| Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia |
medRxiv, 2021.07. 14.21259597 , 2021 |
2021 |
| 126. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection and Vaccination |
Open Forum Infectious Diseases 8 (Supplement_1), S77-S77 , 2021 |
2021 |
| Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid‐19 patients |
International journal of laboratory hematology 43 (4), O152 , 2021 |
2021 |
| P-148: Real-life analysis of the multiple myeloma patient’s survival in a third-level hospital |
Clinical Lymphoma Myeloma and Leukemia 21, S116 , 2021 |
2021 |
| ANALYSIS OF THE INCIDENCE AND SURVIVAL IN THE SHORT AND LONG TERM OF NON-ACUTE LEUKEMIA IN A PERIOD OF 5 YEARS OF THE REGISTRATION OF TUMORS (RTMAD) OF THE COMMUNITY OF MADRID |
HAEMATOLOGICA 106 (10), 224-224 , 2021 |
2021 |
| NEW SCORE PROGNOSIS BASED ON SOMATIC MUTATIONS BY NGS AND THE NUMBER OF BLASTS FOR PREDICTING OVERALL SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROME |
LEUKEMIA RESEARCH 108, S39-S39 , 2021 |
2021 |
| Allogeneic NKG2D-CAR T cells as universal anticancer treatment: new manufacturing strategy based on CRISPR/Cas9 |
HUMAN GENE THERAPY 32 (19-20), A93-A93 , 2021 |
2021 |
| Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci? |
International journal of cancer 148 (7), 1616-1624 , 2021 |
2021 |
| Acute and post-acute COVID-19 severity and mortality in patients with hematologic malignancies: a population-based registry study |
Blood 138 (Supplement 1), 186-186 , 2021 |
2021 |
| Myc-related mitochondrial activity as a novel target for multiple myeloma |
Cancers 13 (7), 1662 , 2021 |
2021 |
| Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project |
haematologica 106 (12), 3079 , 2021 |
2021 |
| Evolving treatment patterns and outcomes in older patients (≥ 60 years) with AML: changing everything to change nothing? |
Leukemia 35 (6), 1571-1585 , 2021 |
2021 |
| Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera |
Scientific Reports 11 (1), 209 , 2021 |
2021 |
| ML TOOL FOR DIAGNOSIS OF SARS-COV2 INFECTION FROM HEMACYTOMETRIC PARAMETERS (QUANTITATIVE AND MORPHOMETRIC) |
HAEMATOLOGICA 106 (10), 13-13 , 2021 |
2021 |
| Early dynamics and depth of response in multiple myeloma patients treated with BCMA CAR-T cells |
Frontiers in Oncology 11, 783703 , 2021 |
2021 |
| Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology |
Leukemia research 108, 106613 , 2021 |
2021 |
| Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis |
Bone marrow transplantation 56 (9), 2160-2172 , 2021 |
2021 |
| Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia |
Therapeutic Advances in Hematology 12, 20406207211039326 , 2021 |
2021 |
| OAB-056: A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM) |
Clinical Lymphoma Myeloma and Leukemia 21, S35 , 2021 |
2021 |
| P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in … |
Clinical Lymphoma Myeloma and Leukemia 21, S109-S110 , 2021 |
2021 |
| A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia |
The Journal of clinical investigation 131 (20) , 2021 |
2021 |
| Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study |
International Journal of Infectious Diseases 105, 319-325 , 2021 |
2021 |
| Tumor cells in light-chain amyloidosis and myeloma show different transcriptional rewiring of normal plasma cell development |
BLOOD , 2021 |
2021 |
| A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple Myeloma (MM) |
Blood 138, 1596 , 2021 |
2021 |
| Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma |
Journal of Hematology & Oncology 14, 1-4 , 2021 |
2021 |
| Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with … |
Blood 138, 1829 , 2021 |
2021 |
| Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients |
International journal of cancer 149 (2), 327-336 , 2021 |
2021 |
| Phase 2 clinical trial of infusing haploidentical K562-mb15-41BBL–activated and expanded natural killer cells as consolidation therapy for pediatric acute myeloblastic leukemia |
Clinical Lymphoma Myeloma and Leukemia 21 (5), 328-337. e1 , 2021 |
2021 |
| CLINICAL CHARACTERISTICS AND EVOLUTION OF PATIENTS WITH MULTIPLE MYELOMA RESISTANT TO ANTI-CD38 TREATMENT |
HAEMATOLOGICA 106 (10), 143-144 , 2021 |
2021 |
| Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change? |
Blood, The Journal of the American Society of Hematology 138 (19), 1901-1905 , 2021 |
2021 |
| P-226: Clinical outcomes of Multiple Myeloma patients after anti-CD38 monoclonal antibodies failure |
Clinical Lymphoma Myeloma and Leukemia 21, S164-S165 , 2021 |
2021 |
| Improving NK cell function in Multiple Myeloma with NKTR-255, a novel polymer-conjugated human IL-15 |
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 21, S40-S41 , 2021 |
2021 |
| Patient‐Reported Quality Of Life (Qol) Following Tisagenlecleucel (Tisa‐Cel) Infusion In Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (R/R Fl) |
Wiley Periodicals, Inc. , 2021 |
2021 |
| Poster: ALL-154: t (1; 19)(q23; p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented … |
Clinical Lymphoma Myeloma and Leukemia 21, S207 , 2021 |
2021 |
| Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial |
Journal of Clinical Oncology 39 (18), 1959-1970 , 2021 |
2021 |
| Long-term human hematopoietic stem cell culture in microdroplets |
Micromachines 12 (1), 90 , 2021 |
2021 |
| ANALYSIS OF INCIDENCE AND SURVIVAL IN ACUTE LEUKEMIAS IN A 5-YEAR PERIOD FROM THE TUMOR REGISTRY (RTMAD) OF THE COMMUNITY OF MADRID |
HAEMATOLOGICA 106 (10), 204-205 , 2021 |
2021 |
| Compassionate use of belantamab mafodotin for treatment of patients with relapsed/refractory multiple myeloma heavily treated. Spanish experience |
Blood 138 (Supplement 1), 3775-3775 , 2021 |
2021 |
| IMMUNOGENETIC AND LONGITUDINAL ANALYSIS OF PERIPHERAL BLOOD TUMOR AND IMMUNE CELLS IN MULTIPLE QUIESCENT MYELOMA: IMMUNOCELL STUDY |
HAEMATOLOGICA 106 (10), 64-64 , 2021 |
2021 |
| PONATINIB AND CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH PHILADELPHIC CHROMOSOME (LAL PH plus). RESULTS OF THE PONALFIL CLINICAL TRIAL WITH MEDIUM 2 … |
HAEMATOLOGICA 106 (10), 94-94 , 2021 |
2021 |
| Prognostic significance of FLT3 -ITD length in AML patients treated with intensive regimens |
Scientific Reports 11 (1), 20745 , 2021 |
2021 |
| Efficacy comparison of tisagenlecleucel versus standard of care in patients with relapsed or refractory follicular lymphoma |
Blood 138, 3528 , 2021 |
2021 |
| IBCL-195: primary analysis of the phase 2 ELARA trial: tisagenlecleucel efficacy and safety in adult patients with relapsed/refractory follicular lymphoma (r/r FL) |
Clinical Lymphoma Myeloma and Leukemia 21, S403-S404 , 2021 |
2021 |
| Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development |
Blood, The Journal of the American Society of Hematology 138 (17), 1583-1589 , 2021 |
2021 |
| Allogeneic Hematopoietic Stem Cell Transplantation for Patients 60 Years Or Older. A Single-Institution Experience |
BONE MARROW TRANSPLANTATION 56 (SUPPL 1), 238-239 , 2021 |
2021 |
| Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial |
Blood Advances 5 (3), 760-770 , 2021 |
2021 |
| Efficient AAV/CRISPR-based genetic engineering strategy for the production of allogeneic NKG2D CAR T cells in a single step process |
HUMAN GENE THERAPY 32 (19-20), A87-A88 , 2021 |
2021 |
| Bite-activated car-t cells |
US Patent App. 16/757,522 , 2021 |
2021 |
| Impact of COVID-19 in patients with multiple myeloma based on a global data network |
Blood cancer journal 11 (12), 198 , 2021 |
2021 |
| A method for determining the efficacy of treatment with a combination of drugs in a subject diagnosed with a disease and a method for classifying the utility of drug … |
US Patent App. 17/284,674 , 2021 |
2021 |
| EXPRESSION OF D CYCLINES IN MULTIPLE MYELOMA AND THEIR IMPACT ON SURVIVAL |
HAEMATOLOGICA 106 (10), 65-66 , 2021 |
2021 |
| Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: NEW SCORE PROGNOSIS BASED ON SOMATIC MUTATIONS BY NGS AND THE NUMBER OF BLASTS FOR PREDICTING … |
Leukemia Research 108, 106681.37 , 2021 |
2021 |
| Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular … |
Blood 138, 128 , 2021 |
2021 |
| Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard-and high-risk myeloma |
Blood, The Journal of the American Society of Hematology 137 (1), 49-60 , 2021 |
2021 |
| Poster: IBCL-195: Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL) |
Clinical Lymphoma Myeloma and Leukemia 21, S245 , 2021 |
2021 |
| IMPACT OF INTESTINAL MICROBIOTA IN PATIENTS WITH NON-HODGKIN LYMPHOMA ON THE RESPONSE TO CAR-T CD19 THERAPY |
HAEMATOLOGICA 106 (10), 63-63 , 2021 |
2021 |
| Definition and clinical significance of the MGUS-like phenotype: a study in 5,114 patients (pts) with monoclonal gammopathies |
Blood 138, 541 , 2021 |
2021 |
| Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study |
International Journal of Infectious Diseases 105, 487-494 , 2021 |
2021 |
| Validation of the IMWG standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change? |
Blood , 2021 |
2021 |
| Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia. |
Clin. lymphoma myeloma leuk.(Online) , 2021 |
2021 |
| Optimizing the procedure to manufacture clinical-grade NK cells for adoptive immunotherapy |
Cancers 13 (3), 577 , 2021 |
2021 |
| Allogeneic stem cell transplantation in mature T cell and natural Killer/T neoplasias: a registry study from Spanish Geth/Geltamo centers |
Transplantation and Cellular Therapy 27 (6), 493. e1-493. e8 , 2021 |
2021 |
| Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the … |
Journal of Clinical Oncology 39 (15_suppl), 8010-8010 , 2021 |
2021 |
| MPL S505C enhances driver mutations at W515 in essential thrombocythemia |
Blood cancer journal 11 (11), 188 , 2021 |
2021 |
| NEW SCORE FORECAST BASED ON THE MOLECULAR STUDY BY NGS AND THE NUMBER OF BLASTES THAT DEFINE THE ASSOCIATED RISK OF DEATH OR PROGRESSION TO ACUTE LEUKEMIA |
HAEMATOLOGICA 106 (10), 246-247 , 2021 |
2021 |
| Genetically determined telomere length and multiple myeloma risk and outcome |
Blood cancer journal 11 (4), 74 , 2021 |
2021 |
| Ixazomib plus lenalidomide/dexamethasone (IRd) versus lenalidomide/dexamethasone (Rd) maintenance after autologous stem cell transplant in patients with newly diagnosed … |
Blood 138, 466 , 2021 |
2021 |
| THE CUTTING AND SPLICING MECHANISM AS A THERAPEUTIC TARGET IN CITARABINE-RESISTANT ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 106 (10), 85-85 , 2021 |
2021 |
| Assessment of treatment response by Ife, next generation flow cytometry and mass spectrometry coupled with liquid chromatography in the GEM2012MENOS65 clinical trial |
Blood 138, 544 , 2021 |
2021 |
| Genetically determined telomere length and multiple myeloma risk and outcome |
Blood Cancer Journal 11 (4) , 2021 |
2021 |
| Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis |
Leukemia 35 (1), 245-249 , 2021 |
2021 |
| CLINICAL RELEVANCE OF SARS-COV-2 VARIANTS IN HEMATOLOGIC PATIENTS IN A TERTIARY LEVEL HOSPITAL DURING THE COVID-19 PANDEMIC |
HAEMATOLOGICA 106 (10), 323-324 , 2021 |
2021 |
| RAS MUTATIONS WORSE THE PROGNOSIS IN PATIENTS WITH AML OF ADVERSE GENETIC RISK: A RETROSPECTIVE STUDY AT A THIRD-LEVEL CENTER |
HAEMATOLOGICA 106 (10), 87-88 , 2021 |
2021 |
| Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group |
Leukemia & Lymphoma 62 (12), 2928-2938 , 2021 |
2021 |
| RESULTS OF TREATMENT WITH BELANTAMAB MAFODOTIN AS COMPASSIONATE USE-EXPANDED ACCESS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS (MMRR) |
HAEMATOLOGICA 106 (10), 142-142 , 2021 |
2021 |
| Triple Combination of Ruxolutinib, Nilotinib and Prednisone Is Safe and Shows Promising Activity for the Treatment of Myelofibrosis Patients, Results of a Phase Ib Clinical … |
Blood 138, 3655 , 2021 |
2021 |
| Polycythemia vera and essential thrombocythemia patients exhibit unique serum metabolic profiles compared to healthy individuals and secondary thrombocytosis patients |
Cancers 13 (3), 482 , 2021 |
2021 |
| Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis. |
Journal of Clinical Oncology 39 (15_suppl), 8034-8034 , 2021 |
2021 |
| Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study |
Journal of medical virology 93 (2), 831-842 , 2021 |
2021 |
| Cereblon enhancer methylation and IMiD resistance in multiple myeloma |
Blood, The Journal of the American Society of Hematology 138 (18), 1721-1726 , 2021 |
2021 |
| Efficacy and safety of Tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: Interim analysis of the phase 2 ELARA trial |
2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR , 2021 |
2021 |
| A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline |
Leukemia 35 (11), 3295-3298 , 2021 |
2021 |
| Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic |
Blood 138, 2719 , 2021 |
2021 |
| The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study |
Leukemia & lymphoma 62 (8), 2040-2043 , 2021 |
2021 |
| The role of tumor microenvironment in multiple myeloma development and progression |
Cancers 13 (2), 217 , 2021 |
2021 |
| Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed … |
Journal of Clinical Oncology 38 (15_suppl), 8529-8529 , 2020 |
2020 |
| Impact of measurable residual disease (MRD) by multiparameter flow cytometry (MFC): a real-world study in 1,076 patients with acute myeloid leukemia (AML) |
Blood 136, 13-15 , 2020 |
2020 |
| Study of the Role of Splicing Factor SRRM2 in Cytarabine Treatment Resistance in Acute Myeloid Leukemia |
Blood 136, 8-9 , 2020 |
2020 |
| Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma |
Blood advances 4 (10), 2163-2171 , 2020 |
2020 |
| Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality |
Blood cancer journal 10 (10), 103 , 2020 |
2020 |
| IMPACT OF THE EXPRESSION OF TP53 ISOFORMS ON THE PROGNOSIS OF MULTIPLE MYELOMA |
HAEMATOLOGICA 105, 7-7 , 2020 |
2020 |
| ALL-257: Unraveling IKZF1 Deletion Therapeutic Vulnerabilities in Adult B-Cell Precursor Acute Lymphoblastic Leukemia |
Clinical Lymphoma Myeloma and Leukemia 20, S167 , 2020 |
2020 |
| Discordances between immunofixation (IFx) and minimal residual disease (MRD) assessment with next-generation flow (NGF) and sequencing (NGS) in patients (Pts) with multiple … |
Blood 136, 5-6 , 2020 |
2020 |
| Differences in the Mutational Landscape of Myeloid Malignancies (acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasm) and Their Clinical Impact |
Blood 136, 41-42 , 2020 |
2020 |
| First-in-human phase I study of ABBV-838, an antibody–drug conjugate targeting SLAMF7/CS1 in patients with relapsed and refractory multiple myeloma |
Clinical Cancer Research 26 (10), 2308-2317 , 2020 |
2020 |
| Daratumumab rapid administration experience |
European journal of clinical pharmacy: atención farmacéutica 22 (2), 84-87 , 2020 |
2020 |
| Microfluidic-assisted engineering of multi-layered microcapsules for 3D stem cell culture |
Microfluidics, BioMEMS, and Medical Microsystems XVIII 11235, 123-131 , 2020 |
2020 |
| Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia increases overall response rates |
Blood 136, 18-19 , 2020 |
2020 |
| Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies and Myeloma |
Available at SSRN 3566136 , 2020 |
2020 |
| ANALYSIS OF THE GENETIC PROFILE IN ASYMPTOMATIC MULTIPLE MYELOMA: MOLECULAR SUB-STUDY OF THE GEM CESAR CLINICAL TRIAL |
HAEMATOLOGICA 105, 28-29 , 2020 |
2020 |
| Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma |
Blood cancer journal 10 (10), 108 , 2020 |
2020 |
| THE CIRCULATING TUMOR CELL FOR A NON-INVASIVE AND MULTI-REGIONAL CHARACTERIZATION OF MULTIPLE MYELOMA |
HAEMATOLOGICA 105, 7-8 , 2020 |
2020 |
| Intravenous Pentamidine for Pneumocystis Jirovecii prophylaxis in Hematological Patients Treated with Chemotherapy, Hematopoietic Stem-cell Transplant (HSCT) and car-t Cell Therapy |
BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 486-487 , 2020 |
2020 |
| Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma |
Blood, The Journal of the American Society of Hematology 136 (2), 199-209 , 2020 |
2020 |
| First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). |
Journal of Clinical Oncology 38 (15_suppl), 8500-8500 , 2020 |
2020 |
| STUDY OF TIGECYCLINE AND ITS EFFECT ON OXIDATIVE PHOSPHOTYLATION, A NEW THERAPEUTIC ALTERNATIVE IN THE TREATMENT OF MULTIPLE MYELOMA |
HAEMATOLOGICA 105, 9-10 , 2020 |
2020 |
| Impacto de la Covid-19 en pacientes adultos con neoplasias hematológicas: informe del registro Covid-19 de la asociación madrileña de hematología y hemoterapia (AMHH) |
Anales de la Real Academia Nacional de Medicina 137 (02), 202 , 2020 |
2020 |
| Clinical-Biological Significance of Dysplastic Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma |
Haematologica 105, 4-4 , 2020 |
2020 |
| Detection of emerging resistant clones in philadelphia-positive leukemia patients exposed to tyrosine kinase inhibitors. Correlation of cDNA and gDNA approaches |
Blood 136, 6-8 , 2020 |
2020 |
| Minimal residual disease monitoring from liquid biopsy by next generation sequencing in follicular lymphoma patients |
Blood 136, 31-33 , 2020 |
2020 |
| Análisis descriptivo del perfil de toxicidad del carfilzomib en pacientes con mieloma múltiple. Experiencia en un centro español de tercer nivel |
Medicina Clínica Práctica 3 (6), 100085 , 2020 |
2020 |
| STUDY OF THE ROLE OF SPLICING FACTOR SRRM2 IN RESISTANCE TO CYTARABINE TREATMENT IN ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 105, 206-206 , 2020 |
2020 |
| Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma |
Leukemia 34 (11), 3007-3018 , 2020 |
2020 |
| Impact of SARS-CoV-2 infection in acute myeloid leukemia patients: experience of the pethema registry |
Blood 136, 7-8 , 2020 |
2020 |
| HNRNPK IS INVOLVED IN ONCOGENESIS AND RESPONSE TO THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 105, 48-49 , 2020 |
2020 |
| Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype |
Scientific reports 10 (1), 5904 , 2020 |
2020 |
| Trends in allogeneic stem cell transplantation for myelofibrosis in Europe between 1995-2018: an EBMT retrospective analysis |
Blood 136, 38-39 , 2020 |
2020 |
| Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS … |
Journal of Clinical Oncology 38 (15_suppl), 8512-8512 , 2020 |
2020 |
| Validation of the High-Risk Prognostic Score Defined By the Presence of Mutations in NRAS or TP53 in a Cohort of 497 Patients with Acute Myeloid Leukemia |
Blood 136, 4-5 , 2020 |
2020 |
| Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial |
Blood 136, 32 , 2020 |
2020 |
| Randomized phase 2 study of weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple myeloma (RRMM) patients (GEM-KyCyDex) |
Blood 136, 8-9 , 2020 |
2020 |
| Upregulated expression and function of the α 4 β 1 integrin in multiple myeloma cells resistant to bortezomib |
The Journal of Pathology 252 (1), 29-40 , 2020 |
2020 |
| Longitudinal immunogenomic profiling of tumor and immune cells for minimally-invasive monitoring of smoldering multiple myeloma (SMM): the Immunocell Study |
Blood 136, 1-2 , 2020 |
2020 |
| Droplet microfluidics for the ex vivo expansion of human primary multiple myeloma cells |
Micromachines 11 (3), 261 , 2020 |
2020 |
| A Machine Learning Approach for the Differential Diagnosis between Sars-COV19 Infection and Influenza Viruses with Hematological Morphologic DATA (CELL MORPHOLOGIC DATA) |
Blood 136, 43 , 2020 |
2020 |
| NATIONAL NETWORK FOR ADVANCED MOLECULAR DIAGNOSIS FOR ACUTE MYELOID LEUKEMIA: PETHEMA NGS-LMA PROJECT |
HAEMATOLOGICA 105, 24-25 , 2020 |
2020 |
| PREANALYTICAL QUALITY IN THE BONE MARROW ASPIRATE. A MULTICENTER REAL-LIFE STUDY |
HAEMATOLOGICA 105, 198-199 , 2020 |
2020 |
| Safety and preliminary efficacy results from a phase Ib/II study of cobimetinib as a single agent and in combination with venetoclax with or without atezolizumab in patients … |
Blood 136, 45-46 , 2020 |
2020 |
| Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance |
Haematologica , 2020 |
2020 |
| Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis |
|
2020 |
| APPLICATION OF A NGS DIAGNOSTIC PANEL TO IMPROVE AND REFINE THE STRATIFICATION OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA B |
HAEMATOLOGICA 105, 26-26 , 2020 |
2020 |
| NKG2D Car Memory T Cells as Therapeutic Approach for Pediatric Non-B Cell Leukemia |
PEDIATRIC BLOOD & CANCER 67, S195-S195 , 2020 |
2020 |
| How to Assess Risk of Progression in Multiple Myeloma Patients Achieving Complete Remission After Autologous Transplant: Sub Analysis from the GEM2012MENOS65 Phase III Clinical … |
BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 128-130 , 2020 |
2020 |
| Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma |
Cancers 12 (11), 3304 , 2020 |
2020 |
| Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity |
British Journal of Haematology 189 (4), 672-683 , 2020 |
2020 |
| Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma (vol 4, pg 3295, 2020) |
BLOOD ADVANCES 4 (18), 4573-4573 , 2020 |
2020 |
| Long-term outcomes and health-related quality of life (HRQoL) by response status for Bortezomib, Melphalan, and Prednisone (VMP)±Daratumumab (DARA) in alcyone |
Blood, The Journal of the American Society of Hematology 136 (Supplement 1 … , 2020 |
2020 |
| Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination |
Leukemia 34 (2), 589-603 , 2020 |
2020 |
| NKG2D Chimeric Antigen receptor-expressing Lymphocytes Target Acute Myeloid Leukemia Cells |
BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 260-261 , 2020 |
2020 |
| Clinical Correlation of a Precision Medicine Test with Treatment Outcome in Acute Myeloid Leukemia Patients |
Blood 136, 1-2 , 2020 |
2020 |
| Dose-and schedule-dependent immunomodulatory effects of the novel celmod agent CC-92480 in patients with relapsed/refractory multiple myeloma |
Blood 136, 47-48 , 2020 |
2020 |
| Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM). |
Journal of Clinical Oncology 38 (15_suppl), 8531-8531 , 2020 |
2020 |
| Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose … |
Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie … , 2020 |
2020 |
| IL-6–based mortality risk model for hospitalized patients with COVID-19 |
Journal of Allergy and Clinical Immunology 146 (4), 799-807. e9 , 2020 |
2020 |
| Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone (d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results … |
Blood 136, 15-16 , 2020 |
2020 |
| Randomized, placebo‐controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated … |
EJHaem 1 (1), 94-102 , 2020 |
2020 |
| Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma |
Blood, The Journal of the American Society of Hematology 135 (26), 2375-2387 , 2020 |
2020 |
| APPLICABILITY OF LIQUID BIOPSY BY NEXT GENERATION SEQUENCING FOR FOLLICULAR LYMPHOMA, DIFFUSE B CELLS, MANTO AND HODGKIN |
HAEMATOLOGICA 105, 89-90 , 2020 |
2020 |
| NOVEL INSIGHTS INTO GENOMIC CLASSIFICATION AND PROGNOSIS IN ACUTE MYELOID LEUKEMIA BASED ON A PANEUROPEAN PUBLIC-PRIVATE PARTNERSHIP, THE HARMONY ALLIANCE |
HEMASPHERE 4 (S1), 16-16 , 2020 |
2020 |
| Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set |
Blood, The Journal of the American Society of Hematology 136 (26), 3033-3040 , 2020 |
2020 |
| Protein carbonylation and lipid peroxidation in hematological malignancies |
Antioxidants 9 (12), 1212 , 2020 |
2020 |
| Restoring NK cell activities in multiple myeloma with IL-15 receptor agonist NKTR-255 |
Abstract presented at: 62nd ASH Annual Meeting and Exposition 20 , 2020 |
2020 |
| Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype |
Scientific Reports (Nature Publisher Group) 10 (1) , 2020 |
2020 |
| Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study |
Journal of hematology & oncology 13, 1-12 , 2020 |
2020 |
| PROPHYLAXIS OF GRAFT VERSUS HOST DISEASE WITH CYCLOPHOSPHAMIDE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. EXPERIENCE OF A CENTER |
HAEMATOLOGICA 105, 268-269 , 2020 |
2020 |
| Thrombosis and antiphospholipid antibodies in patients with SARS‐COV‐2 infection (COVID‐19) |
International journal of laboratory hematology 42 (6), e280 , 2020 |
2020 |
| Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis |
|
2020 |
| Uncovering the role of RNA-binding protein hnRNP K in B-cell lymphomas |
JNCI: Journal of the National Cancer Institute 112 (1), 95-106 , 2020 |
2020 |
| Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma |
Blood Advances 4 (14), 3295-3301 , 2020 |
2020 |
| A large-scale database of T-cell receptor beta (TCRß) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2. |
|
2020 |
| A phase II clinical trial of infusing haploidentical K562-mb-IL15-41BBL activated and expanded Natural Killer cells as consolidation therapy for pediatric acute myeloblastic … |
Authorea Preprints , 2020 |
2020 |
| THE HIGHEST MUTATIONAL LOAD (VAF) OF THE VARIANTS DETECTED IN THE TP53, EZH2, U2AF1, WT1, FLT3, AND SF3B1 GENES IS IDENTIFIED AS AN INDEPENDENT PROGNOSTIC MARKER FOR SG OR SLR … |
HAEMATOLOGICA 105, 44-44 , 2020 |
2020 |
| TRANSFUSION MANAGEMENT IN AUTOIMMUNE HEMOLYTIC ANEMIA IN PATIENTS YOUNGER THAN THREE MONTHS. DESCRIPTION OF THREE CASES AND PROPOSAL OF TRANSFUSION ALGORITHM |
HAEMATOLOGICA 105, 17-18 , 2020 |
2020 |
| NKG2D Car T Cells are not affected by Soluble NKG2D Ligands |
BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 243-243 , 2020 |
2020 |
| Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society COVID-19 Dataset |
medRxiv , 2020 |
2020 |
| Autologous Lymphapheresis for the Production of CAR-T Cells |
BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 698-698 , 2020 |
2020 |
| A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1 -like characteristics |
Blood Cancer Journal 10 (4), 43 , 2020 |
2020 |
| Clinical course and risk factors for mortality from COVID‐19 in patients with haematological malignancies |
European Journal of Haematology 105 (5), 597-607 , 2020 |
2020 |
| Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients |
Blood cancer journal 10 (2), 14 , 2020 |
2020 |
| Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels |
MedRxiv , 2020 |
2020 |
| Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms |
Blood cancer journal 10 (8), 89 , 2020 |
2020 |
| INFECTIOUS COMPLICATIONS ASSOCIATED WITH GATA2 GENE DEFICIENCY. A CASE REPORT |
HAEMATOLOGICA 105, 196-197 , 2020 |
2020 |
| Impact Study of a Microgrid with Battery Energy Storage System (BESS) and Hybrid Distributed Energy Resources using MATLAB Simulink and T-test Analysis |
2020 IEEE 12th International Conference on Humanoid, Nanotechnology … , 2020 |
2020 |
| STUDY OF THE IMPACT OF SUBCLONAL VARIANTS ON THE PROGNOSIS OF AML |
HAEMATOLOGICA 105, 49-50 , 2020 |
2020 |
| Impact of Sars-CoV2 infection on 491 hematological patients: the Ecovidehe multicenter study |
Blood 136, 5-6 , 2020 |
2020 |
| The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements |
PLoS One 15 (8), e0237155 , 2020 |
2020 |
| MOLECULAR DIFFERENCES BETWEEN MYELOID LINEAGE NEOPLASMS (ACUTE MYELOID LEUKAEMIA, MYELODYSPLASTIC SYNDROMES AND MYELOPROLIFERATIVE NEOPLASMS) AND THEIR CLINICAL IMPLICATIONS |
HAEMATOLOGICA 105, 44-45 , 2020 |
2020 |
| Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: interim analysis of the phase 2 Elara trial |
Blood 136, 1-3 , 2020 |
2020 |
| Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma |
Blood 136, 46-48 , 2020 |
2020 |
| Comprehensive custom NGS panel validation for the improvement of the stratification of B-acute lymphoblastic leukemia patients |
Journal of Personalized Medicine 10 (3), 137 , 2020 |
2020 |
| BOSUTINIB IN THE TREATMENT OF CF-CML PATIENTS WHO HAVE NOT REACHED AN OPTIMAL RESPONSE (BOSTRO STUDY) |
HAEMATOLOGICA 105, 126-126 , 2020 |
2020 |
| IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma |
Haematologica 105 (5), e237 , 2020 |
2020 |
| IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection |
Annals of hematology 99, 2953-2956 , 2020 |
2020 |
| Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients With Multiple Myeloma |
Blood 136, 13-14 , 2020 |
2020 |
| SCREENING FOR POTENTIAL THERAPEUTIC OPPORTUNITIES FOR B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH IKZF1 DELETIONS |
HAEMATOLOGICA 105, 207-207 , 2020 |
2020 |
| Measurable residual disease by next-generation flow cytometry in multiple myeloma |
Journal of Clinical Oncology 38 (8), 784-792 , 2020 |
2020 |
| TYK2 variants in B-Acute lymphoblastic leukaemia |
Genes 11 (12), 1434 , 2020 |
2020 |
| VALIDATION OF THE HIGH-RISK PROGNOSTIC SCORE DEFINED BY THE PRESENCE OF NRAS OR TP53 MUTATIONS IN A COHORT OF 497 PATIENTS WITH ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 105, 206-207 , 2020 |
2020 |
| Ponatinib and chemotherapy in young adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia. Results of Ponalfil clinical trial after completion of … |
Blood 136, 29-30 , 2020 |
2020 |
| A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2 |
Research square , 2020 |
2020 |
| NEW CELL DIFFERENTIATION MODULATORS: THE ROLE OF PIEZO1 AND HNRNP K IN STEM CELLS |
HAEMATOLOGICA 105, 321-322 , 2020 |
2020 |
| Interleukin-6-based mortality risk model for hospitalised COVID-19 patients |
J Allergy Clin Immunol 146 (4), 799-807 , 2020 |
2020 |
| Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma |
Blood advances 4 (23), 6023-6033 , 2020 |
2020 |
| Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (ALLO-HSCT) After PD-1 Blockade in Relapsed/Refractory (R/R) Lymphomas-A Single Center Experience |
BONE MARROW TRANSPLANTATION 55 (SUPPL 1), 372-372 , 2020 |
2020 |
| Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma |
Blood 136, 42-43 , 2020 |
2020 |
| Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma |
Blood 136, 5-6 , 2020 |
2020 |
| FRI0050 EFFICACY OF ATORVASTATIN VERSUS COLCHICINE IN DECREASING BIOMARKERS OF MYOCARDIAL DAMAGE IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS |
Annals of the Rheumatic Diseases 79 (Suppl 1), 600-601 , 2020 |
2020 |
| CREATION OF A CAR-T THERAPY UNIT IN THE HOSPITAL 12 OCTOBER DE MADRID |
HAEMATOLOGICA 104, 444-444 , 2019 |
2019 |
| Genetic factors and Waldenström's macroglobulinemia: Systematic review and meta-analysis |
Hematol. Med. Oncol. , 2019 |
2019 |
| INTERRUPTION OF QUINOLONE PROPHYLAXIS IN HEMATOLOGIC PATIENTS WITH PROLONGED NEUTROPENIA: AN OBSERVATIONAL STUDY |
HAEMATOLOGICA 104, 187-188 , 2019 |
2019 |
| IMPLEMENTATION OF TECHNIQUES OF (SNP ARRAYS) TO THE GENETIC STUDY OF PATIENTS WITH MULTIPLE MYELOMA. HIGHER PERFORMANCE IN THE STRATIFICATION OF PATIENTS IN RISK GROUPS |
HAEMATOLOGICA 104, 251-251 , 2019 |
2019 |
| Abstract CT080: Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)(OP-104) |
Cancer Research 79 (13_Supplement), CT080-CT080 , 2019 |
2019 |
| Timing treatment for smoldering myeloma: is earlier better? |
Expert Review of Hematology 12 (5), 345-354 , 2019 |
2019 |
| Ps1002 rhoe, Cxcl12 and Cxcr3 may identify complete responses in acute myeloid leukemia patients treated with tipifarnib |
HemaSphere 3, 450-451 , 2019 |
2019 |
| Role of urine immunofixation in defining CR in MM |
Role of urine immunofixation in defining CR in MM 133 (25), 2731 , 2019 |
2019 |
| MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia |
Scientific reports 9 (1), 18630 , 2019 |
2019 |
| Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in waldenström macroglobulinemia |
Clinical cancer research 25 (1), 369-377 , 2019 |
2019 |
| Prognostic value of expression quantitative trait loci in multiple myeloma prognosis |
|
2019 |
| PF664 46/1 HAPLOTYPE IS ASSOCIATED WITH A HIGHER MONOCYTE/LYMPHOCYTE RATIO IN HEALTHY INDIVIDUALS |
HemaSphere 3 (S1), 285 , 2019 |
2019 |
| STUDY OF THE CLINICAL RELEVANCE AND GENOMIC PROFILE OF MINIMAL RESIDUAL MULTIPLE MYELOMA DISEASE IN PATIENTS WITH STANDARD RISK AND HIGH CYTOGENETIC RISK |
HAEMATOLOGICA 104, 5-5 , 2019 |
2019 |
| Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity |
Blood 134, 4408 , 2019 |
2019 |
| TREATMENT WITH RUXOLITINIB INDUCES CHANGES IN THE GENIC EXPRESSION PROFILE IN T LYMPHOCYTES, BUT NOT IN THE CD34 OF THE PATIENTS WITH MYELOFIBROSIS. RESULTS: BIOLOGICS OF THE … |
HAEMATOLOGICA 104, 63-64 , 2019 |
2019 |
| MOLECULAR CHARACTERIZATION OF REARRANGEMENTS OF THE HEAVY CHAIN OF IMMUNOGLOBULINS IN MYELOMA: CLINICAL IMPLICATIONS |
HAEMATOLOGICA 104, 138-138 , 2019 |
2019 |
| Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study |
Leukemia & lymphoma 60 (7), 1803-1811 , 2019 |
2019 |
| Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role |
Leukemia 33 (4), 1056-1056 , 2019 |
2019 |
| Análisis critico de la respuesta completa estricta en mieloma múltiple. actualización de los datos basados en el estudio fase 3 PETHEMA/GEM2012MENOS65 |
Haematologica , 2019 |
2019 |
| The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies |
Blood 134, 5560 , 2019 |
2019 |
| Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics |
The Journal of Molecular Diagnostics 21 (2), 228-240 , 2019 |
2019 |
| CLONAL COMPETITION MODELS FOR UNDERSTANDING PROGRESSION AND ENDURANCE IN MULTIPLE MYELOMA |
HAEMATOLOGICA 104, 7-8 , 2019 |
2019 |
| PD-1/PD-L1 AS A RESISTANCE MECHANISM IN CAR-T CELL THERAPY |
HAEMATOLOGICA 104, 444-445 , 2019 |
2019 |
| USEFULNESS OF AN NGS PANEL OF APLASIA/ANEMIA IN THE DIAGNOSIS OF ENTITIES WITH MEDULLARY FAILURE: EXPERIENCE IN A THIRD LEVEL CENTER |
HAEMATOLOGICA 104, 243-243 , 2019 |
2019 |
| Final analysis of a phase 1b study of daratumumab in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma (RRMM) |
Blood 134, 1876 , 2019 |
2019 |
| EFFECTIVENESS OF IMMUNOTHERAPY WITH BRENTUXIMAB IN THE HODGKIN LYMPHOMA SECONDARY HEMOPHAGOCYTIC SYNDROME |
HAEMATOLOGICA 104, 389-390 , 2019 |
2019 |
| Spectrum and functional validation of PSMB5 mutations in multiple myeloma |
Leukemia 33 (2), 447-456 , 2019 |
2019 |
| ANALYSIS OF THE RESULTS OBTAINED FROM CLINICAL TRIALS PHASE I/II IN HEMATOLOGICAL DISEASES. CLINICAL EXPERIENCE IN THE CENTER OF THIRD LEVEL |
HAEMATOLOGICA 104, 358-358 , 2019 |
2019 |
| Hierarchy of mono- and biallelic TP53 alterations in multiple myeloma cell fitness |
Blood, The Journal of the American Society of Hematology 134 (10), 836-840 , 2019 |
2019 |
| PROPOSAL OF ALGORITHM" IN 2 STEPS" FOR THE SCREENING OF MYELOPROLIFERATIVE NEOPLASMS IN INDIVIDUALS WITH ERYTHROCYTOSIS |
HAEMATOLOGICA 104, 59-59 , 2019 |
2019 |
| UTILITY OF AN NGS PANEL OF MYELOID IN TRIPLE ESSENTIAL THROMBOCYTHEMIA NEGATIVE (TE-TN) |
HAEMATOLOGICA 104, 247-247 , 2019 |
2019 |
| Differences in ex-vivo chemosensitivity to anthracyclines in first line acute myeloid leukemia |
Mediterranean Journal of Hematology and Infectious Diseases 11 (1) , 2019 |
2019 |
| Circulating Tumor Cells (CTCs) for Comprehensive and Multiregional Non-Invasive Genetic Characterization of Multiple Myeloma (MM) |
Blood 134, 3064 , 2019 |
2019 |
| ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a … |
Clinical Lymphoma, Myeloma and Leukemia 19, S326-S327 , 2019 |
2019 |
| Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: a case report |
Journal of Oncology Pharmacy Practice 25 (4), 998-1002 , 2019 |
2019 |
| FORECAST IN PATIENTS WITH LYMPHOMA B DIFFUSION OF LARGE REFRACTORY CELLS AND IN EARLY RECOVERY: EXPERIENCE IN OUR CENTER |
HAEMATOLOGICA 104, 372-372 , 2019 |
2019 |
| Restoring Innate and Adaptive Immune Repertoire in Multiple Myeloma for Therapeutic Application |
Blood 134, 4398 , 2019 |
2019 |
| Laparoscopic hepatectomy for preoperative suspected hepatocellular carcinoma: perioperative results at a single center |
HPB 21, S147-S148 , 2019 |
2019 |
| Mechanisms of proteasome inhibitor resistance selected by clonal evolution in multiple myeloma |
Blood 134, 4349 , 2019 |
2019 |
| S844 KDM5 inhibition offers a novel therapeutic strategy for the treatment of kmt2d mutant lymphomas |
HemaSphere 3 (S1), 376-377 , 2019 |
2019 |
| Detailed Phenotypic, Molecular and Functional Profiling of Myeloid Derived Suppressor Cells (MDSCs) in the Tumor Immune Micro-Environment (TIME) of Multiple Myeloma (MM) |
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 19 (10), E97-E98 , 2019 |
2019 |
| The poor prognosis of low hypodiploidy in adults with B‐cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients |
British Journal of Haematology 186 (2), 263-268 , 2019 |
2019 |
| Ponatinib and chemotherapy in young adults with de novo Philadelphia chromosome-positive acute lymphoblstic leukemia. Preliminary results of Ponalfil clinical trial |
Blood 134, 3874 , 2019 |
2019 |
| THE TRANSCRIPTOMIC PROFILE OF THE CIRCULATING TUMOUR CELL (CTC) OF MULTIPLE MYELOMA: A NEW MODEL FOR UNDERSTANDING THE SPREAD OF THE DISEASE |
HAEMATOLOGICA 104, 13-14 , 2019 |
2019 |
| Proposal of a “2-Step-Algorithm” for the Screening of Myeloproliferative Neoplasms in Individuals with Erythrocytosis |
Blood 134, 4187 , 2019 |
2019 |
| INTERSTICIAL PULMONARY INFILTRATES AND PROGRESSIVE SPLENOMEGALY |
HAEMATOLOGICA 104, 469-469 , 2019 |
2019 |
| The pathogenesis of multiple myeloma (MM) is preceded by mutated lymphopoiesis and B cell oligoclonality that persist in patients with negative minimal residual disease (MRD) |
Blood 134, 509 , 2019 |
2019 |
| MASSIVE SEQUENCING OF THE CODING AND NON-CODING SEQUENCES OF TP53 IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA |
HAEMATOLOGICA 104, 9-9 , 2019 |
2019 |
| Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease … |
Blood 134, 1852 , 2019 |
2019 |
| Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow |
Clinical Lymphoma, Myeloma and Leukemia 19 (10), e47 , 2019 |
2019 |
| EFFECT OF LIVE MUSIC IN AUTOMATIC TRANSPLANT OF HEMATOPOIETIC PROGENITORS: COHORT STUDY |
HAEMATOLOGICA 104, 448-449 , 2019 |
2019 |
| USE OF AN NGS PANEL OF ANEMIES TO ESTABLISH THE DIAGNOSIS OF CONGENITAL ANEMIES |
HAEMATOLOGICA 104, 76-77 , 2019 |
2019 |
| CHARACTERIZATION OF THE PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILE OF THE MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT OF MULTIPLE MYELOMA (MM) |
HAEMATOLOGICA 104, 149-149 , 2019 |
2019 |
| New gene-editing strategy for allogeneic NKG2D-CAR T cell production |
Human Gene Therapy 30 (11), A49-A49 , 2019 |
2019 |
| Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in … |
Haematologica 104 (12), e551 , 2019 |
2019 |
| Generation of two new immunotherapeutic products with genetically modified NK cells. Comparison of clinically relevant CARS in multiple myeloma |
Haematologica 104, 97-97 , 2019 |
2019 |
| Collaborative intelligence and gamification for on-line malaria species differentiation |
|
2019 |
| GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS prodigy |
Frontiers in Immunology 10, 2361 , 2019 |
2019 |
| S1638 INTERRUPTING QUINOLONE PROPHYLAXIS IN HEMATOLOGIC PATIENTS WITH PROLONGED NEUTROPENIA: AN OBSERVATIONAL STUDY |
HemaSphere 3, 757-758 , 2019 |
2019 |
| PF221 MUTATIONAL PROFILE BY NGS COMBINED WITH EX VIVO DRUG SENSITIVITY PROFILE IMPROVE PREDICTION OF AML PATIENT OUTCOME |
HemaSphere 3 (S1), 62-63 , 2019 |
2019 |
| Monitoring of the minimum residual disease and depth of response in multiple myeloma |
Haematologica 104, 150-150 , 2019 |
2019 |
| Collaborative intelligence and gamification for on-line malaria species differentiation |
Malaria Journal 18, 1-9 , 2019 |
2019 |
| Clonal Competition Models to Understand Progression and Resistance in Myeloma |
Blood 134, 1807 , 2019 |
2019 |
| NKG2D-CAR T cells as an immunotherapy against pediatric hematological malignancies |
BONE MARROW TRANSPLANTATION 54, 178-179 , 2019 |
2019 |
| UNICENTER CLINICAL EXPERIENCE IN THE TREATMENT OF MULTIREFRACTORY DLBCL WITH CAR-T CELL THERAPY: COMPLEXITY BEYOND IDEAL PATIENTS |
HAEMATOLOGICA 104, 186-186 , 2019 |
2019 |
| Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma |
American journal of hematology 94 (8), 853-861 , 2019 |
2019 |
| Minimal residual disease clinical monitoring and depth of response in multiple myeloma. |
Journal of Clinical Oncology 37 (15_suppl), 8026-8026 , 2019 |
2019 |
| EXPLORING THE CELL OF ORIGIN AND THE PATHOLOGICAL TRANSCRIPTIONAL PROGRAMS IN MULTIPLE MYELOMA (MM) AND LIGHT CHAIN AMYLOIDOSIS (AL) BY DISSECTING THE DEVELOPMENT OF NORMAL … |
HAEMATOLOGICA 104, 12-12 , 2019 |
2019 |
| Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease |
Blood, The Journal of the American Society of Hematology 133 (25), 2664-2668 , 2019 |
2019 |
| NKG2D CAR-expressing lymphocytes target acute myeloid leukemia cells |
Blood 134, 2667 , 2019 |
2019 |
| Different Clinical Implications of Kinase Domain BCR-ABL1 Variants Detected in Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia Patients |
Blood 134, 5368 , 2019 |
2019 |
| PS1357 FITNESS SIGNATURES IN MULTIPLE MYELOMA PROGRESSION AND RESISTANCE |
HemaSphere 3 (S1), 620 , 2019 |
2019 |
| OPTIMIZATION OF CAR-T CD19 MONITORING BY FLOW CYTOMETRY AND QUANTITATIVE PCR (Q PCR) |
HAEMATOLOGICA 104, 164-164 , 2019 |
2019 |
| MONOMORPHIC EPITHELIOTROPIC INTESTINAL T CELL LYMPHOMA (LITME), A RARE CAUSE OF ENTEROPATHY: A PURPOSE OF TWO CASES AND REVIEW OF BIBILIOGRAPHY |
HAEMATOLOGICA 104, 394-394 , 2019 |
2019 |
| Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma: primary analysis of the phase 2 ELARA trial |
N. Engl. J. Med 380, 45-56 , 2019 |
2019 |
| INTRODUCTION OF PHOTOAFERESIS IN THE HEMATOLOGY SERVICE |
HAEMATOLOGICA 104, 445-445 , 2019 |
2019 |
| Fatal graft-versus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab |
Journal of Oncology Pharmacy Practice 25 (2), 502-506 , 2019 |
2019 |
| Exploring NKG2D and BCMA-CAR NK-92 for adoptive cellular therapy to multiple myeloma |
Clinical Lymphoma, Myeloma and Leukemia 19 (10), e24-e25 , 2019 |
2019 |
| Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature |
Blood Cancer Journal 9 (4), 36 , 2019 |
2019 |
| Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin … |
Blood 134, 1584 , 2019 |
2019 |
| Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy |
Antioxidants 8 (11), 508 , 2019 |
2019 |
| Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)(OP-104) |
CANCER RESEARCH 79 (13) , 2019 |
2019 |
| Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients |
Frontiers in pharmacology 10, 1340 , 2019 |
2019 |
| PERIOPERATIVE MANAGEMENT OF CARDIAC VALVE REPLACEMENT IN PATIENTS WITH LUPUS ANTICOAGULANT-HYPOPROTHROMBINEMIA SYNDROME |
HAEMATOLOGICA 104, 115-115 , 2019 |
2019 |
| Real World Data (RWD) of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): clinical benefit from a Spanish single … |
Annals of Oncology 30, iv62 , 2019 |
2019 |
| Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase … |
AMERICAN JOURNAL OF HEMATOLOGY 94, S23-S24 , 2019 |
2019 |
| Clinical relevance of Minimal residual Disease assessment by NGS in Multiple Myeloma |
Clinical Lymphoma, Myeloma and Leukemia 19 (10), e179-e180 , 2019 |
2019 |
| PS1348 DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO‐ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM) |
HemaSphere 3, 615-616 , 2019 |
2019 |
| UTILITY OF THE AUTHENTIC TRANSPLANT OF HEMATOPOIETIC PROGENITORS (TASPE) IN CROHN'S DISEASE |
HAEMATOLOGICA 104, 451-452 , 2019 |
2019 |
| PROGNOSTIC VALUE OF THE RESPONSE TO THE TREATMENT ACCORDING TO THE CLASSIFICATION OF LUGANO IN PATIENTS WITH LYMPHOMA B DIFFUSION OF LARGE CELLS IN OUR CENTER |
HAEMATOLOGICA 104, 371-372 , 2019 |
2019 |
| Prolonged Lenalidomide Maintenace Therapy Improves the Quality and Deep of Response in Multiple Myeloma |
Clinical Lymphoma Myeloma and Leukemia 19 (10), e285-e286 , 2019 |
2019 |
| Molecular profiling refines minimal residual disease‐based prognostic assessment in adults with Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia |
Genes, Chromosomes and Cancer 58 (11), 815-819 , 2019 |
2019 |
| PF608 ANCHOR (OP‐104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN … |
HemaSphere 3, 257-258 , 2019 |
2019 |
| Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma |
Blood, The Journal of the American Society of Hematology 134 (5), 421-431 , 2019 |
2019 |
| Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies |
International Journal of Molecular Sciences 20 (11), 2832 , 2019 |
2019 |
| Papain‐treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti‐CD38‐based therapies |
Transfusion Medicine 29 (3), 193-196 , 2019 |
2019 |
| PF630 MINIMAL RESIDUAL DISEASE MONITORING AND DEPTH OF RESPONSE IN MULTIPLE MYELOMA |
HemaSphere 3, 268 , 2019 |
2019 |
| PF250 HNRNP K OVEREXPRESSION INDUCE NUCLEOLAR STRESS, A HALLMARK OF ACUTE MYELOID LEUKEMIA |
HemaSphere 3, 76-77 , 2019 |
2019 |
| Cost-effectiveness of midostaurin in the treatment of acute myeloid leukemia with the FLT3 mutation in Spain |
ClinicoEconomics and Outcomes Research, 683-694 , 2019 |
2019 |
| PB2170 HEPATITIS C VIRUS-DRIVEN MULTIPLE MYELOMA IN STABLE COMPLETE REMISSION AFTER ANTIVIRAL TREATMENT |
HemaSphere 3 (S1), 974-975 , 2019 |
2019 |
| Automated manufacturing of clinical grade NKG2D-CAR memory T cells using clinimacs prodigy |
BONE MARROW TRANSPLANTATION 54, 184-185 , 2019 |
2019 |
| Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the … |
Blood 134, 3891 , 2019 |
2019 |
| PF566 INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY |
HemaSphere 3, 235-236 , 2019 |
2019 |
| PF657 USE OF A NGS MYELOID PANEL TO FIND CLONALITY IN TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA. IDENTIFICATION OF NEW MUTATIONS IN DRIVER GENES |
HemaSphere 3 (S1), 281 , 2019 |
2019 |
| THE PRESENCE OF OBESOGENIC POLYMORPHISMS IDENTIFIED BY GWAS DOES NOT INFLUENCE THE RISK OF DEVELOPING MULTIPLE MYELOMA |
HAEMATOLOGICA 104, 14-14 , 2019 |
2019 |
| S871 CURATIVE STRATEGY (GEM‐CESAR) FOR HIGH‐RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT‐ASCT, CONSOLIDATION WITH KRD … |
HemaSphere 3, 390 , 2019 |
2019 |
| Multicentre Implementation of Next Generation Sequencing to Acute Myeloid Leukemia Patients in PETHEMA Spanish Collaborative Group |
ANNALS OF HEMATOLOGY 98, S38-S39 , 2019 |
2019 |
| The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data |
BMC cancer 19, 1-10 , 2019 |
2019 |
| DESCRIPTIVE ANALYSIS OF THE CARFILZOMIB EFFECTIVENESS PROFILE IN PATIENTS WITH MULITPLE MYELOMA. EXPERIENCE IN A THIRD LEVEL CENTER |
HAEMATOLOGICA 104, 202-203 , 2019 |
2019 |
| PB1981 RESULTS OBTAINED FROM CLINICAL TRIALS PHASE I/II IN HEMATOLOGICAL MALIGNANCIES. CLINICAL EXPERIENCE OF A SINGLE CENTER: HOSPITAL 12 OCTUBRE. |
HemaSphere 3 (S1), 899 , 2019 |
2019 |
| LONG-LASTING CYTOPENIAS AS A COMPLICATION OF CAR T-CELL THERAPY |
HAEMATOLOGICA 104, 316-316 , 2019 |
2019 |
| Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma |
Leukemia 33 (9), 2324-2330 , 2019 |
2019 |
| MUTATIONS IN BCR-ABL1 IN PATIENTS WITH PH LEUKAEMIAS. CORRELATION WITH CLINICAL DATA |
HAEMATOLOGICA 104, 240-240 , 2019 |
2019 |
| SINGULARITIES OF HIGH-RISK MIELODISPLASIC SYNDROMES OF LEUCEMIC TRANSFORMATION |
HAEMATOLOGICA 104, 87-88 , 2019 |
2019 |
| Ps1209 Nkg2d and bcma-car Nk cells efficiently eliminate multiple myeloma cells. A comprehensive comparison between two clinically relevant cars |
HemaSphere 3 (S1), 550-551 , 2019 |
2019 |
| INCREASE OF MITOCHONDRIAL ACTIVITY AS A MECHANISM OF PROGRESSION AND MULTIPLE MYELOMA RESISTANCE, A NOVEL THERAPEUTIC OPPORTUNITY |
HAEMATOLOGICA 104, 10-11 , 2019 |
2019 |
| Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis |
Leukemia 33 (5), 1256-1267 , 2019 |
2019 |
| Explorando la celula de origen y los programas transcripcionales patologicos en mieloma multiple (MM) y amiloidosis de cadena ligera (AL) mediante la diseccion del desarrollo … |
Haematologica , 2019 |
2019 |
| AUTOLOGOUS LYMPHOAPHERESIS FOR THE PRODUCTION OF CAR T-CELL LYMPHOCYTES |
HAEMATOLOGICA 104, 314-315 , 2019 |
2019 |
| MINIMAL RESIDUAL DISEASE IN THE CLINICAL PRACTICE OF MULTIPLE MYELOMA PATIENTS |
HAEMATOLOGICA 104, 15-15 , 2019 |
2019 |
| El perfil transcriptómico de la célula tumoral circulante (CTD) del mieloma múltiple: un nuevo modelo para comprender la diseminación de la enfermedad |
Haematologica , 2019 |
2019 |
| Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime |
Blood 134, 3325 , 2019 |
2019 |
| GENERATION OF NKG2D-CAR LYMPHOCYTES FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 104, 47-47 , 2019 |
2019 |
| PS1351 CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL |
HemaSphere 3, 617 , 2019 |
2019 |
| THE OVEREXPRESSION OF ONCOGEN HNRNPK INDUCES NUCLEOLAR STRESS, MOLECULAR FOOTPRINT OF ACUTE MIELOID LEUKEMIA |
HAEMATOLOGICA 104, 48-49 , 2019 |
2019 |
| A Report on Double Stars Observed During the Year 2015 by Students and Faculty of the Humacao University Observatory |
Journal of Double Star Observations 15 (3), 416-420 , 2019 |
2019 |
| DESCRIPTIVE ANALYSIS OF THE CARFILZOMIB TOXICITY PROFILE IN PATIENTS WITH MULTIPLE MYELOMA. EXPERIENCE IN A THIRD LEVEL CENTER |
HAEMATOLOGICA 104, 201-202 , 2019 |
2019 |
| Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with … |
Blood 134, 781 , 2019 |
2019 |
| A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients |
Leukemia Research 76, 1-10 , 2019 |
2019 |
| Qip-mass spectrometry in high risk smoldering multiple myeloma patients included in the GEM-CESAR trial: comparison with conventional and minimal residual disease IMWG response … |
Blood 134, 581 , 2019 |
2019 |
| VALIDATION OF A PANEL OF NGS FOR THE DETECTION OF THE MAIN GENETIC ALTERATIONS PRESENT IN ACUTE LYMPHOBLASTIC LEUKEMIA B |
HAEMATOLOGICA 104, 275-276 , 2019 |
2019 |
| A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia |
Ferrata Storti Foundation , 2019 |
2019 |
| CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. UPDATING DATA BASED ON PHASE 3 STUDY PETHEMA/GEM2012MINUS65 |
HAEMATOLOGICA 104, 7-7 , 2019 |
2019 |
| ANAPLASIC LARGE CELL LYMPHOMA (LACG) ASSOCIATED WITH BREAST IMPLANTS: EXPERIENCE IN A THIRD LEVEL CENTER |
HAEMATOLOGICA 104, 376-377 , 2019 |
2019 |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial |
The Lancet Oncology 19 (6), 747-757 , 2018 |
2018 |
| Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials |
PLoS One 13 (9), e0203392 , 2018 |
2018 |
| Prevalence of JAK2 V617F in individuals that meet World Health Organization erythrocytosis criteria for polycythemia vera |
Blood 132, 1775 , 2018 |
2018 |
| STUDY OF THE LENGTH OF FLT3-ITD FRAGMENTS IN DIAGNOSED PATIENTS OF ACUTE MYELODE LEUKEMIA (AML) |
HAEMATOLOGICA 103, 198-199 , 2018 |
2018 |
| THE PROTEIN CARBONYLATION PATTERN IS ALTERED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME |
HAEMATOLOGICA 103, 181-182 , 2018 |
2018 |
| Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia |
Cancer letters 422, 107-117 , 2018 |
2018 |
| Genetic Profiling and Novel Recurrent Chromosomal Alterations in Patients with Light Chain Amyloidosis |
Blood 132, 4488 , 2018 |
2018 |
| POST-INTERVENTION STUDY AFTER THE WITHDRAWAL OF PROPHYLAXIS WITH QUINOLONES IN HEMATOLOGICAL PATIENTS WITH NEUTROPENIA |
HAEMATOLOGICA 103, 297-298 , 2018 |
2018 |
| Estudio del perfil genético en pacientes con Amiloidosis de cadenas ligeras |
Haematologica , 2018 |
2018 |
| VTD (bortezomib/thalidomide/dexamethasone) as pretransplant induction therapy for multiple myeloma: definitive results of a randomized phase 3 pethema/GEM study |
Blood 132, 126 , 2018 |
2018 |
| Abstract B012: A novel in vitro approach elucidates a new mode of cytotoxic action of bispecific antibodies on hematologic malignancies |
Molecular Cancer Therapeutics 17 (1_Supplement), B012-B012 , 2018 |
2018 |
| EFFECT OF THE IMIDS ON NATURAL KILLER CELLS ACTIVATED AND EXPANDED IN MULTIPLE MYELOMA |
HAEMATOLOGICA 103, 193-194 , 2018 |
2018 |
| Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis |
Leukemia 32 (2), 553-555 , 2018 |
2018 |
| Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients |
British Journal of Haematology 183 (3), 375-384 , 2018 |
2018 |
| VDJH gene repertoire analysis in multiple myeloma (MM) patients: correlation with clinical data |
Blood 132, 4446 , 2018 |
2018 |
| Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia |
|
2018 |
| ROSAI-DORFMAN DISEASE: CASUISTIC REVIEW, SEARCH OF MOLECULAR ALTERATIONS AND POSSIBLE THERAPEUTIC TARGETS |
HAEMATOLOGICA 103, 281-282 , 2018 |
2018 |
| NEW GENERATION ALTERNATIVES FOR THE DETECTION AND QUANTIFICATION OF MINIMUM RESIDUAL DISEASE (EMR) IN PATIENTS WITH MULTIPLE MYELOMA |
HAEMATOLOGICA 103, 103-103 , 2018 |
2018 |
| LENALIDOMIDE AS A THERAPY IN PATIENTS WITH MYELODYSPLASIA 5Q+ WITH LOW LEVELS OF RPS14 |
HAEMATOLOGICA 103, 176-176 , 2018 |
2018 |
| Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology. |
British Journal of Haematology 181 (4) , 2018 |
2018 |
| DETECTION OF MUTATIONS IN BCR-ABL1 WITH A SENSITIVITY OF 1% IN PATIENTS WITH PH plus LEUKEMIAS |
HAEMATOLOGICA 103, 53-53 , 2018 |
2018 |
| Daratumumab in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide-refractory patients with relapsed multiple myeloma: subgroup analysis of MMY1001 |
Annual Meeting of the American Society of Clinical Oncology (ASCO) , 2018 |
2018 |
| IMMUNE RESPONSE INDUCED BY DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA PREVIOUSLY TREATED WITH DASATINIB. RESULTS DASAPOST CLINICAL TRIAL |
HAEMATOLOGICA 103, 69-69 , 2018 |
2018 |
| Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM) |
Blood 132, 3170 , 2018 |
2018 |
| EVALUATION OF APOPTOSIS IN MONONUCLEAR CELLS IN PHOTOPHERESIS PRODUCTS OF PATIENTS WITH GVHD AND CUTANEOUS T-CELL LYMPHOMAS |
HAEMATOLOGICA 103, 192-193 , 2018 |
2018 |
| Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1,265 patients enrolled in four consecutive clinical trials |
|
2018 |
| Clinical significance and transcriptional profiling of persistent minimal residual disease (MRD) in multiple myeloma (MM) patients with standard-risk (SR) and high-risk (HR … |
Blood 132, 112 , 2018 |
2018 |
| A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia |
haematologica 104 (2), 288 , 2018 |
2018 |
| Detailed phenotypic, molecular and functional profiling of myeloid derived suppressor cells (MDSCs) in the tumor immune microenvironment (TIME) of multiple myeloma (MM) |
Blood 132, 4436 , 2018 |
2018 |
| How do we manufacture clinical‐grade interleukin‐15–stimulated natural killer cell products for cancer treatment? |
Transfusion 58 (6), 1340-1347 , 2018 |
2018 |
| STUDY OF MUTATIONAL PROFILE AND CORRELATION OF RESPONSE TO EX VIVO PHARMACOLOGICAL TEST, IN THE DIAGNOSTIC OF THE AML |
HAEMATOLOGICA 103, 2-3 , 2018 |
2018 |
| The role of Hepatitis C virus in the development of multiple myeloma: A case study |
Blood 132, 5592 , 2018 |
2018 |
| Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination |
Blood, The Journal of the American Society of Hematology 132 (Supplement 1 … , 2018 |
2018 |
| Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS-like Signature Is the Most Relevant Predictor |
Blood 132, 4503 , 2018 |
2018 |
| THE COMBINATION OF MEDULAR STUDIES AND IMAGE TECHNIQUES IMPROVES THE EVALUATION OF MINIMUM RESIDUAL DISEASE IN MULTIPLE MYELOMA |
HAEMATOLOGICA 103, 88-88 , 2018 |
2018 |
| STUDY OF PREVALENCE OF JAK2V617F MUTATION IN PATIENTS WITH POTENTIAL POLYTETHEMIA VERA (PV) |
HAEMATOLOGICA 103, 69-70 , 2018 |
2018 |
| PROGNOSTIC IMPACT OF GENETIC MUTATIONS ON THE ROUTE OF RASEN PATIENTS WITH LAL-B |
HAEMATOLOGICA 103, 28-29 , 2018 |
2018 |
| hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis |
Blood 132 (Supplement 1), 1346-1346 , 2018 |
2018 |
| NKG2D-CAR transduced primary natural killer cells efficiently target multiple myeloma cells |
Blood 132, 590 , 2018 |
2018 |
| IDENTIFICATION OF A GROUP OF ADOLESCENT AND ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH BCR-ABL1-LIKE CHARACTERISTICS USING A RNASEQ DIRECTED PANEL |
HAEMATOLOGICA 103, 52-53 , 2018 |
2018 |
| A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility |
haematologica 103 (5), 880 , 2018 |
2018 |
| Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role |
Leukemia 32 (11), 2427-2434 , 2018 |
2018 |
| EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective … |
Lancet Oncol 19 (6), 747-757 , 2018 |
2018 |
| Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes [Oncotarget, 8 (2017)(106948-106961 |
Correction: Mutations in the DNA methylation pathway and number of driver … , 2018 |
2018 |
| Focusing PI and IMiD resistance in multiple myeloma: Impact of DNA methylation |
Blood 132, 404 , 2018 |
2018 |
| Prognostic risk models for transplant decision-making in myelofibrosis |
Annals of hematology 97, 813-820 , 2018 |
2018 |
| A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia |
Oncotarget 9 (40), 26019 , 2018 |
2018 |
| Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms |
haematologica 104 (5), 937 , 2018 |
2018 |
| Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials |
Leukemia 32 (4), 971-978 , 2018 |
2018 |
| Absence of contribution to a differential outcome of the stringent complete response IMWG category respect to the conventional CR in multiple myeloma. A validation analysis … |
Blood 132, 1943 , 2018 |
2018 |
| STUDY OF THE GENETIC PROFILE IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS |
HAEMATOLOGICA 103, 91-91 , 2018 |
2018 |
| A PURPOSE OF A CASE: GRANULOCYTIC SARCOMA ISOLATED AS THE FIRST MANIFESTATION OF PROMIELOCYTIC ACUTE LEUKEMIA |
HAEMATOLOGICA 103, 326-327 , 2018 |
2018 |
| Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple … |
Blood 132, 595 , 2018 |
2018 |
| Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments |
Blood, The Journal of the American Society of Hematology 132 (Supplement 1 … , 2018 |
2018 |
| Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma |
N Engl J Med 78 (6), 518-528 , 2018 |
2018 |
| Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia |
Journal of hematology & oncology 11, 1-4 , 2018 |
2018 |
| PHOSPHOPROTEOMIC CHARACTERIZATION OF THE RESISTANCE IN LMA: MEK AS A NEW DIANA TO ENHANCE THE RESPONSE TO ITKS |
HAEMATOLOGICA 103, 24-25 , 2018 |
2018 |
| Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing |
haematologica 103 (11), e544 , 2018 |
2018 |
| Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial |
Blood 132, 474 , 2018 |
2018 |
| Microengineering double layer hydrogel structures towards the recapitulation of the hematopoietic stem cell niche |
Science Bulletin 63 (20), 1319-1323 , 2018 |
2018 |
| Curativestategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, Lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd … |
Blood 132, 2142 , 2018 |
2018 |
| Protein Carbonylation Pattern Is Altered in Myelodisplastic Syndromes |
Blood, The Journal of the American Society of Hematology 132 (Supplement 1 … , 2018 |
2018 |
| MONITORING MINIMUM RESIDUAL DISEASE (EMR) THROUGH NGS CONFIRMS PROGNOSTIC VALUE |
HAEMATOLOGICA 103, 27-28 , 2018 |
2018 |
| Long-Term Follow-Up of the Gem2010 Trial of Bortezomib-Melphalan-Prednisone and Lenalidomide-Dexamethasone in Elderly, Newly Diagnosed Multiple Myeloma Patients: Impact of Age … |
|
2018 |
| Study of the Clinical Significance of the Length of FLT3-ITD in Acute Myeloid Leukemia Patients |
Blood 132, 5278 , 2018 |
2018 |
| CD20-Tcb (RG6026), a novel “2: 1” format T-cell-engaging bispecific antibody, induces complete remissions in relapsed/refractory B-cell non-Hodgkin's lymphoma: preliminary … |
Blood 132, 226 , 2018 |
2018 |
| NK-NKG2D-CAR CELLS ARE EFFECTIVE TO MULTIPLE MYELOMA |
HAEMATOLOGICA 103, 97-97 , 2018 |
2018 |
| DIFFERENTIAL EXPRESSION OF HLA-E IN PLASMA CELLS OF MULTIPLE MYELOMA AND ITS ROLE IN RESISTANCE TO NEW IMMUNOTHERAPY TREATMENTS |
HAEMATOLOGICA 103, 58-59 , 2018 |
2018 |
| Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia |
British journal of haematology 181 (3), 397-400 , 2018 |
2018 |
| Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma … |
Blood, The Journal of the American Society of Hematology 132 (Supplement 1 … , 2018 |
2018 |
| POEMS SYNDROME WITH SEVERE PULMONARY HYPERTENSION: ABOUT A CASE |
HAEMATOLOGICA 103, 124-124 , 2018 |
2018 |
| THE VALUE OF MINIMAL RESIDUAL DISEASE IN FOLICULAR LYMPHOMA |
HAEMATOLOGICA 103, 229-230 , 2018 |
2018 |
| The OP-104 Anchor study: a phase 1/2 study of safety and efficacy of melflufen and dexamethasone in combination with either bortezomib or daratumumab in patients with RRMM … |
Blood 132, 1967 , 2018 |
2018 |
| VALIDATION OF THE LYMPHOTRACK COMMERCIAL KIT FOR THE CHARACTERIZATION OF CLONOTYPIC REORDINATION IN MULTIPLE MYELOMA PATIENTS |
HAEMATOLOGICA 103, 116-116 , 2018 |
2018 |
| THE ROLE OF HEPATITIS C IN THE DEVELOPMENT OF MULTIPLE MYELOMA: A CASE STUDY |
HAEMATOLOGICA 103, 124-125 , 2018 |
2018 |
| MITOCHONDRIAL ACTIVITY PLAYS A CRITICAL ROLE IN THE RESISTANCE OF MULTIPLE MYELOMA |
HAEMATOLOGICA 103, 85-86 , 2018 |
2018 |
| PROFILING OF RECURRENT COPY NUMBER ALTERATIONS IN RELAPSED ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA |
HAEMATOLOGICA 102, 342-343 , 2017 |
2017 |
| Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene … |
Clinical Lymphoma, Myeloma and Leukemia 17 (1), e4-e5 , 2017 |
2017 |
| MUTATIONAL PROFILE STUDY OF DOUBLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA BY HIGH-DEPTH NEXT GENERATION SEQUENCING (NGS) |
HAEMATOLOGICA 102, 540-540 , 2017 |
2017 |
| Role of MAX as a tumor suppressor driver gene in multiple myeloma |
Blood 130, 4347 , 2017 |
2017 |
| LOW RPS14 EXPRESSION IN MDS PATIENTS WITHOUT 5Q-ABERRATION SEEMS NOT TO BE RELATED WITH GENOMIC ALTERATIONS IN 5Q REGION |
HAEMATOLOGICA 102, 763-764 , 2017 |
2017 |
| Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma |
Blood, The Journal of the American Society of Hematology 129 (16), 2233-2245 , 2017 |
2017 |
| HNRNPK, NEW" DRIVER" DRIVER ONCOGEN OF LYMPHOMAS THROUGH C-MYC REGULATION |
HAEMATOLOGICA 102, 38-39 , 2017 |
2017 |
| A new precision medicine test to guide personalized treatments decision for acute myeloid leukemia patients |
Clinical Cancer Research 23 (24), 47-48 , 2017 |
2017 |
| Depth of response as surrogate marker for progression-free survival and overall survival in elderly newly diagnosed myeloma patients treated with VMP and Rd: GEM2010MAS65 |
Haematologica 102, 143-143 , 2017 |
2017 |
| NGS ANALYSIS AND IMPACT OF VARIANT ALLELIC FREQUENCY AT RELAPSE AND REFRACTORINESS STATUS IN AML PATIENTS |
HAEMATOLOGICA 102, 369-369 , 2017 |
2017 |
| Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and … |
Blood 130, 402 , 2017 |
2017 |
| VASCULAR RISK IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TIROSIN-KINASE INHIBITORS: MULTIDISCIPLINARY HANDLING EXPERIENCE |
HAEMATOLOGICA 102, 262-262 , 2017 |
2017 |
| HEMATOLOGIC TOXCITIY GRADE III-IV IS ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS |
HAEMATOLOGICA 102, 432-433 , 2017 |
2017 |
| Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema/GEM2012 trial |
Blood 130, 905 , 2017 |
2017 |
| Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea |
haematologica 102 (1), 103 , 2017 |
2017 |
| Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis |
European journal of haematology 98 (4), 407-414 , 2017 |
2017 |
| Activated and expanded natural killer cells expressing an NKG2D-CAR efficiently target multiple myeloma cells |
Blood 130, 4466 , 2017 |
2017 |
| Serum-free light-chains (sFLC) instead of urine protein electrophoresis (UPEP) for monitoring light-chain multiple myeloma (LCMM) |
Haematologica 102, 524-524 , 2017 |
2017 |
| Optofluidic device for the quantification of circulating tumor cells in breast cancer |
|
2017 |
| Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients |
Blood 130, 2891 , 2017 |
2017 |
| Low expression of CD39 and CD73 genes in centenarians compared with octogenarians |
Immunity & Ageing 14, 1-5 , 2017 |
2017 |
| IMPLEMENTATION OF MASSIVE SEQUENCING TECHNOLOGIES TO THE DETECTION OF MUTATIONS IN THE ABL KINASE DOMAIN OF BCR-ABL REORDERING |
HAEMATOLOGICA 102, 165-165 , 2017 |
2017 |
| PREDICTORS OF EARLY DEATH RELATED TO ACTIVE MULTIPLE MYELOMA IN ELDERLY PATIENTS RECEIVING OPTIMIZED FRONTLINE TREATMENT COMBINATIONS |
HAEMATOLOGICA 102, 274-275 , 2017 |
2017 |
| Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed multiple myeloma (MMY1001): an open-label, phase 1b study |
Blood 130, 1869 , 2017 |
2017 |
| EVOLUTION OF THE TREATMENT WITH TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA: LINES OF TREATMENT, TOXICITY, DISCONTINUATION AND SURVIVAL |
HAEMATOLOGICA 102, 283-283 , 2017 |
2017 |
| RUXOLITINIB/NILOTINIB/PREDNISOLONE COMBINATION: A PROMISING NOVEL TREATMENT FOR MYELOFIBROSIS |
HAEMATOLOGICA 102, 277-278 , 2017 |
2017 |
| Low expression of CD39 and CD73 genes in centenarians compared with octogenarians |
|
2017 |
| Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia |
British Journal of Haematology 178 (5), 764-771 , 2017 |
2017 |
| STUDY OF NON-CANONIC MUTATIONS OF JAK2 AND MPL IN THREE-NEGATIVE TRIPLE THYME TROMBOCYTEMIA THROUGH NEXT GENERATION SEQUENCING |
HAEMATOLOGICA 102, 22-22 , 2017 |
2017 |
| CYTOMORPHOLOGICAL EFFECTS OF DARATUMUMAB IN BONE MARROW |
HAEMATOLOGICA 102, 244-244 , 2017 |
2017 |
| FREQUENCY AND CLINICAL IMPACT OF CDKN2A/B GENE LOCUS IN AN ADULT T-ALL COHORT OF PATIENTS ENROLLED IN THE SPANISH PETHEMA GROUP PROTOCOLS |
HAEMATOLOGICA 102, 655-655 , 2017 |
2017 |
| THE PROTEIN CARBONYLATION PATTERN IS ALTERED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME |
HAEMATOLOGICA 102, 274-275 , 2017 |
2017 |
| MULTIPLE MYELOMA IN TREATMENT WITH ANTI CD38: NEGATIVIZATION OF CD38 AND OTHER PROGNOSTIC FACTORS |
HAEMATOLOGICA 102, 92-93 , 2017 |
2017 |
| A next-generation sequencing strategy for evaluating the most common genetic abnormalities in multiple myeloma |
The Journal of Molecular Diagnostics 19 (1), 99-106 , 2017 |
2017 |
| MUTATIONAL STUDY BY MASS SEQUENCING OF THE RPS14 GENE IN THE PATIENTS OF MYELODISPLASICO SYNDROME NO 5-Q |
HAEMATOLOGICA 102, 32-33 , 2017 |
2017 |
| Differentiation stage of myeloma plasma cells: biological and clinical significance |
Leukemia 31 (2), 382-392 , 2017 |
2017 |
| OBSERVATIONAL CLINICAL TRIAL FOR THE VALIDATION OF A TEST OF PRECISION MEDICINE IN ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 102, 76-77 , 2017 |
2017 |
| DETECTION BY NGS OF NEW EMERGING CLONES DURING TREATMENT ALLOWS BETTER PREDICTION OF RISK IN PATIENTS WITH MULTIPLE MYELOMA |
HAEMATOLOGICA 102, 12-12 , 2017 |
2017 |
| PROGNOSTIC VALUE OF EMR BY FLOW CYTOMETRY AND PET/CT POST-INDUCTION AND/OR POST-TRANSPLANT AND DURING MAINTENANCE IN MULTIPLE MYELOMA |
HAEMATOLOGICA 102, 105-105 , 2017 |
2017 |
| PRODUCTION OF AUTOLOGOUS, ACTIVATED AND EXPANDED NATURAL KILLER CELLS AND NK-CAR CELLS AS TREATMENT FOR MULTIPLE MYELOMA |
HAEMATOLOGICA 102, 52-53 , 2017 |
2017 |
| Altered Carbonylation Pattern in Myelodisplastic Syndromes |
Blood 130, 5302 , 2017 |
2017 |
| New alternatives for the evaluation of minimal residual disease (MRD) detection by next generation sequencing in multiple myeloma |
Blood 130, 1783 , 2017 |
2017 |
| hnRNPK as a Driver of Lymphomagenesis |
Clinical Lymphoma, Myeloma and Leukemia 17, S374-S375 , 2017 |
2017 |
| ACTIVATED AND EXPANDED NATURAL KILLER CELLS FROM MULTIPLE MYELOMA PATIENTS DESTROY TUMOR DRUG RESISTANT CELLS AND CLONOGENIC TUMOR CELLS |
HAEMATOLOGICA 102, 505-506 , 2017 |
2017 |
| DRUG INTERACTIONS IN PATIENTS TREATED WITH TYROSINCINASE INHIBITORS (ITC). IS A REAL PROBLEM? |
HAEMATOLOGICA 102, 24-25 , 2017 |
2017 |
| CLINICAL APPLICATION OF THE MASSIVE SEQUENCING ADDRESSED IN ACUTE MYELOBLASTIC LEUKEMIA |
HAEMATOLOGICA 102, 7-8 , 2017 |
2017 |
| Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in … |
Annals of hematology 96, 1069-1075 , 2017 |
2017 |
| COST MANAGEMENT IN AN INTEGRATED LABORATORY OF THIRD LEVEL HEMATOLOGY: KEY TOOL FOR THE CONTRIBUTION OF VALUE |
HAEMATOLOGICA 102, 252-252 , 2017 |
2017 |
| EVALUATION OF REMISSION IN MYELOMA. BONE MARROW ASPIRATION VS BIOPSY |
HAEMATOLOGICA 102, 293-294 , 2017 |
2017 |
| MYELODYSPLASTIC SYNDROME AND MULTIPLE MYELOMA HAVE THE SAME CLONAL ORIGIN IN PATIENTS WHO HAVE THEM CONCOMITANTLY |
HAEMATOLOGICA 102, 139-139 , 2017 |
2017 |
| Copy number profiling of adult relapsed B‐cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms |
Genes, Chromosomes and Cancer 56 (11), 810-820 , 2017 |
2017 |
| IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations associate with IMiD resistance in relapsed multiple myeloma |
Blood 130, 270 , 2017 |
2017 |
| FORECAST IMPACT OF THE NUMBER OF COPIES OF MITOCHONDRIAL DNA IN MULTIPLE MYELOMA |
HAEMATOLOGICA 102, 10-11 , 2017 |
2017 |
| Identification of miRSNPs associated with the risk of multiple myeloma |
International journal of cancer 140 (3), 526-534 , 2017 |
2017 |
| Targeted RNA-Seq Identify a Subset of Adolescent and Adult Patients with Acute Lymphoblastic Leukemia with BCR-ABL1-like Characteristics |
Blood 130, 2710 , 2017 |
2017 |
| Differential Diagnosis Between Myelodysplastic Syndromes and Non-Clonal Cytopenias by Flow Cytometry Analysis Using a Myeloid Maturation Database |
Leukemia Research 1 (55), S94-S95 , 2017 |
2017 |
| Minimal residual disease testing for multiple myeloma |
Hematology in Clinical Practice 8 (3), 219-227 , 2017 |
2017 |
| RUXOLITINIB/NILOTINIB/PREDNISOLONA, A PROMISING COMBINATION FOR THE TREATMENT OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS |
HAEMATOLOGICA 102, 287-287 , 2017 |
2017 |
| GENOTYPE CHARACTERIZATION OF LIGHT CHAIN AMYLOIDOSIS BY WHOLE EXOME SEQUENCING |
HAEMATOLOGICA 102, 106-106 , 2017 |
2017 |
| A phase Ib study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCDI) in patients with newly diagnosed multiple myeloma non-eligible for … |
Blood 130, 3160 , 2017 |
2017 |
| Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial |
Leukemia 31 (9), 1922-1927 , 2017 |
2017 |
| COMPARISON OF THE METHOD OF FLUORESCENCE, IMPEDANCE AND OPTICAL MICROSCOPY IN PLATELET COUNT IN DIFFERENT GROUPS OF PATIENTS |
HAEMATOLOGICA 102, 156-157 , 2017 |
2017 |
| Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array |
Hematological Oncology 35 (4), 746-751 , 2017 |
2017 |
| Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer |
Cancer Research , 2017 |
2017 |
| Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity |
Pharmacogenomics 18 (13), 1215-1223 , 2017 |
2017 |
| Characterization of Ex-Vivo PTCH1 Expression Under Tyrosine Kinase Inhibitors Treatment and Determination of Downstream Effectors Oh Hedgehog Pathway in CML |
Blood 130, 5245 , 2017 |
2017 |
| Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia |
British journal of cancer 117 (2), 256-265 , 2017 |
2017 |
| NEW MODEL TO QUANTIFY THE IN VITRO PHARMACOLOGICAL ACTIVITY OF BI-SPECIFIC ANTIBODIES IN HAEMATOLOGIC MALIGNANCIES |
HAEMATOLOGICA 102, 37-38 , 2017 |
2017 |
| Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells |
Clinical Cancer Research 23 (19), 5824-5835 , 2017 |
2017 |
| Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy |
Blood 130, 2289 , 2017 |
2017 |
| ANALYSIS OF THE IMMUNOGLOBULIN REPERTORY THROUGH NGS IN PERIPHERAL BLOOD INCREASES THE CLONAL DETECTION RANGE IN THE MM STUDY |
HAEMATOLOGICA 102, 11-11 , 2017 |
2017 |
| EFFECTIVENESS OF CHANGE TO DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND LATE ALARM AFTER IMATINIB. RELATION OF RESPONSE TO TREATMENT AND IMMUNOLOGICAL STATUS |
HAEMATOLOGICA 102, 24-24 , 2017 |
2017 |
| Pharmacologic evaluation of bispecific antibodies: A novel method to quantify their in vitro activity in hematologic samples. |
CLINICAL CANCER RESEARCH 23 (24), 46-47 , 2017 |
2017 |
| Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma |
Leukemia 31 (6), 1446-1449 , 2017 |
2017 |
| Drug discovery testing compounds in patient samples by automated flow cytometry |
SLAS Technology: Translating Life Sciences Innovation 22 (3), 325-337 , 2017 |
2017 |
| Gestión administrativa en los procesos académicos de la unidad Educativa Luis Augusto Mendoza Moreira, Cantón la Libertad, Provincia de Santa Elena, año 2016 |
Tesis de titulación). Universidad Estatal Península de Santa Elena , 2017 |
2017 |
| PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase |
PLoS One 12 (7), e0181366 , 2017 |
2017 |
| Interlaboratory Assessment Of Mutation Detection In Myeloid Malignancies By Targeted Next-Generation Sequencing |
Haematologica , 2017 |
2017 |
| Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma |
Leukemia 31 (10), 2094-2103 , 2017 |
2017 |
| Microfluidic device with dual-channel fluorescence acquisition for quantfication/identification of cancer cells |
|
2017 |
| DETECTION OF MINIMAL RESIDUAL DISEASE (EMR) IN ACUTE MYELOID LEUKEMIA THROUGH HIGH DEPTH SEQUENCE |
HAEMATOLOGICA 102, 76-76 , 2017 |
2017 |
| Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes |
Oncotarget 8 (63), 106948 , 2017 |
2017 |
| Safety and efficacy of filanesib in combination with pomalidomide and dexamethasone in refractory MM patients. Phase Ib/II pomdefil clinical trial conducted by the Spanish MM Group |
Blood 130, 1873 , 2017 |
2017 |
| The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients With MDS/AML-Related Somatic Mutations And Inferior Survival |
Clinical Lymphoma, Myeloma and Leukemia 17 (1), e11 , 2017 |
2017 |
| 5q+ MDS Patients with Low RPS14 Expression Are Candidates to Immune-Modulating Drugs |
Blood 130, 5303 , 2017 |
2017 |
| Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. |
Journal of Health Economics and Outcomes Research 5 (2), 162-174 , 2017 |
2017 |
| Interlaboratory Study Of Mutations Detection In Myeloid Neoplasms Through New Generation Sequencing |
Haematologica , 2017 |
2017 |
| STATES OF RESISTANCE TO TREATMENT IN LMA AND CORRELATION WITH THE FREQUENCY OF ALLELIC VARIANTS DETECTED BY NGS |
HAEMATOLOGICA 102, 80-80 , 2017 |
2017 |
| MRD ANALYSIS BY NEXT-GENERATION SEQUENCING APPROACH FOR ACUTE MYELOID LEUKEMIA FOLLOW-UP |
HAEMATOLOGICA 102, 366-366 , 2017 |
2017 |
| VCAM-1 AS A NOVEL DRUG THERAPY TARGET OF BONE MARROW MESENCHYMAL STEM CELLS IN MULTIPLE MYELOMA |
HAEMATOLOGICA 102, 771-771 , 2017 |
2017 |
| Maintenance treatment with lenalidomide for multiple myeloma increases the proportion of MRD negative (Flow-/PET-CT-) patients |
Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 3098 … , 2017 |
2017 |
| Harsh-Environment Resistant OH-Vibrations Sensitive Mid-Infrared Water-Ice Photonic Sensor |
|
2017 |
| TRAMETINIB PROMOTES RESPONSE TO TYROSINE KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 102, 79-80 , 2017 |
2017 |
| EFFICACY OF SWITCHING TO DASATINIB IN CHRONIC MYELOID PATIENTS WITH LATE WARNING RESPONSES TO IMATINIB. STUDY OF THE ASSOCIATION OF RESPONSE TO DASATINIB TO IMMUNOLOGIC STATUS |
HAEMATOLOGICA 102, 239-240 , 2017 |
2017 |
| ADVANCED STAGE MYELOMA IS CHARACTERIZED BY A SIGNIFICANT INCREASE OF MUTATIONS IN GENES ASSOCIATED WITH DRUG RESPONSE |
HAEMATOLOGICA 102, 102-102 , 2017 |
2017 |
| Abnormalities in mitochondrial DNA copy number have pathogenetic and prognostic implications in multiple myeloma |
Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 4378 … , 2017 |
2017 |
| NGS ANALYSIS IN ADULTS GREATER THAN 65 YEARS DIAGNOSED OF ACUTE MYELOID LEUKEMIA IN LOW INTENSITY TREATMENTS |
HAEMATOLOGICA 102, 133-133 , 2017 |
2017 |
| CRITICAL REVIEW OF THE DOUBLE NEGATIVITY IN THE SERUM AND URINE IMMUNOFIXATION (IF) TO ESTABLISH THE CATEGORY OF COMPLETE REMISSION IN MULTIPLE MYELOMA (MM) |
HAEMATOLOGICA 102, 99-99 , 2017 |
2017 |
| APPLICATION OF THE LYMPHOTRACK MASS SEQUENCING KIT (R) IN THE STUDY OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA. COMPARISON WITH CMF AND ASO-PCR |
HAEMATOLOGICA 102, 9-9 , 2017 |
2017 |
| Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials |
Journal of Clinical Oncology 35 (25), 2900-2910 , 2017 |
2017 |
| DETECTION OF NEW EMERGING CLONES DURING TREATMENT BY NGS ALLOWS A BETTER RISK PREDICTION ON MULTIPLE MYELOMA PATIENTS |
HAEMATOLOGICA 102, 271-271 , 2017 |
2017 |
| Risk factors for non‐melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera |
European Journal of Haematology 96 (3), 285-290 , 2016 |
2016 |
| MUTATIONAL PROFILE IN THE CLINICAL EVOLUTION OF ACUTE MYELOID LEUKEMIA ASSOCIATED WITH RESISTANCE, REFRACTORY AND RELAPSE |
HAEMATOLOGICA 101, 5-6 , 2016 |
2016 |
| Evaluation of the potential therapeutic benefits of macrophage reprogramming in Multiple Myeloma Running |
American Society of Hematology , 2016 |
2016 |
| Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia |
Blood, The Journal of the American Society of Hematology 128 (22), 5281-5281 , 2016 |
2016 |
| Safety and efficacy of dasatinib treatment change for patients previosly treated with imatinib with late warning response. Results from the phase II, open, multicenter dasapost … |
Blood 128 (22), 5450 , 2016 |
2016 |
| THE SERUM FREE LIGHT CHAINS TEST (FLCS) MAY BE SUPERIOR TO ELECTROPHORESIS IN URINE (EEFO) FOR DEFINING THE RESPONSE IN MMBJ |
HAEMATOLOGICA 101, 92-92 , 2016 |
2016 |
| Ex Vivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity for Idelalisib and Ibrutinib on CLL Cells |
Haematologica 101 (suppl. 1), 426 , 2016 |
2016 |
| Safety and efficacy of filanesib in combination with pomalidomide and dexamethasone in refractory MM patients. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM Group |
Blood 128 (22), 4503 , 2016 |
2016 |
| The poor prognosis of high cytogenetics abnormalities in elderly patients might be overcome with an optimized total therapy approach including proteasome inhibitors, IMiD's … |
Blood 128 (22), 5688 , 2016 |
2016 |
| IMPACT OF THE MOLECULAR PROFILE ON THE RISK OF ACUTE MYELOID TRANSFORMATION IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA |
HAEMATOLOGICA 101, 163-163 , 2016 |
2016 |
| Response rate to the treatment of Waldenström macroglobulinemia: a meta-analysis of the results of clinical trials |
Critical Reviews in Oncology/Hematology 105, 118-126 , 2016 |
2016 |
| Cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared to bortezomib, thalidomide and dexamethasone (VTD) as induction therapy for the treatment of transplant … |
Blood, The Journal of the American Society of Hematology 128 (22), 4505-4505 , 2016 |
2016 |
| Identification of novel regulators and therapeutic targets in hematologic malignancies |
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 38, S53-S53 , 2016 |
2016 |
| Pattern of CNS relapse in acute lymphoblastic leukemia BCR-ABL positive, the importance of characterization of ABL1 mutations in cerebrospinal fluid. |
Ferrata Storti Foundation , 2016 |
2016 |
| Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera |
British Journal of Haematology 172 (5), 786-793 , 2016 |
2016 |
| ESSENTIAL THROMBOCYTHEMIA WITH JAK2 V617F OR CALR MUTATION: TWO DIFFERENT PHENOTYPES |
HAEMATOLOGICA 101, 811-811 , 2016 |
2016 |
| COLCHICINE VERSUS PLACEBO FOR PREVENTION OF POST-PROCEDURAL ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS |
CARDIOLOGY 134, 227-227 , 2016 |
2016 |
| TRAMETINIB ENHANCES RESPONSE AGAINST TYROSINE KINASE INHIBITORS IN PRECLINICAL MODELS OF MYELOID LEUKAEMIA |
HAEMATOLOGICA 101, 175-175 , 2016 |
2016 |
| Preclinical evidence that trametinib enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia |
Blood, The Journal of the American Society of Hematology 128 (22), 1581-1581 , 2016 |
2016 |
| An ex vivo native environment precision medicine AML test and the correlation with responses to 1st line treatment. |
Journal of Clinical Oncology 34 (15_suppl), e18510-e18510 , 2016 |
2016 |
| Nilotinib Plus Ruxolitinib Produces Anti-Fibrotic Effect |
Blood 128 (22), 5497 , 2016 |
2016 |
| Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma |
Blood, The Journal of the American Society of Hematology 128 (18), 2241-2252 , 2016 |
2016 |
| IMPACT OF PROTEIN EXPRESSION OF CEREBLON, IKAROS, AIOLOS, CYCLIN D1 AND CYCLIN D2 QUANTIFIED BY MEANS OF CAPILLARY IMMUNOASSAY IN THE SURVIVAL OF PATIENTS WITH MYELOMA |
HAEMATOLOGICA 101, 23-23 , 2016 |
2016 |
| THE ROLE OF COMORBIDITY ON EARLY MORTALITY IN MULTIPLE MYELOMA. A SINGLE INSTITUTION POPULATION-BASED STUDY EMPHASIZING THE NEED FOR STANDARDIZATION |
HAEMATOLOGICA 101, 787-787 , 2016 |
2016 |
| DEEP SEQUENCING OF 23 GENES DESIGNATED BY TCGA STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE |
HAEMATOLOGICA 101, 366-367 , 2016 |
2016 |
| HNRNP K: A NOVEL ONCOGENE THAT DRIVES C-MYC-DEPENDENT LYMPHOMAS AS A POTENTIAL THERAPY TARGET |
HAEMATOLOGICA 101, 269-269 , 2016 |
2016 |
| (clone) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open … |
|
2016 |
| The impact of the type of myeloma-defining event on early mortality and survival |
Haematologica 101, 544-545 , 2016 |
2016 |
| Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up … |
Annals of hematology 95, 2033-2041 , 2016 |
2016 |
| REAL-WORLD CHARACTERISTICS, TREATMENT PATHWAYS AND HEALTHCARE RESOURCE USE IN PATIENTS TREATED FOR RELAPSED REFRACTORY MULTIPLE MYELOMA IN SPAIN: PRELIMINARY RESULTS FROM THE … |
HAEMATOLOGICA 101, 835-835 , 2016 |
2016 |
| A FUNCTIONAL VARIANT IN THE HNF1B GENE ASSOCIATED WITH THE OVERALL SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA: RESULTS OF IMMENSE CONSORTIUM AND META-ANALYSIS |
HAEMATOLOGICA 101, 24-25 , 2016 |
2016 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … |
The Lancet Oncology 17 (1), 27-38 , 2016 |
2016 |
| Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderly multiple myeloma |
American Society of Hematology , 2016 |
2016 |
| Non-invasive genetic profiling is highly applicable in multiple myeloma (MM) through characterization of circulating tumor cells (CTCs) |
Blood 128 (22), 801 , 2016 |
2016 |
| AN EX VIVO NATIVE ENVIRONMENT PRECISION MEDICINE TEST SHOWS HIGH CLINICAL CORRELATION WITH RESPONSES TO 1ST LINE ACUTE MYELOID LEUKEMIA TREATMENT |
|
2016 |
| Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer |
Oncology Research and Treatment, 182-183 , 2016 |
2016 |
| CLINICAL VALIDATION OF SIMPLIFIED METHOD OF MASSIVE SEQUENCING FOR QUANTIFICATION OF RESIDUAL DISEASE IN MULTIPLE MYELOMA |
HAEMATOLOGICA 101, 22-23 , 2016 |
2016 |
| Daratumumab, bortezomib, and dexamethasone for multiple myeloma |
New England Journal of Medicine 375 (8), 754-766 , 2016 |
2016 |
| Two distinct molecular subtypes of chronic lymphocytic leukemia give new insights on the pathogenesis of the disease and identify novel therapeutic targets |
Leukemia & Lymphoma 57 (1), 134-142 , 2016 |
2016 |
| Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma |
British Journal of Haematology 175 (3), 448-456 , 2016 |
2016 |
| Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph … |
Annals of hematology 95, 719-732 , 2016 |
2016 |
| ANALYSIS OF PROGNOSTIC IMPACT OF MOLECULAR RESPONSE ASSESSED BY 2 METHODS OF NGS IN MULTIPLE MYELOMA |
HAEMATOLOGICA 101, 23-24 , 2016 |
2016 |
| ANALYTICAL CHARACTERISTICS OF METASTASIC INFILTRATION OF MEDULA OSEA BY NON HEMATOLOGICAL TUMOURS. MORE FREQUENT ETIOLOGY. ROLE OF LACITHOLOGY |
HAEMATOLOGICA 101, 110-111 , 2016 |
2016 |
| PREDICTION OF RESPONSE TO TREATMENT OF ACUTE MIELOID LEUKEMIA: MUTATIONAL PROFILE (NGS) AND EX VIVO PHARMACOLOGICAL TEST |
HAEMATOLOGICA 101, 3-4 , 2016 |
2016 |
| MUTATIONS IN TYP53 AND EZH2 IMPLICATE WORST PROGNOSIS IN PATIENTS WITH SMD TREATED WITH HYPOMETHYLATION |
HAEMATOLOGICA 101, 67-68 , 2016 |
2016 |
| HYPERLEUCOCYTOSIS AND LEUCOSTASIS IN ACUTE MYELOBLASTIC LEUKEMIA: ASSOCIATED CLINICAL AND BIOLOGICAL FACTORS |
HAEMATOLOGICA 101, 317-317 , 2016 |
2016 |
| Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients |
Blood, The Journal of the American Society of Hematology 127 (25), 3165-3174 , 2016 |
2016 |
| Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale |
Leukemia 30 (9), 1844-1852 , 2016 |
2016 |
| TP53 AND EZH2 MUTATIONS PREDICT POOR SURVIVAL IN PATIENTS TREATED WITH HYPOMETHYLATING AGENTS IN MDS |
HAEMATOLOGICA 101, 68-68 , 2016 |
2016 |
| 2 DIFFERENT PHENOTYPES IN ESSENTIAL THROMBOCYTHEMIA: MUTATION JAK2 V617F OR CALR |
HAEMATOLOGICA 101, 187-187 , 2016 |
2016 |
| Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial |
Blood, The Journal of the American Society of Hematology 128 (22), 2078-2078 , 2016 |
2016 |
| p21-Associated Kinase 4 (PAK4) Addiction in Multiple Myeloma: A Potential Therapeutic Application with Enhanced Activity in FGFR3 Expressing Myeloma |
Blood 128 (22), 3302 , 2016 |
2016 |
| Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis |
Blood, The Journal of the American Society of Hematology 127 (24), 3035-3039 , 2016 |
2016 |
| FAMILIAL MYELODISPLASTIC SYNDROME. ABOUT A CASE WITH 2 NEW MUTATIONS |
HAEMATOLOGICA 101, 266-266 , 2016 |
2016 |
| Early mortality in multiple myeloma: the time‐dependent impact of comorbidity: a population‐based study in 621 real‐life patients |
American journal of hematology 91 (7), 700-704 , 2016 |
2016 |
| Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain |
Blood 128 (22), 3074 , 2016 |
2016 |
| EFFICACY AND SAFETY OF DASATINIB IN PATIENTS WITH UNDERSTIMATED LATE RESPONSE TOWARDS IMATINIB. RESULTS OF DASAPOST PHASE II, MULTICENTRIC, OPEN AND NON RANDOMIZED STUDY |
HAEMATOLOGICA 101, 79-79 , 2016 |
2016 |
| Method for quantifying the level of minimal residual disease in a subject |
US Patent App. 14/932,267 , 2016 |
2016 |
| Prognostic impact of molecular response assessed by next-generation sequencing in a large cohort of multiple myeloma patients |
Blood, The Journal of the American Society of Hematology 128 (22), 3283-3283 , 2016 |
2016 |
| A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis |
Oncotarget 7 (37), 59029 , 2016 |
2016 |
| SURVIVAL ANALYSIS AND CHARACTERISTICS OF PATIENTS DIAGNOSED WITH CML IN THE TYROSINE KINASE INHIBITORS ERA |
HAEMATOLOGICA 101, 346-346 , 2016 |
2016 |
| Analysis of renal impairment in MM-003, a phase III study of pomalidomide+ low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory … |
Haematologica 101 (7), 872 , 2016 |
2016 |
| EVALUATION OF RESIDUAL DISEASE BY FLOW CYTOMETRY AND PET/CT IN PATIENTS WITH MULTIPLE MYELOMA IN THE TREATMENT OF LENALIDOMIDE MAINTENANCE |
HAEMATOLOGICA 101, 26-26 , 2016 |
2016 |
| IL-15/4-1BBL activated and expanded Natural Killer cells in paediatric patients with refractory acute leukaemia |
BONE MARROW TRANSPLANTATION 51, S255-S256 , 2016 |
2016 |
| Prevention of thrombosis in patients with polycythemia vera treated with hydroxuyurea plus phlebotomies or hydroxyurea alone |
HAEMATOLOGICA 101, 95-96 , 2016 |
2016 |
| QUANTIFICATION OF CYCLIN D1, CYCLIN D2, IKAROS, AIOLOS AND CEREBLON PROTEINS BY CAPILARY IMMUNOASSAY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND ANALYSIS OF THEIR … |
HAEMATOLOGICA 101, 78-78 , 2016 |
2016 |
| CHARACTERISTICS OF THE PROGRESSION OF DISEASE AND TREATMENT OF MULTIPLE MYELOMA IN RELAPSE OR REFRACTORY IN SPAIN: RESULTS OF THE PREMIERE STUDY |
HAEMATOLOGICA 101, 301-301 , 2016 |
2016 |
| HNRNP K: AN ONCOGENE AND TUMOR SUPPRESSOR, TWO DISCRETE PATHS TO AML THROUGH ON GENE |
HAEMATOLOGICA 101, 11-12 , 2016 |
2016 |
| A novel evolutionary pattern revealed using deep sequencing of immunoglobulin loci at diagnosis and over the course of treatment in multiple myeloma patients |
Blood 128 (22), 238 , 2016 |
2016 |
| The presence of MDS-like phenotypic abnormalities (MDS-PA) identifies newly diagnosed multiple myeloma (MM) patients with MDS/AML-related somatic mutations and inferior survival |
Blood 128 (22), 375 , 2016 |
2016 |
| GENOME-WIDE ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISM (SNPS) IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE |
HAEMATOLOGICA 101, 368-368 , 2016 |
2016 |
| Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma |
Oncoimmunology 5 (12), e1250051 , 2016 |
2016 |
| In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins |
Leukemia 30 (4), 861-872 , 2016 |
2016 |
| Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM |
Blood, The Journal of the American Society of Hematology 127 (4), 420-425 , 2016 |
2016 |
| IMPORTANCE OF SERINE/THREONINE KINASE PAK4 IN MULTIPLE MYELOMA: THERAPEUTIC APPLICATIONS OF A NEW CLASS OF INHIBITORS |
HAEMATOLOGICA 101, 21-21 , 2016 |
2016 |
| PROGNOSTIC VALUE AND USEFULNESS OF SERUM-FREE-LIGHT-CHAINS-RATIO (SFLCR) AND SERUM HEAVY-LIGHT-CHAINS-RATIO (SHLCR) IN SYMPTOMATIC MULTIPLE MYELOMA IN THE CONTEXT OF THREE GEM … |
HAEMATOLOGICA 100, 90-91 , 2015 |
2015 |
| Multiple Infusions of Autologous Activated and Expanded Natural Killer Cells: A New Therapeutic Option for Multiple Myeloma |
Clinical Lymphoma, Myeloma and Leukemia 15, e297-e298 , 2015 |
2015 |
| Bortezomib plus melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) in newly diagnosed elderly myeloma patients overcome the poor prognosis of high … |
Blood 126 (23), 4243 , 2015 |
2015 |
| QUADRUPLING OF THE GENE OF ALPHA GLOBIN IN A CASE OF THALASSEMIA INTERMEDIA |
HAEMATOLOGICA 100, 96-97 , 2015 |
2015 |
| INDUCED LYMPHOCYTOSIS FOLLOWING THE INTAKE OF DASATINIB IS ASSOCIATED WITH THE INHIBITION OF LYMPHOCYTARY MIGRATION AND MODIFICATION OF THE EXPRESSION OF CHEMOKINE RECEPTORS … |
HAEMATOLOGICA 100, 25-26 , 2015 |
2015 |
| Bortezomib, melphalan, prednisone (VMP) and lenalidomide plus dexamethasone (Rd) is the optimal combination for patients with newly diagnosed multiple myeloma (MM) patients … |
Blood 126 (23), 1848 , 2015 |
2015 |
| DARATUMUMAB INTERFERES IN THE PRE-TRANSFUSION TESTS IN THE BLOOD BANK |
HAEMATOLOGICA 100, 36-36 , 2015 |
2015 |
| CHRONIC MYELOID LEUKEMIA (LMC) IS CURRENTLY DIAGNOSED IN LESS ADVANCED SITUATION, AND IN SPAIN IN LOW RISK STAGES THAN IN NEIGHBOURING COUNTRIES |
HAEMATOLOGICA 100, 193-193 , 2015 |
2015 |
| Current management of multiple myeloma treatment in Spain: meetings of experts from 41 hospitals |
Haematologica 100, 736-736 , 2015 |
2015 |
| EXPRESSION OF RPS14 IN THE MYELODYSPLASTIC SYNDROMES |
HAEMATOLOGICA 100, 188-188 , 2015 |
2015 |
| Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. |
|
2015 |
| Targeted Genomic Mutation Panel (M3 P) Results from 504 Multiple Myeloma (MM) Patients |
Blood 126 (23), 1795 , 2015 |
2015 |
| Blood First Edition Paper, prepublished online June 18, 2015; DOI 10.1182/blood-2015-04-638742 |
|
2015 |
| A Way to Individualized Therapy in Acute Myeloid Leukemia (AML): NGS Mutational Profile and Ex Vivo Pharmacological Test (Ex-viTech) |
Blood 126 (23), 1376 , 2015 |
2015 |
| A Delphi method-based consensus for the management of IFI in HSCT recipients |
BONE MARROW TRANSPLANTATION 50, S193-S193 , 2015 |
2015 |
| Treatment for patients with newly diagnosed multiple myeloma in 2015 |
Blood Reviews 29 (6), 387-403 , 2015 |
2015 |
| Matched-pairs analysis of outcomes with bortezomib, melphalan, and prednisone (VMP) treatment for previously untreated multiple myeloma (MM) using long-term follow-up data from … |
Clinical Lymphoma, Myeloma and Leukemia 15, e73-e74 , 2015 |
2015 |
| The relevance of minimal residual disease (MRD) monitoring in elderly multiple myeloma (MM) patients |
Blood 126 (23), 4181 , 2015 |
2015 |
| Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase |
Blood 126 (23), 2791 , 2015 |
2015 |
| ACUTE PROMYELOCYTIC LEUKEMIA VARIANT. INCIDENCE AND CHARACTERISTICS OF THE REPORTED CASES IN THE PEHTEMA-LPA CASE |
HAEMATOLOGICA 100, 144-144 , 2015 |
2015 |
| 146 MUTATIONAL PROFILE AND COPY NUMBER VARIATIONS IN MYELODYSPLASTIC SYNDROMES BY HIGH-DEPTH NEXT GENERATION SEQUENCING |
Leukemia Research, S73-S74 , 2015 |
2015 |
| Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length |
International journal of cancer 136 (5), E351-E358 , 2015 |
2015 |
| Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium |
Endocrine-Related Cancer 22, 545-559 , 2015 |
2015 |
| Prognostic value of antigen expression in multiple myeloma (MM): a large GEM/Pethema Study based in four consecutive clinical trials |
Blood 126 (23), 19 , 2015 |
2015 |
| Drug induced depletion of myeloid progenitors in bone marrow samples as an ex vivo estimation of hematotoxicity |
Clinical Lymphoma, Myeloma and Leukemia 15, S240-S241 , 2015 |
2015 |
| CALR mutations screening should not be studied in splanchnic vein thrombosis. |
British journal of haematology 170 (4) , 2015 |
2015 |
| P-225 Mutation detection rate among patients with adenomatous polyposis |
Annals of Oncology 26, iv65 , 2015 |
2015 |
| Autologous Activated and Expanded Natural Killer Cells Destroy Multiple Myeloma Clonogenic Tumor Cells through NKG2D and Its Ligands |
Clinical Lymphoma, Myeloma and Leukemia 15, e245-e246 , 2015 |
2015 |
| CURRENT MANAGEMENT OF THE TREATMENT OF MULTIPLE MYELOMA IN SPAIN: MEETING OF EXPERTS OF 41 HOSPITALS |
HAEMATOLOGICA 100, 248-249 , 2015 |
2015 |
| Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose … |
Haematologica 100 (10), 1334 , 2015 |
2015 |
| Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression |
Blood 126 (23), 4015 , 2015 |
2015 |
| Myeloproliferative neoplasm in a thalassaemic patient: response to treatment with a JAK inhibitor |
Annals of Hematology 94, 1237-1239 , 2015 |
2015 |
| TREATMENT OF POLYCYTHEMIA VERA WITH HYDROXYUREA: RATE OF RESPONSE, RESISTANCE/INTOLERANCE AND EVOLUTIVE COMPLICATIONS IN A SERIES OF 1165 PATIENTS |
HAEMATOLOGICA 100, 24-24 , 2015 |
2015 |
| Switching to second‐generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib‐treated patients with chronic myeloid leukemia with more than … |
Cancer Medicine 4 (7), 995-1002 , 2015 |
2015 |
| REPEATED INFUSIONS OF NK AUTOLOGOUS CELLS ACTIVATED AND EXPANDED IN COMBINATION WITH ANTIMYELOMA DRUGS: A NEW THERAPEUTIC OPTION AGAINST REFRACTORY MULTIPLE MYELOMA |
HAEMATOLOGICA 100, 50-51 , 2015 |
2015 |
| Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols |
Cancer 121 (21), 3809-3817 , 2015 |
2015 |
| hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21. 32 Locus That Defines a Subset of AML |
Blood, The Journal of the American Society of Hematology 126 (23), 439-439 , 2015 |
2015 |
| ASSESSMENT OF IMPACT OF TP53 IN DIFFERENT HAEMATOLOGICAL NEOPLASIAS |
HAEMATOLOGICA 100, 81-82 , 2015 |
2015 |
| Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma |
Blood 126 (23), 2972 , 2015 |
2015 |
| Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium |
Endocrine-Related Cancer 22 (4), 545-559 , 2015 |
2015 |
| Clinical grade activated natural killer products for adoptive immunotherapy against high-risk malignancies |
Haematologica 100, 289-290 , 2015 |
2015 |
| Next generation flow (NGF) for high sensitive detection of minimal residual disease (MRD) in multiple myeloma (MM) |
Blood 126 (23), 367 , 2015 |
2015 |
| Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial |
haematologica 100 (8), 1096 , 2015 |
2015 |
| IDENTIFICATION OF ALTERATIONS IN THE NUMBER OF COPIES (CNA) AND IMPLIED MUTATIONS IN THE PROGRESION AND RELAPSE OF LAL-T |
HAEMATOLOGICA 100, 150-150 , 2015 |
2015 |
| An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL |
Blood 126 (23), 2485 , 2015 |
2015 |
| Antiphospholipid syndrome in a patient suffering from congenital dyserythropoietic anemia type III |
Annals of hematology 94, 1411-1412 , 2015 |
2015 |
| Usefulness of serum-free-light-chains-ratio (SFLCR) and serum heavy-light-chains-ratio (SHLCR) in multiple myeloma in the context of three GEM/Pethema clinical trials |
Blood 126 (23), 2962 , 2015 |
2015 |
| Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients |
Nature communications 6 (1), 7539 , 2015 |
2015 |
| Patterns of relapse and outcome of elderly multiple myeloma patients treated with VMP or VTP as induction followed by maintenance with VT or VP in the Spanish GEM2005MAS65 trial |
Clinical Lymphoma, Myeloma and Leukemia 15, e278-e280 , 2015 |
2015 |
| Autologous Activated and Expanded Natural Killer Cells Are Safe and Clinically Actives in Multiple Myeloma |
Blood 126 (23), 1856 , 2015 |
2015 |
| MUTATIONAL PROFILE STUDY OF DIAGNOSIS OF ACUTE MYELOID LEUKEMIA (AML) BY NEXT GENERATION SEQUENCING (NGS) |
HAEMATOLOGICA 100, 19-20 , 2015 |
2015 |
| Prognostic Significance of Copy Number Alterations in B-lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled in Risk-adapted Protocols from the PETHEMA Group |
Clinical Lymphoma, Myeloma and Leukemia 15, S173-S174 , 2015 |
2015 |
| High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test |
Blood, The Journal of the American Society of Hematology 126 (23), 4837-4837 , 2015 |
2015 |
| PROGNOSTIC IMPACT OF TRANSPORTER GENE POLYMORPHISMS IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA ADULTS |
HAEMATOLOGICA 100, 367-368 , 2015 |
2015 |
| ABL QUINASE DOMAIN MUTATIONS IN LCR IN TWO PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA PHI plus WITH RELAPSE IN CENTRAL NERVOUS SYSTEM |
HAEMATOLOGICA 100, 256-256 , 2015 |
2015 |
| An open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis: results from HARMONY study |
Blood 126 (23), 827 , 2015 |
2015 |
| Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations |
Leukemia Research Reports 4 (2), 64-69 , 2015 |
2015 |
| Spatiotemporal analysis of intraclonal heterogeneity in multiple myeloma: unravelling the impact of treatment and the propagating capacity of subclones using whole exome sequencing |
Blood 126 (23), 371 , 2015 |
2015 |
| Detailed characterization of MLH1 p. D41H and p. N710D variants coexisting in a Lynch syndrome family with conserved MLH1 expression tumors |
Clinical Genetics 87 (6), 543-548 , 2015 |
2015 |
| MUTATIONAL PROFILE IN MYELODYSPLASTIC SYNDROMES BY HIGH-DEPTH NEXT GENERATION SEQUENCING AND CLINICAL RELEVANCE |
HAEMATOLOGICA 100, 479-479 , 2015 |
2015 |
| Deep response in multiple myeloma: a critical review |
BioMed research international 2015 (1), 832049 , 2015 |
2015 |
| Prognostic value of immune profiling multiple myeloma patients during minimal residual disease monitoring in the Pethema/GEM2010MAS65 study |
Blood 126 (23), 721 , 2015 |
2015 |
| Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM) |
Blood 126 (23), 2963 , 2015 |
2015 |
| What is the frequency of transplant-eligible multiple myeloma patients being cured? The impact of an MGUS-like signature at diagnosis and MRD-negativity |
Blood 126 (23), 725 , 2015 |
2015 |
| ANALYSIS OF RESULTS OBTAINED IN CLINICAL TRIAL PHASE I/II FOR HAEMATOLOGICAL PATHOLOGY. EXPERIENCE IN THE HOSPITAL 12TH OCTOBER |
HAEMATOLOGICA 100, 117-118 , 2015 |
2015 |
| IMPLEMENTATION OF A MULTIPLE MYELOMA SPECIFIC CUSTOM 77-GENE MUTATION PANEL |
HAEMATOLOGICA 100, 60-60 , 2015 |
2015 |
| MUTATIONAL PROFILE STUDY OF ADULT DE NOVO ACUTE MYELOID LEUKEMIA BY HIGH-DEPTH NEXT GENERATION SEQUENCING (NGS) |
HAEMATOLOGICA 100, 647-647 , 2015 |
2015 |
| hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies |
Cancer cell 28 (4), 486-499 , 2015 |
2015 |
| Pretransplant induction with VTD (Bortezomib/Thalidomide/Dexamethasone) significantly improves PFS: long-term results of the randomized phase 3 PETHEMA/GEM study |
Clinical Lymphoma, Myeloma and Leukemia 15, e49-e50 , 2015 |
2015 |
| SPANISH RECORD OF MYELOFIBROSIS: DESCRIPTIVE ANALYSIS |
HAEMATOLOGICA 100, 189-189 , 2015 |
2015 |
| Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality |
Blood, The Journal of the American Society of Hematology 126 (7), 858-862 , 2015 |
2015 |
| Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone |
haematologica 100 (10), 1327 , 2015 |
2015 |
| TEST OF PERSONALIZED MEDICINE FOR PHARMACOLOGY EX VIVO IN NATIVE ENVIRONMENT FOR ACUTE MYELOID LEUKEMIA |
HAEMATOLOGICA 100, 145-145 , 2015 |
2015 |
| DEREGULATION OF MICRO RNA'S IN PATIENTS WITH POLYCYTHEMIA VERA (PV) AND ESSENTIAL THROMBOSIS (TE) |
HAEMATOLOGICA 100, 191-191 , 2015 |
2015 |
| IN HOUSE NEXT GENERATION SEQUENCING METHOD OF INMUNOGLOBULIN GENES FOR MINIMAL RESIDUAL DISSEASE QUANTIFICATION IN MULTIPLE MYELOMA |
HAEMATOLOGICA 100, 495-496 , 2015 |
2015 |
| PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: MM-003 SUBANALYSIS OF ELDERLY PATIENTS (> 65 AND … |
Haematologica 99, 364-365 , 2014 |
2014 |
| Comparison of sequential vs alternating administration of bortezomib, melphalan, prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly pts with newly diagnosed … |
Blood, The Journal of the American Society of Hematology 124 (21), 178-178 , 2014 |
2014 |
| hnRNP K: A Tumor Suppressor or Oncogene? |
Blood 124 (21), 259 , 2014 |
2014 |
| The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia … |
Haematologica 99 (4), e55 , 2014 |
2014 |
| HARMONY: an open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis (MF) |
Blood 124 (21), 710 , 2014 |
2014 |
| 1st Line AML Equivalent Treatments Cytarabine Plus an Anthracyclin (Ida, Dau, Mit) Show Alternative Sensitive/Resistant Profiles in ex vivo Patient Sample Chemosensitivity … |
Clinical Lymphoma, Myeloma and Leukemia 14, S117-S118 , 2014 |
2014 |
| Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute … |
ABSTRACTS, 10-10 , 2014 |
2014 |
| DO CHRONIC MYELOID LEUKEMIA PATIENTS WITH LATE" WARNING" RESPONSES BENEFIT FROM SWITCHING THERAPY TO A SECOND GENERATION TYROSINE KINASE INHIBITOR? |
HAEMATOLOGICA 99, 327-328 , 2014 |
2014 |
| Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients |
Cancer Research 74 (19_Supplement), 5078-5078 , 2014 |
2014 |
| 427 Hematotoxicity potential of new drug candidates measured in hematopoietic progenitors in bone marrow samples |
European Journal of Cancer, 136-137 , 2014 |
2014 |
| IDENTIFICATION OF A POTENTIALLY NOVEL TUMOR SUPPRESSOR IN AML |
HAEMATOLOGICA 99, 257-257 , 2014 |
2014 |
| CALR-MUTATED OR TRIPLE-NEGATIVE (JAK-2 AND MPL) IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS |
HAEMATOLOGICA 99, 658-658 , 2014 |
2014 |
| Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 … |
Blood, The Journal of the American Society of Hematology 124 (21), 3798-3798 , 2014 |
2014 |
| HIGH THROUGHPUT SCREENING ON PERIFPERHAL BLOOD CD34 CELLS WITH A FLOW CYTOMETRY AUTOMATED PLATFORM (EXVITECH), TO IDENTIFY SENSITIVITY TO RUXOLITINIB IN MYELOFIBROSIS PATIENTS |
HAEMATOLOGICA 99, 124-125 , 2014 |
2014 |
| THE EFFECT OF BORTEZOMIB ON DIFFERENT CELL SUBSETS: AN APPROACH FOR AN INDIVIDUAL PERSONALIZED MEDICINE |
HAEMATOLOGICA 99, 97-98 , 2014 |
2014 |
| Ruxolitinib in combination with nilotinib and prednisolone, a new synergistic approach to treat myelofibrosis |
Blood 124 (21), 903 , 2014 |
2014 |
| PHARMACOLOGICAL PROFILES OF AML TREATMENTS IN PATIENT SAMPLES TO PERSONALIZE TREATMENT |
HAEMATOLOGICA 99, 292-292 , 2014 |
2014 |
| Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium |
Blood 124 (21), 2044 , 2014 |
2014 |
| A phase II single-arm safety study of elotuzumab in combination with thalidomide and low dose dexamethasone in patients with relapsed and/or refractory multiple myeloma |
Haematologica 99, 361-362 , 2014 |
2014 |
| Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma |
Blood, The Journal of the American Society of Hematology 123 (20), 3073-3079 , 2014 |
2014 |
| The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis |
Blood 124 (21), 3421 , 2014 |
2014 |
| Age at onset should be a major criterion for subclassification of colorectal cancer |
The Journal of Molecular Diagnostics 16 (1), 116-126 , 2014 |
2014 |
| MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR … |
Haematologica 99, 110-110 , 2014 |
2014 |
| Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens |
Blood 124 (21), 2108 , 2014 |
2014 |
| Autologous Activated and Expanded Natural Killer Cells Kill Clonogenic Myeloma Cells: A New Therapeutic Option for Multiple Myeloma |
Blood 124 (21), 3467 , 2014 |
2014 |
| Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry |
Leukemia 28 (2), 391-397 , 2014 |
2014 |
| Feasibility of tyrosine kinase inhibitor (TKI) treatment in older patients with Ph+ chronic myeloid leukemia (CML): A Spanish group of CML (GELMC) retrospective study |
Journal of Geriatric Oncology 5, S24 , 2014 |
2014 |
| Wilms’ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML |
Blood, The Journal of the American Society of Hematology 124 (21), 1036-1036 , 2014 |
2014 |
| GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? |
Blood, The Journal of the American Society of Hematology 124 (12), 1887-1893 , 2014 |
2014 |
| Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor? |
American journal of hematology 89 (11), E206-E211 , 2014 |
2014 |
| Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine |
Clinical Lymphoma Myeloma and Leukemia 14 (4), 305-318 , 2014 |
2014 |
| 230 High correlation between clinical responses to first line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured … |
European Journal of Cancer, 77-78 , 2014 |
2014 |
| Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells. |
Blood 124 (21), 3639 , 2014 |
2014 |
| Eric Lippert, Olivier Mansier, Marina Migeon, Barbara Denys, Asa Nilsson, et al.. Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden … |
< bound method Organization. get_name_with_acronym of< Organization: Inserm … , 2014 |
2014 |
| The Pharmacological Profiles of Approved Cytotoxic AML Treatments ex vivo Identifies Sensitive vs Resistant Treatments in Patient’s Leukemic Cells |
Clinical Lymphoma, Myeloma and Leukemia 14, S117 , 2014 |
2014 |
| Clinical significance of sensitive Flow-MRD monitoring in elderly multiple myeloma patients on the Pethema/GEM2010MAS65 Trial |
Blood 124 (21), 3390 , 2014 |
2014 |
| Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database |
Nature genetics 46 (2), 107-115 , 2014 |
2014 |
| ACTIVATED AND EXPANDED NATURAL KILLER (NKAE) CELLS KILL MULTIPLE MYELOMA (MM) CLONOGENIC PLASMA CELLS THROUGH NKG2D AND NKP30 RECEPTORS AND THEIR LIGANDS |
HAEMATOLOGICA 99, 96-97 , 2014 |
2014 |
| JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis |
European Journal of Gastroenterology & Hepatology 26 (3), 362-363 , 2014 |
2014 |
| Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations—an extensive replication of the associations from the candidate gene era |
Cancer epidemiology, biomarkers & prevention 23 (4), 670-674 , 2014 |
2014 |
| Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation |
Leukemia 28 (6), 1334-1340 , 2014 |
2014 |
| HIGH CORRELATION BETWEEN CLINICAL RESPONSES TO 1ST LINE AML PATIENTS TREATED WITH CYTARABINE AND IDARUBICIN AND THEIR PHARMACOLOGICAL PROFILES IN PATIENT SAMPLES MEASURED BY … |
HAEMATOLOGICA 99, 37-38 , 2014 |
2014 |
| Efficient Identification of Response to Cytarabine Idarubicin in Newly Diagnosed Acute Myeloid Leukemia by a New Individualized Medicine Test Based on ex vivo Pharmacology |
Clinical Lymphoma, Myeloma and Leukemia 14, S118-S119 , 2014 |
2014 |
| Persistent benefit of VTD (bortezomib/thalidomide/dexamethasone) as pretransplant induction therapy for multiple myeloma: long-term follow-up of a randomized phase 3 PETHEMA … |
Blood 124 (21), 3457 , 2014 |
2014 |
| Novel Assay for Ex Vivo Evaluation of Antiproliferative Effect of Hypomethylating Agents 5-Azacytidine and Decitabine in AML Patient Samples |
Blood, The Journal of the American Society of Hematology 124 (21), 5311-5311 , 2014 |
2014 |
| CYTOGENETICS AND LONG-TERM SURVIVAL IN MM-003, A PHASE 3 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY … |
Haematologica 99, 365-365 , 2014 |
2014 |
| Clinical and biological characterization of patients with low (0.1–2%) JAK2V617F allele burden at diagnosis |
Haematologica 99 (7), e098 , 2014 |
2014 |
| Chronic Lymphocytic Leukemia Patients Harbor Very Low Frequency Stereotypic Immunoglobulin CDR3 Sequences |
Blood 124 (21), 5635 , 2014 |
2014 |
| Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity |
Blood 124 (21), 5785 , 2014 |
2014 |
| POTENTIAL HEMATOTOXICITY OF NEW DRUG CANDIDATES MEASURED IN HEMATOPOIETIC PROGENITORS IN BONE MARROW SAMPLES |
HAEMATOLOGICA 99, 728-728 , 2014 |
2014 |
| Comparison of sequential vs alternating administration of bortezomib, melphalan and prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly … |
Blood 122 (21), 403 , 2013 |
2013 |
| Randomized placebo-controlled phase III study of perifosine combined with bortezomib and dexamethasone in relapsed, refractory multiple myeloma patients previously treated with … |
Blood, The Journal of the American Society of Hematology 122 (21), 3189-3189 , 2013 |
2013 |
| Correlation Between Clinical Features, CRLF2 Expression and Copy Number Alterations In Acute Lymphoblastic Leukemia |
Blood 122 (21), 4953 , 2013 |
2013 |
| Phase III trial of bortezomib, melphalan, and prednisone (VMP) versus bortezomib, thalidomide, and prednisone (VTP) In elderly multiple myeloma (MM) patients: update follow-up … |
Blood 122 (21), 1973 , 2013 |
2013 |
| FLT3, PIM and CXCR4 Expression In Acute Myeloid Leukemia |
Blood 122 (21), 4957 , 2013 |
2013 |
| MM-003 phase 3 study of pomalidomide in combination with low-dose dexamethasone (POM+ LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM … |
Blood 122 (21), 3198 , 2013 |
2013 |
| Prognostic value of deep sequencing approach for minimal residual disease (MRD) detection in multiple myeloma patients |
Blood 122 (21), 1848 , 2013 |
2013 |
| Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma |
British journal of haematology 163 (2), 223-234 , 2013 |
2013 |
| A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control |
Leukemia 27 (10), 2056-2061 , 2013 |
2013 |
| ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY … |
Haematologica 98, 329-330 , 2013 |
2013 |
| Proteomic analysis reveals heat shock protein 70 has a key role in polycythemia Vera |
Molecular Cancer 12, 1-12 , 2013 |
2013 |
| High throughput screening, with a flow cytometry automated platform (ex vivo biotech), to identify potential combination partners, for the JAK 2 inhibitor ruxolitinib |
Blood, The Journal of the American Society of Hematology 122 (21), 2534-2534 , 2013 |
2013 |
| Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm |
British journal of haematology 161 (5), 667-676 , 2013 |
2013 |
| Efficacy and safety of pomalidomide plus low-dose dexamethasone in advanced multiple myeloma: results of randomized phase 2 and 3 trials (MM-002/MM-003) |
Blood 122 (21), 3185 , 2013 |
2013 |
| Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a phase 3 study comparing pomalidomide+ low-dose dexamethasone (POM+ LoDEX) vs high-dose … |
Blood 122 (21), 408 , 2013 |
2013 |
| ANALYSIS OF MM-003 PATIENTS WITH MODERATE RENAL IMPAIRMENT USING POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED … |
Haematologica 98, 105-105 , 2013 |
2013 |
| MC13-0007 Metabolomic profile of multiple myeloma patients |
European Journal of Cancer, S14 , 2013 |
2013 |
| Trasplante hepático en pacientes con trombosis de la vena porta |
|
2013 |
| Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study |
British journal of haematology 163 (5), 581-589 , 2013 |
2013 |
| Phase 2 study of bendamustine, bortezomib (velcade) and prednisone (BVP) for newly diagnosed multiple myeloma (MM) |
Blood 122 (21), 2155 , 2013 |
2013 |
| Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders |
Blood, The Journal of the American Society of Hematology 122 (21), 3923-3923 , 2013 |
2013 |
| Prognostic impact of comorbidity in multiple myeloma |
Blood 122 (21), 5340 , 2013 |
2013 |
| The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: deep-sequencing analyses of hematological malignancies performed in 8,867 cases by an … |
Blood 122 (21), 743 , 2013 |
2013 |
| Prognostic Value of Angiogenic and Invasion Markers in Hodgkin Lymphoma |
International Journal of Radiation Oncology, Biology, Physics 87 (2), S553 , 2013 |
2013 |
| Chronic myeloid leukemia (CML) patients with atypical e1a2 P190 BCR-ABL translocation show a poor response to therapy with tyrosine kinase inhibitors (TKI) |
Blood 122 (21), 5193 , 2013 |
2013 |
| Deep sequencing reveals oligoclonality at the immunoglobulin locus in multiple myeloma patients |
Blood 122 (21), 401 , 2013 |
2013 |
| Phase 3 pharmacokinetics (PK) and safety study of posaconazole (POS) tablet in patients at risk for invasive fungal infection |
Abstract presented at: 23rd European congress of clinical microbiology and … , 2013 |
2013 |
| Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry |
Haematologica 98 (1), 79 , 2013 |
2013 |
| Patient outcomes by prior therapies and depth of response: analysis of MM-003, a phase 3 study comparing pomalidomide+ low-dose dexamethasone (POM+ LoDEX) vs high-dose … |
Blood 122 (21), 686 , 2013 |
2013 |
| Effectiveness of 5-azacitidine (5-aza) for the treatment of patients with acute myeloidleukaemia (AML) who relapsed after haematopoietic stem cell transplantation (HSCT) |
BONE MARROW TRANSPLANTATION 48, S259-S259 , 2013 |
2013 |
| Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma. |
Journal of Clinical Oncology 31 (15_suppl), 8511-8511 , 2013 |
2013 |
| The Presence Of Residual Disease After Induction and/Or Consolidation Therapy Based On Wilms’ Tumor 1 (WT1) Expression Is a Strong Prognostic Factor For Relapse and Survival In AML |
Blood, The Journal of the American Society of Hematology 122 (21), 1329-1329 , 2013 |
2013 |
| PROGNOSTIC VALUE OF DEEP SEQUENCING METHOD FOR MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA |
HAEMATOLOGICA 98, 102-103 , 2013 |
2013 |
| Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype |
Leukemia 27 (4), 925-931 , 2013 |
2013 |
| p53 Pathway alterations influence survival and treatment response in chronic lymphocytic leukemia |
Blood, The Journal of the American Society of Hematology 122 (21), 2885-2885 , 2013 |
2013 |
| SIMULACIÓN COMPUTACIONAL DE UN CONCENTRADOR SOLAR CILINDRO-PARABÓLICO-ENCAPSULADO DE MEDIANA TEMPERATURA. |
ASADES 2013-XXXVI Reunión de Trabajo-Tucuman , 2013 |
2013 |
| EFFICACY, SAFETY, AND QOL IN MM-003, A PHASE3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF POMALIDOMIDE (POM) plus LOW-DOSE DEXAMETHASONE (LODEX) VS HIGH-DOSE DEXAMETHASONE … |
Haematologica 98, 475-476 , 2013 |
2013 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … |
The lancet oncology 14 (11), 1055-1066 , 2013 |
2013 |
| BET bromodomain inhibition reduces leukemic burden and prolongs survival in the Eμ-TCL1 transgenic mouse model of chronic lymphocytic leukemia (CLL) independent of TP53 … |
Blood 122 (21), 876 , 2013 |
2013 |
| Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission |
Clinical cancer research 19 (17), 4770-4779 , 2013 |
2013 |
| Natural killer cell production under good manufacturing practice conditions to treat cancer patients |
HUMAN GENE THERAPY 24 (12), A165-A166 , 2013 |
2013 |
| Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine |
Blood, The Journal of the American Society of Hematology 122 (21), 1347-1347 , 2013 |
2013 |
| EARLY AND DEEP RESPONSES TO IMATINIB PREDICT NOT ONLY COMPLETE MOLECULAR RESPONSE BUT ALSO THE PROBABILITY FOR MAINTAINING THE RESPONSE |
HAEMATOLOGICA 98, 300-301 , 2013 |
2013 |
| Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML … |
Blood, The Journal of the American Society of Hematology 122 (21), 3824-3824 , 2013 |
2013 |
| Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs. thalidomide vs. alfa2b-interferon: final results of a phase III PETHEMA … |
Blood, The Journal of the American Society of Hematology 120 (21), 334-334 , 2012 |
2012 |
| www. elsevier. es/medicinaclinica |
Med Clin (Barc) 139 (15), 700 , 2012 |
2012 |
| Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial |
Blood, The Journal of the American Society of Hematology 120 (13), 2581-2588 , 2012 |
2012 |
| A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials |
Blood, The Journal of the American Society of Hematology 120 (21), 3762-3762 , 2012 |
2012 |
| Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma |
Therapeutic Advances in Hematology 3 (3), 147-154 , 2012 |
2012 |
| THE NEW EUTOS SCORE HAS PROGNOSTIC VALUE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) OUTSIDE CLINICAL TRIALS |
HAEMATOLOGICA 97, 310-310 , 2012 |
2012 |
| Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients |
Blood 120 (21), 5049 , 2012 |
2012 |
| Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients |
Leukemia 26 (8), 1862-1869 , 2012 |
2012 |
| Cord Blood Transplantation from Unrelated Donors Versus Stem Cell Transplantation from HLA-Identical Sibling in Adults with Philadelphia-Positive Acute Lymphoblastic Leukemia |
Biology of Blood and Marrow Transplantation 18 (2), S344 , 2012 |
2012 |
| Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model |
Haematologica 97 (7), 1020 , 2012 |
2012 |
| Analysis of the immune system of multiple myeloma patients achieving long-term disease control, by multidimensional flow cytometry |
|
2012 |
| Blood First Edition Paper, prepublished online August 13, 2012; DOI 10.1182/blood-2012-05-427815 |
|
2012 |
| Inhibition of Related JAK/STAT Pathways with Molecular Targeted Drugs Shows Strong Synergy with Ruxolitinib in Chronic Myeloproliferative Neoplasms |
Blood 120 (21), 5054 , 2012 |
2012 |
| Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone … |
Blood 120 (8), 1589-1596 , 2012 |
2012 |
| Characterization of Subclonal Changes Along Progression in Multiple Myeloma. |
Blood 120 (21), 2924 , 2012 |
2012 |
| SECOND-GENERATION TYROSINE KINASE INHIBITORS AS SECOND LINE TREATMENT IMPROVE OUTCOME OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA RESISTANT OR INTOLERANT TO IMATINIB |
HAEMATOLOGICA 97, 535-535 , 2012 |
2012 |
| Busulphan Plus Melphalan (Bumel) Versus Melphalan-200 Mg (Mel) As Conditioning Regimens for Multiple Myeloma (Mm): A Sequential Prospective Comparative Study of Efficacy and … |
Haematologica-the Hematology Journal , 2012 |
2012 |
| Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia |
Annals of hematology 91, 1-7 , 2012 |
2012 |
| Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3. |
British journal of haematology 158 (4) , 2012 |
2012 |
| Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF) |
Cancer Cell International 12, 1-13 , 2012 |
2012 |
| A phase III PETHEMA/GEM randomised trial of post-transplant maintenance in multiple myeloma: superiority of bortezomib |
BONE MARROW TRANSPLANTATION 47, S2-S2 , 2012 |
2012 |
| Response to imatinib mesylate in patients with hypereosinophilic syndrome |
International journal of hematology 96, 320-326 , 2012 |
2012 |
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation … |
Blood, The Journal of the American Society of Hematology 119 (3), 687-691 , 2012 |
2012 |
| Integration of CC®, IAQ, and EM for an Optimum and Proactive Energy Performance at Alamo Colleges, San Antonio, Texas. |
Energy Systems Laboratory (http://esl. tamu. edu) , 2012 |
2012 |
| New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid … |
Modern Chemotherapy 1 (2), 11 , 2012 |
2012 |
| Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated … |
Blood 120 (21), 3949 , 2012 |
2012 |
| Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients |
BMC gastroenterology 12, 1-6 , 2012 |
2012 |
| Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study |
Blood, The Journal of the American Society of Hematology 120 (8), 1589-1596 , 2012 |
2012 |
| COMPARATIVE GENE EXPRESSION ANALYSIS PROVIDES NOVEL THERAPEUTIC TARGETS IN CLL |
HAEMATOLOGICA 97, 293-294 , 2012 |
2012 |
| Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and … |
The American journal of pathology 181 (5), 1870-1878 , 2012 |
2012 |
| Outcomes of chronic myeloid leukemia (CML) Patients who stopped second generation tyrosine kinase inhibitors (2GTKIs) as second line treatment. Results of the CML Spanish … |
Blood 120 (21), 3764 , 2012 |
2012 |
| Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs |
American Society of Clinical Oncology , 2011 |
2011 |
| Knowledge and practice of PAP smear in women from Sucre, Bolivia |
TROPICAL MEDICINE & INTERNATIONAL HEALTH 16, 295-295 , 2011 |
2011 |
| Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma |
Leukemia Research 35 (4), 431-437 , 2011 |
2011 |
| Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia |
Springer-Verlag , 2011 |
2011 |
| Results of pre-and post-autologous stem cell transplantation with three induction regimens in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over … |
BONE MARROW TRANSPLANTATION 46, S38-S38 , 2011 |
2011 |
| Malaria Hidden in a Patient with Diffuse Large-B-Cell Lymphoma and Sickle-Cell Trait |
|
2011 |
| Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control |
Blood, The Journal of the American Society of Hematology 118 (21), 810-810 , 2011 |
2011 |
| Under Scope of the Current Redefinition Process of Optimal Response in Multiple Myeloma: Assesment of Molecular Response by Fluorescent PCR of Ig Genes Has Similar … |
Blood, The Journal of the American Society of Hematology 118 (21), 3951-3951 , 2011 |
2011 |
| Theoretical Study of the Structural Stability and the Electronic Properties of AlmHn Clusters |
Journal of Computational and Theoretical Nanoscience 8 (4), 609-615 , 2011 |
2011 |
| Epigenomic profiling in polycythaemia vera and essential thrombocythaemia shows low levels of aberrant DNA methylation |
Journal of clinical pathology 64 (11), 1010-1013 , 2011 |
2011 |
| Protein profile in chronic myeloproliferative neoplasms (MPN) |
Universidad de Córdoba, Servicio de Publicaciones , 2011 |
2011 |
| Emprirical Antifungal Therapy of Persistent Neutropenic Fever After Allogeneic Hematopoietic Stem Cell Transplantation With Caspofungin or Liposomal Amphotericin B |
Biology of Blood and Marrow Transplantation 17 (2), S275-S276 , 2011 |
2011 |
| Ahorra energía:¡ Tú puedes! |
Una unidad didáctica web para el desarrollo de la competencia científica y … , 2011 |
2011 |
| Multiparameter flow cytometry (MFC) evaluation of plasma cell (PC) DNA ploidy status and proliferative rate in 595 multiple myeloma (MM) patients (pts) included in the Spanish … |
Blood 118 (21), 3938 , 2011 |
2011 |
| Isotope composition of iron delivered to the oceans by intertropical rivers: The Amazon River Basin case |
AGU Fall Meeting Abstracts 2011, PP33D-05 , 2011 |
2011 |
| Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance |
Blood, The Journal of the American Society of Hematology 118 (17), 4547-4553 , 2011 |
2011 |
| Influence of Genetic Polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included … |
Blood 118 (21), 1412 , 2011 |
2011 |
| Metalloproteases Could Be Involved in Erythroid Differenciation in MPN |
Blood 118 (21), 5161 , 2011 |
2011 |
| High-Risk Cytogenetics and Persistent Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) Predict Unsustained Complete Response (CR) After Autologous Stem … |
Blood 118 (21), 630 , 2011 |
2011 |
| Molecular basis of antithrombin deficiency. Identification of 27 new mutations and associations with other genetic risk factors |
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 9, 816-816 , 2011 |
2011 |
| Grupo Español de MM; Programa para el Estudio de la Terapé utica en Hemopatía Maligna. Long-term prognostic significance of response in multiple myeloma after stem cell … |
Blood 118, 529-534 , 2011 |
2011 |
| Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs |
Journal of clinical oncology 29 (18), 2543-2549 , 2011 |
2011 |
| Accessibility in the university environment and its perception by students with disability |
Observatorio Universidad y Discapacidad , 2011 |
2011 |
| A phase III PETHEMA/GEM randomized trial of postransplant (ASCT) maintenance in multiple myeloma: superiority of bortezomib/thalidomide compared with thalidomide and alfa-2b … |
Blood 118 (21), 3962 , 2011 |
2011 |
| Efficacy of NK-92 Against Human Multiple Myeloma in a NOD/SCID Gamma Null Mouse Model |
Blood 118 (21), 1854 , 2011 |
2011 |
| Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect … |
Leukemia & Lymphoma 52 (3), 409-416 , 2011 |
2011 |
| Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia |
Annals of hematology 90, 939-946 , 2011 |
2011 |
| Hyperdiploidy in multiple myeloma is associated with a distinct pattern of microRNA |
CHROMOSOME RESEARCH 19, S31-S32 , 2011 |
2011 |
| Ecosistema bento-demersal de la plataforma costera vasca, información para su aplicación en la Directiva Marco de la Estrategia Marina europea |
Revista de Investigación Marina 18 (4), 45-75 , 2011 |
2011 |
| B CELL ANTIGEN EXPRESSION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY |
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 107 (5), A96-A97 , 2011 |
2011 |
| Malaria hidden in a patient with diffuse large-B-cell lymphoma and sickle-cell trait |
Journal of Clinical Microbiology 49 (12), 4401-4404 , 2011 |
2011 |
| Multidimensional Flow Cytometric (MFC) Analysis of the Immune System of Multiple Myeloma (MM) Patients Achieving Long Term Disease Control |
BLOOD 118 (21), 367-368 , 2011 |
2011 |
| The RC protein, a translational repressor that coordinates carbon metabolism in pseudomonas |
Universidad de Córdoba, Servicio de Publicaciones , 2011 |
2011 |
| Proteomic Analysis Identifies HSP70 As a Novel Target Therapy to Polycythemia Vera |
Blood 118 (21), 2827 , 2011 |
2011 |
| Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma |
Journal of clinical oncology 29 (12), 1627-1633 , 2011 |
2011 |
| Long-term prognostic significance of response in multiple myeloma after stem cell transplantation |
Blood, The Journal of the American Society of Hematology 118 (3), 529-534 , 2011 |
2011 |
| Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients |
BMC gastroenterology 11, 1-9 , 2011 |
2011 |
| Biological and clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma (MM) patients |
Blood 118 (21), 3936 , 2011 |
2011 |
| EFFICACY AND SAFETY OF LENALIDOMIDE IN PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY EXTRAMEDULLARY PLASMACYTOMAS |
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 95, 588-588 , 2010 |
2010 |
| A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide … |
Blood 116 (21), 307 , 2010 |
2010 |
| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … |
The lancet oncology 11 (10), 934-941 , 2010 |
2010 |
| Pharmacological inhibition of PIM kinases in chronic lymphocytic leukemia cases with unfavorable prognosis markers |
Blood 116 (21), 2468 , 2010 |
2010 |
| Pyogranulomatous Pleuropneumonia and Mediastinitis in Ferrets Associated with Chryseomonas-like Bacteria |
Journal of Comparative Pathology 143 (4), 321 , 2010 |
2010 |
| Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients … |
haematologica 95 (11), 1913 , 2010 |
2010 |
| Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC) |
Blood, The Journal of the American Society of Hematology 116 (21), 1237-1237 , 2010 |
2010 |
| Real‐time PCR quantification of haematopoietic chimerism after transplantation: a comparison between TaqMan and hybridization probes technologies |
International Journal of Laboratory Hematology 32 (1p1), e17-e25 , 2010 |
2010 |
| Analysis of immunophenotypic response (IR) by multiparameter flow cytometry in 516 myeloma patients included in three consecutive Spanish trials |
Blood 116 (21), 1910 , 2010 |
2010 |
| Policitemia vera: cuadro clínico, diagnóstico y tratamiento en la era de JAK2 |
Jano: Medicina y humanidades, 63-69 , 2010 |
2010 |
| Simplifying the detection of MUTYH mutations by high resolution melting analysis |
BMC cancer 10, 1-9 , 2010 |
2010 |
| Simplifying the detection of MUTYH mutations by high resolution melting analysis |
|
2010 |
| Thalidomide/dexamethasone (TD), bortezomib (Velcade)/thalidomide/dexamethasone (VTD) and VBMCP/VBAD/Velcade as induction therapy prior to high-dose therapy/autologous stem cell … |
BONE MARROW TRANSPLANTATION 45, S18-S18 , 2010 |
2010 |
| THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF THE IMMUNOPHENOTYPIC ASSESSMENT OF CD81 IN MULTIPLE MYELOMA CLONAL PLASMA CELLS |
CYTOMETRY PART B-CLINICAL CYTOMETRY 78 (6), 445-446 , 2010 |
2010 |
| Grupo Español de MM and Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 … |
Haematologica 95 (11), 1913-1920 , 2010 |
2010 |
| Influence of Saharan dust on particulate matter and its short term effect on mortality |
EUROPEAN JOURNAL OF PUBLIC HEALTH 20, 23-23 , 2010 |
2010 |
| Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC). |
BLOOD 116 (21), 528-529 , 2010 |
2010 |
| Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples |
Blood 116 (21), 2470 , 2010 |
2010 |
| IMMUNOPHENOTYPIC REMISSIONS CAN BE ACHIEVED IN ELDERLY MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS |
CYTOMETRY PART B-CLINICAL CYTOMETRY 78 (6), 454-454 , 2010 |
2010 |
| Content-based Dynamic Threshold Method for Real Time Keyframe Selecting |
|
2010 |
| Clinical outcome according to both cytogenetic abnormalities (CA) detected by fluorescence in situ hibridization (FISH) and hyperdiploidy assessed by flow cytometry (FCM) in … |
Blood, The Journal of the American Society of Hematology 116 (21), 309-309 , 2010 |
2010 |
| IMMUNOPHENOTYPIC RESPONSES CAN BE ACHIEVED IN ELDERLY MULTIPLE MYELOMA PATIENS TREATED WITH NOVEL AGENTS |
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 95, 236-236 , 2010 |
2010 |
| Efficacy of Lenalidomide-Based Regimens in Multiple Myeloma Complicated by Extramedullary Plasmacytomas at Relapse or Progression. |
Blood 114 (22), 4952 , 2009 |
2009 |
| High-dose therapy/autologous stem cell transplantation increases complete remission rate in multiple myeloma irrespective of the induction regimen used: TD (Thalidomide … |
Bone Marrow Transplantation 43 (S1), S18-S18 , 2009 |
2009 |
| Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide |
Leukemia & lymphoma 50 (8), 1283-1289 , 2009 |
2009 |
| Efficacy of Lenalidomide-Based Regimens in Multiple Myeloma Complicated by Extramedullary Plasmacytomas at Relapse or Progression. |
Blood, The Journal of the American Society of Hematology 114 (22), 4952-4952 , 2009 |
2009 |
| A160 Thalidomide/Dexamethasone (TD) Versus Bortezomib (Velcade)/Thalidomide/Dexamethasone (VTD) Versus VB |
Clinical Lymphoma & Myeloma, S26 , 2009 |
2009 |
| Tratamiento del mieloma múltiple: nuevos enfoques |
JANO 1 (727), 24-7 , 2009 |
2009 |
| A154 Bortezomib (Velcade)/Melphalan/Prednisone (VMP) Versus Velcade/Thalidomide/Prednisone (VTP) in Elderly |
Clinical Lymphoma & Myeloma, S25 , 2009 |
2009 |
| Long‐term follow‐up of donor chimerism and tolerance after human liver transplantation |
Liver transplantation 15 (6), 581-591 , 2009 |
2009 |
| β ‐Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39 C → T/−28 A → C |
Advances in hematology 2009 (1), 476342 , 2009 |
2009 |
| Bortezomib (Velcade)/melphalan/prednisone (VMP) versus Velcade/thalidomide/prednisonse (VTP) in el-derly untreated multiple myeloma (MM) patients |
Haematologica 94 (2), 190 , 2009 |
2009 |
| Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation. |
Blood, The Journal of the American Society of Hematology 114 (22), 1811-1811 , 2009 |
2009 |
| Gastrojejunostomy Web After Laparoscopic Roux-En-Y Gastric Bypass |
OBESITY SURGERY 19 (8), 1074-1074 , 2009 |
2009 |
| Long-Term Follow-up of Donor Chimerism and Tolerance After Human Liver Transplantation. |
Blood 114 (22), 3534 , 2009 |
2009 |
| Tailored Low Dose Lenalidomide with Low Dose Dexamethasone (len/dex) in Previously Treated Patients with Multiple Myeloma Older Than 70 Years Requiring Treatment. |
Blood 114 (22), 4950 , 2009 |
2009 |
| Thalidomide/Dexamethasone (TD) Vs. Bortezomib (Velcade) â/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcadeâ as Induction Regimens Prior Autologous Stem Cell … |
Blood 114 (22), 130 , 2009 |
2009 |
| Clinical significance of Gata‐1, Gata‐2, EKLF, and c‐MPL expression in acute myeloid leukemia |
American journal of hematology 84 (2), 79-86 , 2009 |
2009 |
| Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response. |
Blood 114 (22), 459-460 , 2009 |
2009 |
| Living donor liver transplantation: usefulness of hemostatic and prothrombotic screening in potential donors |
Transplantation proceedings 41 (9), 3791-3795 , 2009 |
2009 |
| Stomaphx for Dilated Gastrojejunstomy After Roux-En-Y Gastric Bypass |
OBESITY SURGERY 19 (8), 1074-1074 , 2009 |
2009 |
| Simulación numérica del proceso de rotura de las olas mediante un método" level set" con refinamiento local adaptivo |
Métodos numéricos en Ingeniería, 2009:[comunicaciones presentadas al III … , 2009 |
2009 |
| Manejo quirúrgico del cáncer colorrectal hereditario: cirugía basadas en el análisis molecular y los antecedentes familiares |
Revista Española de Enfermedades Digestivas 101 (8), 536-540 , 2009 |
2009 |
| Effect of Age and Body Mass Index on Weight Loss After Laparoscopic Adjustable Gastric Banding |
OBESITY SURGERY 19 (8), 961-961 , 2009 |
2009 |
| Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response. |
Blood 114 (22), 1121 , 2009 |
2009 |
| Thalidomide/dexamethasone (TD) vs bortezomib (Velcade)^ a/thalidomide/dexamethasone (VTD) vs VBMCP/VBAD/velcade^ a as induction regimens prior autologous stem cell … |
Blood 114, 59a , 2009 |
2009 |
| High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms |
The Journal of Molecular Diagnostics 11 (2), 155-161 , 2009 |
2009 |
| Simulación de estructuras dentríticas mediante un método de tipo VOF |
Métodos numéricos en Ingeniería, 2009:[comunicaciones presentadas al III … , 2009 |
2009 |
| Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis |
The Journal of Molecular Diagnostics 11 (5), 458-463 , 2009 |
2009 |
| A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by … |
Blood 114 (22), 3 , 2009 |
2009 |
| NIK and the Alternative NF-κB Pathway in Human Lymphomas. |
Blood 114 (22), 3943 , 2009 |
2009 |
| Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for … |
Blood 112 (11), 651 , 2008 |
2008 |
| Evaluation of minimal residual disease in multiple myeloma patients by fluorescent‐polymerase chain reaction: the prognostic impact of achieving molecular response |
British journal of haematology 142 (5), 766-774 , 2008 |
2008 |
| Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a … |
Blood 112 (11), 161 , 2008 |
2008 |
| Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are … |
Journal of Clinical Oncology 26 (35), 5775-5782 , 2008 |
2008 |
| Manual de producción de jabalí europeo en sistema de crianza al aire libre |
Universidad de Concepción , 2008 |
2008 |
| Thalidomide/dexamethasone (TD) vs. bortezomib (Velcade®)/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade® as induction regimens prior autologous stem cell … |
Blood 112 (11), 654 , 2008 |
2008 |
| Adult patent ductus arteriosus: treatment with a stent-graft |
Cardiovascular and interventional radiology 31, 383-385 , 2008 |
2008 |
| The effects of grazing pressure and concentrate use on efficient dairy production in Galicia. |
|
2008 |
| Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure? |
Clinical Colorectal Cancer 7 (6), 398-401 , 2008 |
2008 |
| Surgical resection of a solitary pancreatic metastasis from colorectal cancer: a new step to a cure |
Clin Colorectal Cancer 7, 398-401 , 2008 |
2008 |
| el arte prehistórico en el Campo de Hellín (albacete). Cuenca media y baja del río mundo. programa para el estudio de investigación y difusión (2005-2008) |
Congreso Nacional de Arte Rupestre Levantino, 7-9 , 2008 |
2008 |
| Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases |
Annals of hematology 87, 741-749 , 2008 |
2008 |
| Patients with Relapsed or Progressive Multiple Myeloma Treated with Lenalidomide in the Compassionate Use Program. Spanish Registry, Preliminary Analysis. |
Blood 110 (11), 4821 , 2007 |
2007 |
| Linear Discriminant Analysis on Brain Computer Interface |
2007 IEEE. International Symposium on Intelligent Signal Processing … , 2007 |
2007 |
| Melphalan-200 mg (MEL) versus busulphan plus melphalan (bumel) as conditioning regimens for multiple myeloma (MM): A comparative study of efficacy and toxicity |
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 92 (6), 193-193 , 2007 |
2007 |
| Impact of the immunophenotypical and molecular response evaluated by flow cytometry and fluorescent pcr in the follow up of multiple myeloma patients achieving conventional … |
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 92 (6), 205-206 , 2007 |
2007 |
| Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease |
International journal of cardiology 118 (3), 345-349 , 2007 |
2007 |
| Importance of JAK2 V617F Allele Burden in the Diagnosis of Myeloproliferative Diseases and Its Association to Age. |
Blood, The Journal of the American Society of Hematology 110 (11), 4654-4654 , 2007 |
2007 |
| Underestimation of total cardiovascular risk in patients with essential hypertension: A real consequence of clinical inertia |
JOURNAL OF HYPERTENSION 25, S106-S106 , 2007 |
2007 |
| Prognostic impact of postransplantation complete remission (CR) in multiple myeloma (MM). Final results of a prospective study in a series of homogenously treated patients |
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 92 (6), 42-42 , 2007 |
2007 |
| Induction with fludarabine, cyclophosphamide and rituximab as front-line therapy against follicular lymphoma: Results from a cooperative Spanish trial |
Blood, The Journal of the American Society of Hematology 110 (11), 1286-1286 , 2007 |
2007 |
| Fast shot detection for high quality low delay H. 264 video coding |
Recall (R) 1, 3 , 2007 |
2007 |
| Comparison of the MagNA pure LC automated system and the RiboPure‐Blood RNA manual method for RNA extraction from multiple myeloma bone marrow samples conserved in an RNA … |
International Journal of Laboratory Hematology 29 (2), 139-144 , 2007 |
2007 |
| Mo-P5: 353 Folic acid treatment effect on carotid intima-media thickness of patients with coronary disease |
Atherosclerosis (Supplements)(Component) 3 (7), 123 , 2006 |
2006 |
| Original Reports-BREAST CANCER-Breast Cancer-Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast … |
Journal of Clinical Oncology 24 (22), 3611-3618 , 2006 |
2006 |
| Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03). |
Blood, The Journal of the American Society of Hematology 108 (11), 2762-2762 , 2006 |
2006 |
| A methodology for the sizing of slurry storages, and for measuring nutrient excretion on dairy farms |
DIAS report, 317 , 2006 |
2006 |
| Prognostic factors for bacteraemia in patients receiving autologous, haematopoietic stem cell transplantation |
BONE MARROW TRANSPLANTATION 37, S170-S170 , 2006 |
2006 |
| Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma |
The Journal of Molecular Diagnostics 8 (3), 364-370 , 2006 |
2006 |
| Rearrangement Patterns of Igs and bcl2/IgH and Clinical Significance in Follicular Lymphoma. |
Blood 108 (11), 4629 , 2006 |
2006 |
| Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach |
Leukemia 20 (6), 1047-1054 , 2006 |
2006 |
| Papel de la enfermedad mínima residual en el seguimiento del linfoma no Hodgkin folicular |
XIV SEMINARIO TRASPLANTE CON CÉLULAS STEM PERIFÉRICAS 28 (Supl 1), 35-39 , 2006 |
2006 |
| Concentrate supplementation effects on dairy cows grazing Galician pastures during spring. |
Grassland Productivity , 2006 |
2006 |
| Cohort Study of Thrombophilia and Thombotics Events in Recipients of Liver Transplantation and Their Respective Donors. |
Blood, The Journal of the American Society of Hematology 108 (11), 4093-4093 , 2006 |
2006 |
| Monitorización de la enfermedad mínima residual en la leucemia mieloide crónica mediante la reacción en cadena de la polimerasa en tiempo real |
Methods and Findings in Experimental & Clinical Pharmacology 28, 47-54 , 2006 |
2006 |
| Breast Cancer–Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High … |
Journal of clinical oncology 24 (22), 3611-3618 , 2006 |
2006 |
| Influence of GST Gene Polimorphisms in the Develovement of Liver Sinusoidal Obstructive Syndrome in Patients with Multiple Myeloma Undergoing Hematopoietic Stem Cell … |
Blood, The Journal of the American Society of Hematology 108 (11), 3084-3084 , 2006 |
2006 |
| Tranexamic acid reduces blood loss in total knee arthroplasty. A double blind study: A-310 |
European Journal of Anaesthesiology| EJA 23, 82 , 2006 |
2006 |
| DIFFERENCES IN GENE EXPRESSION PROFILE BETWEEN EARLY AND DEVELOPED RHEUMATOID ARTHRITIS. |
ANNALS OF THE RHEUMATIC DISEASES 65, 295-296 , 2006 |
2006 |
| Síndromes mieloproliferativos crónicos cromosoma Filadelfia negativos |
haematologica/edición española 91 (Supl 1), 231 , 2006 |
2006 |
| Nutrient management on Galician dairy farms |
Grassland Productivity , 2006 |
2006 |
| FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy. |
Blood 108 (11), 2348 , 2006 |
2006 |
| Response to Call for Evidence on Multi-View Video Encoding |
International Organization for Standardization, ISO/IEC JTC1/SC29/WG11 … , 2005 |
2005 |
| Shot detection method for low bitrate video coding |
Proceedings of the IASTED International Conference Visualization, Imaging … , 2005 |
2005 |
| Efecto de la hiperhomocisteinemia y de la mutación metilentetrahidrofolato reductasa 677C-> T en el riesgo de tromboembolia venosa en adultos jóvenes |
Medicina clínica 124 (14), 532-534 , 2005 |
2005 |
| Hiperhomocisteinemia y mutaciones de la metilentetrahidrofolato reductasa 677C→ T y 1298A→ C en pacientes con enfermedad inflamatoria intestinal |
Revista Española de Enfermedades Digestivas 97 (7), 497-504 , 2005 |
2005 |
| Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry |
haematologica 90 (10), 1365-1372 , 2005 |
2005 |
| Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression |
Blood 106 (5), 1851-1856 , 2005 |
2005 |
| Efecto de la hiperhomocisteinemia y de la mutación metilentetrahidrofolato reductasa 677C→ T en el riesgo de tromboembolia venosa en adultos jóvenes |
Medicina clínica 124 (14), 532-534 , 2005 |
2005 |
| Improved Huffman code tables for H. 263/H. 263+ based video compression applications |
Proceedings of the Eighth International Symposium on Signal Processing and … , 2005 |
2005 |
| REVIEW ARTICLES-RED CELLS-Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression |
Blood 106 (5), 1851-1856 , 2005 |
2005 |
| Safety and tolerability of Inosine plus subcutaneous interferon beta 1a (IFN beta 1a) in Multiple Sclerosis: Could Inosine protect from IFN beta 1a-related adverse effects? |
Neurology 64 (6), A385-A385 , 2005 |
2005 |
| [The horticultural scene in the Region of Murcia [Spain]] |
Seminario de Técnicos y Especialistas en Horticultura, 34., Murcia (España … , 2005 |
2005 |
| Efectos del manejo de praderas dentro de una explotación de ganado vacuno en la evolución de nutrientes en suelo durante el periodo de drenaje |
VII Jornadas de Investigación en la Zona No Saturada del Suelo: ZNS'05, 57-62 , 2005 |
2005 |
| Hipoacusia laboral |
Madrid: Instituto Regional de Seguridad y Salud en el Trabajo. Consejería de … , 2005 |
2005 |
| The Role of a Thrombofilia Screening in Prospective Liver Donors (LDLT, Live Donor Liver Transplant). |
Blood 106 (11), 4125 , 2005 |
2005 |
| Hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C→ Τ and 1298A→ C mutations in patients with inflammatory bowel disease |
Revista Española De Enfermedades Digestivas 2005 (97/7), 497-504 , 2005 |
2005 |
| Discrepancy between Phenotype and Genotype for Factor V Leiden Mutation in Recipients of Liver Transplant. |
Blood 106 (11), 4120 , 2005 |
2005 |
| Effect of hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C--> T mutation in venous thromboembolism risk of young adults |
Medicina Clinica 124 (14), 532-534 , 2005 |
2005 |
| Imipenem/cilastatin with/without a glycopeptide as initial empirical antibiotic therapy in recipients of autologous haematopoietic stem cell transplants: results of a … |
BONE MARROW TRANSPLANTATION 33, S210-S210 , 2004 |
2004 |
| Populational dynamics and management of nematodes in guavas (Psidium guajava), Calvillo, Aguascalientes, Mexico |
PHYTOPATHOLOGY 94 (6), S143-S143 , 2004 |
2004 |
| Dual-function stem molecular beacons to assess mRNA expression in AT-rich transcripts of Plasmodium falciparum |
Biotechniques 36 (3), 488-494 , 2004 |
2004 |
| Hiperhomocisteinemia y trombosis arteriales múltiples en un paciente joven con la mutación de la metilentetrahidrofolato reductasa C677T |
Rev. clín. esp.(Ed. impr.), 607-608 , 2004 |
2004 |
| Adaptación y optimización del sistema de producción porcina al aire libre (out door) para la obtención de carne y productos elaborados de jabalí (Sus scrofa L.) orientada a la … |
Informe final proyecto FDICORFO. Universidad de Concepción. Chillán, Chile , 2004 |
2004 |
| A study of different release techniques for a captive population of northern bald ibis (Geronticus eremita) in the region of La Janda (Cádiz, southern Spain) |
IAGNBI? rd Newsletter, 20-2 , 2004 |
2004 |
| Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell … |
International journal of hematology 80, 168-173 , 2004 |
2004 |
| Minimal Residual Disease Studies in Multiple Myeloma Patients Achieving Complete Remission after Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) by RQ-PCR. |
Blood, The Journal of the American Society of Hematology 104 (11), 2418-2418 , 2004 |
2004 |
| Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial |
Clinical chemistry 50 (6), 1088-1092 , 2004 |
2004 |
| LIVERAID-A novel bioartificial liver. |
HEPATOLOGY 40 (4), 220A-220A , 2004 |
2004 |
| Husbandry and Management |
Aquaculture 230, 585-588 , 2004 |
2004 |
| The use of fluorescent molecular beacons in real time PCR of IgH gene rearrangements for quantitative evaluation of multiple myeloma |
Clinical & Laboratory Haematology 26 (1), 31-35 , 2004 |
2004 |
| Long-term follow-up report on autologous bone marrow transplantation for patients with acute myeloid leukemia in first relapse after autologous blood stem cell transplantation |
BONE MARROW TRANSPLANTATION 31, S174-S175 , 2003 |
2003 |
| Perfil de las competencias profesionales del diplomado en nutrición humana y dietética |
Fundación Alimentación Saludable , 2003 |
2003 |
| Homocisteína y progresión de la aterosclerosis de la arteria carótida en pacientes con enfermedad coronaria |
Medicina clínica 121 (15), 561-564 , 2003 |
2003 |
| Long-lasting response in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) treated with imatinib mesylate (Glivec, STI-571) |
BONE MARROW TRANSPLANTATION 31, S179-S180 , 2003 |
2003 |
| Homocysteine and progression of carotid atherosclerosis in patients with coronary disease |
Medicina Clinica 121 (15), 561-564 , 2003 |
2003 |
| Tandem transplants with different high‐dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos … |
British journal of haematology 120 (2), 296-303 , 2003 |
2003 |
| Hipertension renovascular como manifestacion inicial de la enfermedad de Takayasu |
Rev. colomb. cardiol, 510-510 , 2003 |
2003 |
| Electronic Letters to |
Clin Chem 49, 769-776 , 2003 |
2003 |
| LIVERAID (R)-A novel hybrid bioartificial liver. |
HEPATOLOGY 36 (4), 681A-681A , 2002 |
2002 |
| Significado clínico de la enfermedad mínima residual en el mieloma múltiple |
Significado clínico de la enfermedad mínima residual en el mieloma múltiple , 2002 |
2002 |
| Estudio comparativo de biopsia hepatica por laparoscopia vs. puncion |
REVISTA DE GASTROENTEROLOGIA DE MEXICO 67, 164-164 , 2002 |
2002 |
| Tratamiento laparoscopico de la hernia hiatal gigante |
REVISTA DE GASTROENTEROLOGIA DE MEXICO 67, 147-147 , 2002 |
2002 |
| Hipertensión renovascular asociada a enfermedad de Takayasu. Presentación de un caso |
Acta Med Colomb 27 (5), 325-328 , 2002 |
2002 |
| Early liver dysfunction after unrelated donor cord blood transplantation (Ud-Cbt) |
BONE MARROW TRANSPLANTATION 29, S219-S219 , 2002 |
2002 |
| Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple … |
Leukemia & lymphoma 43 (1), 67-75 , 2002 |
2002 |
| Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases |
Haematologica 87 (8), ELT35-ELT35 , 2002 |
2002 |
| Overexpression of GATA-2, EKLF and c-MPL transcription factor genes and prognosis in acute myeloid leukemia. |
BLOOD 98 (11), 184B-184B , 2001 |
2001 |
| Hematopoyesis. Eritropoyesis. Fisiopatología eritroide |
Medicine: Programa de Formación Médica Continuada Acreditado 8 (50), 2613-2620 , 2001 |
2001 |
| Treatment of refractory chronic Graft-Versus-Host disease (GVHD) with Mycophenolate Mofetil (MMF). Preliminary results |
BONE MARROW TRANSPLANTATION 27, S190-S190 , 2001 |
2001 |
| Molecular beacon real-time PCR of IgH gene rearrangements in multiple myeloma |
LEUKEMIA 15 (12), 2016-2016 , 2001 |
2001 |
| Early transplant related mortality in lymphoma patients undergoing autologous hematopoietic stem cell transplantation after conditioning with CBV (cyclophosphamide, carmustine … |
BONE MARROW TRANSPLANTATION 27, S264-S264 , 2001 |
2001 |
| Re-expression of HLA class I antigens and restoration of antigen-specific cytotoxic T lymphocytes in melanoma cells following 5-AZA-2'deoxycytidine treatment |
European Journal of Cancer 37, S417-S418 , 2001 |
2001 |
| Characterization of small hepatocellular carcinoma with contrast-enhanced ultrasonography: Preliminary results. |
HEPATOLOGY 34 (4), 670A-670A , 2001 |
2001 |
| Karyotype and prognosis in adult Spanish acute lymphoblastic leukemia |
haematologica 86 (4), 438-439 , 2001 |
2001 |
| Qualitative IgH gene PCR to follow up residual disease in multiple myeloma patients undergoing high-dose chemotherapy. |
LEUKEMIA 15 (12), 2016-2017 , 2001 |
2001 |
| ECG of the month. Reality check. Complicated right bundle branch block |
The Journal of the Louisiana State Medical Society: official organ of the … , 2001 |
2001 |
| Unrelated Cord Blood Transplantation (UD-CBT) in adult patients with hematologic malignancies: a report from a single centre |
BONE MARROW TRANSPLANTATION 27, S96-S97 , 2001 |
2001 |
| Insuficiencia medular. Anemia aplásica |
Medicine-Programa de Formación Médica Continuada Acreditado 8 (50), 2625-2631 , 2001 |
2001 |
| Percutaneous alcohol injection in hepatocellular carcinoma: Assessment of residual disease using contrast-enhanced ultrasonography. |
HEPATOLOGY 34 (4), 667A-667A , 2001 |
2001 |
| Protocolo disgnóstico de los cuadros de insuficiencia medular |
Medicine: Programa de Formación Médica Continuada Acreditado 8 (50), 2662-2663 , 2001 |
2001 |
| Evaluacion de 17 lineas precoces de arroz para riego, generacion F6. Rio Hato, Cocle. |
|
2001 |
| Hematopoyesis. Eritropoyesis. Fisiopatología eritroide |
Medicine-Programa de Formación Médica Continuada Acreditado 8 (50), 2613-2620 , 2001 |
2001 |
| Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients |
British Journal of Haematology: TRANSPLANTATION 109 (2), 438-446 , 2000 |
2000 |
| CD34 (+) positive selection results in a marked reduction of the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation. |
BLOOD 96 (11), 389A-389A , 2000 |
2000 |
| Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation … |
British Journal of Haematology 109 (1), 138-147 , 2000 |
2000 |
| Prognostic value of tumoral ploidy in a series of Spanish patients with acute lymphoblastic leukemia |
Cancer genetics and cytogenetics 122 (2), 124-130 , 2000 |
2000 |
| La indicència dels programes motivacionals en la conducta social. Un estudi evolutiu (1988-2000) a la presó de dones de Barcelona |
Invesbreu Criminologia , 2000 |
2000 |
| The effect of pamidronate on bone disease in patients with multiple myeloma in remission after autologous transplantation. |
BLOOD 94 (10), 308B-309B , 1999 |
1999 |
| Autologous hematopoietic stem cell transplantation in patients older than sixty years. |
BONE MARROW TRANSPLANTATION 23, S208-S208 , 1999 |
1999 |
| Qualitative IgH gene PCR to monitor residual disease in multiple myeloma patients undergoing high-dose chemotherapy. |
BLOOD 94 (10), 177B-177B , 1999 |
1999 |
| Purines de porcino, 3: Análisis en laboratorio y en campo |
Navarra Agraria (España) , 1999 |
1999 |
| Hematopoietic stem cell transplantation for multiple myeloma (MM). Results from a single institution. |
BONE MARROW TRANSPLANTATION 23, S139-S139 , 1999 |
1999 |
| Minimal residual disease (MRD) by flow cytommetry immediately before autologous stem cell transplantation (ASCT) in acute myeloid leukemia (AML): A critical factor in outcome? |
Blood 94 (10), 580A-580A , 1999 |
1999 |
| Allogeneic bone marrow transplantation conditioned by BUCY2 in paroxysmal nocturnal hemoglobinuria: A report of six cases from a single institution. |
BONE MARROW TRANSPLANTATION 23, S31-S31 , 1999 |
1999 |
| Characterization of distinct prognostic groups by response definition with electrophoresis (EP) versus immunofixation (IF) in multiple myeloma (MM) after autologous … |
Blood 94 (10), 576A-576A , 1999 |
1999 |
| Efficacy and toxicity of conditioning regimens in autologous stem cell transplantation (ASCT) for multiple myeloma (MM): A comparative study based on the Spanish registry of … |
BLOOD 94 (10), 577A-577A , 1999 |
1999 |
| [Swine liquid manures, 3: Analysis in laboratory and in field].[Spanish] |
Navarra Agraria , 1999 |
1999 |
| Unrelated donor cord blood transplantation (UD-CBT) in adults with chronic myeloid leukemia (CML): Preliminary results in seven patients from a single institution. |
BLOOD 94 (10), 394B-394B , 1999 |
1999 |
| PANCOLITIS Y MARCADORES GENETICOS EN LA POBLACION ESPANOLA |
Revista español de enfermedades digestivas 91 (4), 269-276 , 1999 |
1999 |
| Comparison of two methods for definition of complete remission in multiple myeloma: Zonal electrophoresis vs immunofixation electrophoresis. |
BLOOD 92 (10), 266B-266B , 1998 |
1998 |
| Lactic acidosis during fulminant hepatic failure: determinants and infectious complications |
BRITISH JOURNAL OF ANAESTHESIA 80, A. 537-A. 537 , 1998 |
1998 |
| Orthotopic liver transplantation for hepatic cirrhosis secondary to hepatitis C virus for an allogeneic bone marrow transplant recipient. |
BONE MARROW TRANSPLANTATION 21, S159-S159 , 1998 |
1998 |
| Prognostic relevance of AML1/ETO and CBF beta/MYH11 molecular rearrangements in AML patients undergoing hematopoietic stem cell transplantation (HSCT) in first remission (CR1). |
BLOOD 92 (10), 205B-205B , 1998 |
1998 |
| contabilidad general y tesorería |
España: Centro de publicaciones, secretaria general y técnica , 1998 |
1998 |
| Libertad y conformidad de prescripción del médico en atención primaria |
Centro de salud 6 (11), 712-717 , 1998 |
1998 |
| Thalassemia intermedia caused by interaction of IVS-1 1 (G--A) mutation in the beta-globin gene and heterozygotic triplication in the alpha-globin gene |
Revista Clinica Espanola 198 (3), 153-155 , 1998 |
1998 |
| TALASEMIA INTERMEDIA CAUSADA POR INTERACCION DE LA MUTACION IVS-1 1 (GA) EN EL GEN DE LA GLOBINA BETA Y TRIPLICACION HETEROCIGOTA DEL GEN DE LAS GLO BINAS ALPHA |
Revista clinica espanola 198 (3), 153-155 , 1998 |
1998 |
| Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk ALL. Final results of the prospective randomized trial … |
BLOOD 92 (10), 399A-399A , 1998 |
1998 |
| Quiste lateral cervical como primer sintoma de un microcarcinoma papilar de tiroides: presentacion de 2 casos |
ENDOCRINOLOGIA-BARCELONA- 45, 290-291 , 1998 |
1998 |
| Prognosis factors in low grade non Hodgkin's lymphoma (NHL). Results of an analysis performed in 124 patients homogeneously treated. |
BLOOD 90 (10), 3868-3868 , 1997 |
1997 |
| Regeneration through somatic embryogenesis of Cuban cassava clones. |
|
1997 |
| Immunologic reconstitution of peripheral blood lymphocytes in patients treated by bone marrow transplantation |
Medicina Clinica 106 (5), 169-173 , 1996 |
1996 |
| Reconstitución inmunológica de los linfocitos de sangre periférica en pacientes tratados con trasplante de medula ósea |
Medicina clínica 106 (5), 169-173 , 1996 |
1996 |
| PML/RARa rearrangement detection by a reverse PCR method in acute promyelocytic leukaemia. |
Sangre-Trabajos de Hematologia y Hemoterapia 41 (3), 189-194 , 1996 |
1996 |
| Tricholeukaemua variant and autoimmune haemolytic anaemia. |
Sangre-Trabajos de Hematologia y Hemoterapia 41 (3), 260-260 , 1996 |
1996 |
| PROSPECTIVE AND RANDOMIZED TRIAL COMPARING ENDOSCOPIC SPHINCTEROTOMY LEAVING THE GALLBLADDER IN-SITU WITH OPEN SURGERY FOR TREATMENT OF BILE-DUCT STONES IN THE HIGH-RISK PATIENT |
BRITISH JOURNAL OF SURGERY 82, 17-17 , 1995 |
1995 |
| Influencia de la toxina killer durante la vinificación |
Vitivinicultura 5 (6), 52-56 , 1995 |
1995 |
| UNA NUEVA FORMA DEL CARBONO: LOS FULLERENOS |
Homenaje a Vicente Aleixandre, 357 , 1994 |
1994 |
| Hip prosthesis infection: diagnostic approach and treatment of 27 cases |
Enfermedades Infecciosas y Microbiologia Clinica 12 (10), 490-496 , 1994 |
1994 |
| Laproscopic cholecystectomy for billiary pancreatitis |
Journal of British Surgery 81 (11), 1694-1696 , 1994 |
1994 |
| Subcutaneous venous reservoirs: comparative study of their efficacy in patients with AIDS versus oncology and hematology patients |
Enfermedades Infecciosas y Microbiologia Clinica 11 (4), 190-194 , 1993 |
1993 |
| Surface plasmon excitations in C [sub 60], C [sub 60] K and C [sub 60] H clusters |
Physica B. Condensed Matter;(Netherlands) 183 (3) , 1993 |
1993 |
| Effect of endoscopic sphincterotomy on gallbladder. Isotopic and echographic study |
GASTROENTEROLOGIA Y HEPATOLOGIA 15, 503-503 , 1992 |
1992 |
| Juxta-anastomotic sacciform dilation: an unusual complication of colonic stapled suture. |
The European Journal of Surgery= Acta Chirurgica 158 (4), 253-255 , 1992 |
1992 |
| ECG of the month. Primum non nocere! Ventricular premature impulses |
The Journal of the Louisiana State Medical Society: official organ of the … , 1991 |
1991 |
| Association between distemper and rabies virus |
|
1989 |
| Acute microgranular promyelocytic leukemia (M3 variant). Study of 14 patients |
Sangre 33 (2), 102-107 , 1988 |
1988 |
| Aris A, Solanes H, Camara ML, Junque C, Escartin A, Caralps JM, Vendrell P: Arterial line filtration during cardiopulmonary bypass. 1986; 91: 526-33 Artiz M (see Cortina et al … |
chest 91, 937-9 , 1986 |
1986 |
| Mitral Valve Replacement in Children under 16 Years of Age: Experience with the Bjork-Shiley Prosthesis |
Pediatric Cardiology: Proceedings of the Second World Congress, 1308-1310 , 1986 |
1986 |
| Acute promyelocytic leukemia. Analysis and results of treatment with daunorubicin in 29 patients |
Sangre 31 (4), 411-424 , 1986 |
1986 |
| Ecology of Collembola in an Eucalyptus forest in Vizcaya.). |
|
1983 |
| THROMBOEMBOLIC PROPHYLAXIS WITH STANDARD AND INDIVIDUALIZED DOSES OF SUBCUTANEOUS CALCIUM HEPARIN IN TRAUMATOLOGY-A COMPARATIVE-STUDY OF 223 CASES |
HAEMOSTASIS 12 (1-2), 183-183 , 1982 |
1982 |
| Carbenicillin-trimethoprim/sulphamethoxazole or carbenicillin-tobramycin as empirical treatment of infection in granulocytopenic patients. A controlled prospective trial … |
Sangre 26 (3), 335-346 , 1981 |
1981 |
| T-cell leukaemia with receptors for IgG Fc-fraction (author's transl) |
Sangre 25 (2), 227-230 , 1980 |
1980 |
